other	G-A609//Other//SNMI	2.16.840.1.113883.1.11.10616//Other//HL7V3.0	NHIS//Adult//NCI	CES-D//Other//NCI	C17649//Other//NCI_NICHD	TCGA//Enterovirus//NCI	LA46-8//Other//LNC	74964007//Other//SNOMEDCT_US	U003446//Other//MTH	U000265//OTHER//CCPSS	SDTM-NSYSPCID//OTHER//NCI_CDISC	SDTM-ACSPCAT//OTHER//NCI_CDISC	SDTM-INTTYPE//OTHER//NCI_CDISC	SDTM-NCOMPLT//OTHER//NCI_CDISC	SDTM-SDTHSDTP//OTHER//NCI_CDISC	U000081//Other//AIR	C53289//Other Health Care Professional//NCI	C38290//OTHER//NCI_FDA	135//OTHER//NCI_FDA	O//In Process//HL7V2.5	ORH//Other//HL7V2.5	OT//Occupational Therapy//HL7V2.5	5//Conservator//HL7V2.5	99//Other//HL7V2.5	4//2nd Operative//HL7V2.5	OTH//Other manufacturer//HL7V2.5	MTHU000080//Other//OMIM	LP21049-9//Other//LNC	MTHU029809//Other//LNC	52483-5//Other:-:Pt:^Patient:-//LNC	349//Other//SOP	C118472//Other//NCI_FDA	C123269//OTHER//NCI_FDA
the following are appropriate:	
seizures	SEIZ//Seizures//AIR	D012640//Seizures//MSH	673//Seizures//MTH	U000217//Seizures//SNM	060315//Seizures//NOC	070819//Seizures//NOC	MTHU000242//Seizures//OMIM	N0000002713//Seizures [Disease/Finding]//NDFRT	396//Seizures//MEDLINEPLUS	LA15899-0//Seizures//LNC	2063//Seizures//NCI_FDA	HP:0001250//Seizures//HPO	10039910//Seizures//MDR	46145//Seizures//PSY	NOCODE//Developmental arithmetic disorder//MTH	BI00559//seizure disorder//BI	0000011162//seizure//CHV
hearing loss	0000003627//deafness//CHV	0000005856//partial hearing loss//CHV	N0000011013//Hearing Loss [Disease/Finding]//NDFRT	D034381//Hearing Loss//MSH	XE0s9//Hearing loss//RCD	F-X6000//Deafness//SNM	LP56780-7//Hearing loss//LNC	204//Hearing Disorders and Deafness//MEDLINEPLUS	MTHU036353//Hearing loss//OMIM	MTHU021608//Hearing loss//LNC	HP:0000365//Hearing impairment//HPO	10019246//Hearing loss//MDR	389//Hearing loss//ICD9CM	15188001//Hearing loss//SNOMEDCT_US	0041617//HEARING LOSS//CCPSS	345//HEARING LOSS//COSTAR	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	141//loss of hearing//MEDCIN	BI00650//hearing loss//BI	0977-5687//hearing disorder//CSP	34076//hearing loss//MEDCIN	6676//hearing loss by exam//MEDCIN	C35731//Hearing Loss//NCI_NICHD	1882//Hearing Loss//NCI_FDA	LA24366-9//Hearing loss//LNC
skeletal	CDR0000044350//skeletal//NCI_NCI-GLOSS	T-11000//Skeletal system, NOS//SNMI	NOCODE//Developmental arithmetic disorder//MTH	0000037923//skeletal//CHV	MTHU000029//SKELETAL//OMIM
cardiovascular	T-30000//Cardiovascular system, NOS//SNMI	C12686//Cardiovascular System//NCI	BI00027//cardiovascular//BI	0060472//CARDIOVASCULAR//CCPSS	LP31409-3//Cardiovascular//LNC	LA18277-6//Cardiovascular//LNC	C25292//Cardiovascular//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000044005//cardiovascular//NCI_NCI-GLOSS	MTHU000109//CARDIOVASCULAR//OMIM
respiratory	D012122//Respiratory//MSHPOL	BI00201//respiratory//BI	NOCODE//Developmental arithmetic disorder//MTH	0041936//RESPIRATORY//CCPSS	R//RESPIRATORY//ICPC	MTHU000104//RESPIRATORY//OMIM	T-20000//Respiratory system, NOS//SNMI	LA16975-7//Respiratory//LNC	MTHU052973//Respiratory//LNC	LP208442-6//Respiratory//LNC	C25656//Respiratory//NCI	RES//Respiratory//HL7V2.5
dental	DNTL//Dental//HL7V3.0	T-54010//Tooth, NOS//SNMI	LP89803-8//Dental//LNC	MTHU031898//Dental//LNC	MTHU000053//Dental//LNC	C41136//Dental//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000022081//dental//CHV	LP31759-1//DENTAL//LNC	C69059//Dental//NCI_NCPDP	C38197//Dental//NCI_FDA	DT//Dental//HL7V2.5	038//DENTAL//NCI_FDA	D//Significant change down//HL7V2.5	DENTA//Dental//HL7V2.5	54571-5//Dental:-:Pt:^Patient:-//LNC	561//Dental//SOP
treatment includes the following:	
gastrointestinal	BI00029//gastrointestinal//BI	0000037933//gastrointestinal (GI)//CHV	CDR0000045692//gastrointestinal//NCI_NCI-GLOSS	NOCODE//Developmental arithmetic disorder//MTH	T-50100//Digestive tract, NOS//SNMI	LP89777-4//Gastrointestinal//LNC	MTHU031867//Gastrointestinal//LNC	TCGA//Enterovirus//NCI	LA16968-2//Gastrointestinal//LNC	C13359//Gastrointestinal//NCI	MTHU000224//Gastrointestinal//OMIM	C53802//GASTROINTESTINAL//NCI_CTCAE	54534-3//Gastrointestinal:-:Pt:^Patient:-//LNC
hearing	U002101//Hearing//LCH	D006309//Hearing//MSH	X75pr//Perception of sound//RCD	19//Hearing//OMS	LP30518-2//Hearing//LNC	MTHU015042//Hearing//LNC	sh85059612//Hearing//LCH_NW	LA22109-5//Hearing//LNC	MTHU051593//Hearing//LNC	47078008//Hearing//SNOMEDCT_US	C16670//Hearing//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000006094//hearing//AOD	0973-7729//hearing//CSP	GO:0007605//sensory perception of sound//GO	0000005854//hearing//CHV	6674//examination of hearing//MEDCIN	091305//Hearing//NOC	0000042156//audiological observations//CHV	133083//outcomes otolaryngology hearing//MEDCIN
the following are indicated:	
neurologic	G-B119//Neurologic//SNMI	LA16973-2//Neurologic//LNC	C25262//Neurologic//NCI	1199008//Neurologic//SNOMEDCT_US	BI00565//neurologic//BI	0000020628//neurological//CHV	CDR0000044117//neurologic//NCI_NCI-GLOSS	0045754//NEUROLOGIC//CCPSS	MTHU000057//NEUROLOGIC//OMIM
treatment is symptomatic	
motor dysfunction	MTHU024651//Motor dysfunction//OMIM	10061296//Motor dysfunction//MDR	52559000//Motor dysfunction//SNOMEDCT_US	0000023247//motor dysfunction//CHV
gross motor dysfunction	
consider use of durable medical equipment as needed (e	
fine motor dysfunction	
oral motor dysfunction	
eyes	D005123//Eye//MSH	LP7222-5//Eyes//LNC	MTHU001409//Eyes//LNC	MTHU000020//Eyes//OMIM	0000004810//eye//CHV
skin	SKN//Skin//HL7V3.0	U004333//Skin//LCH	D012867//Skin//MSH	NOCODE//Developmental arithmetic disorder//MTH	7N7..//Skin//RCD	T-01000//Skin//SNM	7163//Skin//UWDA	MTHU000083//Skin//OMIM	26//Skin//OMS	LP76007-1//Skin//LNC	LP36760-4//Skin//LNC	LP130014-6//Skin//LNC	MTHU001414//Skin//LNC	sh85123164//Skin//LCH_NW	TCGA//Enterovirus//NCI	C12470//SKIN//NCI_CDISC	LA4332-8//Skin//LNC	39937001//Skin structure//SNOMEDCT_US	0000002281//skin//AOD	2716-0373//skin//CSP	0000054821//skin//CHV	0012516//SKIN//CCPSS	S//SKIN//ICPC
developmental pediatricians can provide assistance with transition to adulthood	
some issues to consider:	
renal disease	X30Hc//Disorder of kidney//RCD	D-6502//Kidney disease//SNM	91//Kidney Diseases//MEDLINEPLUS	MTHU047531//Renal disease//OMIM	10051051//Renal disease//MDR	90708001//Kidney disease//SNOMEDCT_US	0000023503//renal disease//AOD	BI00465//renal disease//BI	0000007090//kidney disease//CHV	236575//renal disease//MEDCIN	0013357//RENAL DISEASE//CCPSS	C3149//Kidney Disorder//NCI
eye	NOCODE//Sepsis//COSTAR	U001714//Eye//LCH	D005123//Eye//MSH	X74in//Eye//RCD	T-XX000//Eye//SNM	54448//Eye//UWDA	LP7218-3//Eye//LNC	LP117007-7//Eye//LNC	MTHU001430//Eye//LNC	MTHU000064//Eye//LNC	MTHU038905//Eye//LNC	sh85046642//Eye//LCH_NW	TCGA//Enterovirus//NCI	LP207778-4//Eye//LNC	81745001//Eye structure//SNOMEDCT_US	C12401//Eye//NCI	EYE//Eye//HL7V2.5	U003284//Eye//MTH	0000002468//eye//AOD	1107-6922//eye//CSP	0000004810//eye//CHV	0057369//EYE//CCPSS	F//EYE//ICPC	LP7797-6//EYE//LNC
sensorineural hearing loss	XE17N//Sensorineural hearing loss//RCD	MTHU001056//Sensorineural hearing loss//OMIM	10040016//Sensorineural hearing loss//MDR	389.1//Sensorineural hearing loss//ICD9CM	60700002//Sensorineural hearing loss//SNOMEDCT_US	BI00649//sensorineural hearing loss//BI	0977-6000//sensorineural hearing loss//CSP	34075//sensorineural hearing loss//MEDCIN	0000005863//sensorineural hearing loss//CHV	HP:0000407//Sensorineural hearing impairment//HPO	NOCODE//Sepsis//COSTAR	N0000001427//Hearing Loss, Sensorineural [Disease/Finding]//NDFRT	C26739//Sensorineural Hearing Loss//NCI	46555//Sensorineural Hearing Loss//PSY	D006319//Hearing Loss, Sensorineural//MSH
nutrition	C16927//Nutritional Science//NCI	2116-4900//nutrition//CSP	0000032037//nutritional status//CHV	K//Nutrition//NOC	2//Nutrition//NANDA-I	36//Nutrition//MEDLINEPLUS	1006812//NUTRITION//CCPSS	Xa97T//Feeding and dietary regimes//RCD	U003305//Nutrition//LCH	35//Nutrition//OMS	LP172860-1//Nutrition//LNC	MTHU047298//Nutrition//LNC	sh85093451//Nutrition//LCH_NW	C28294//Nutrition//NCI_NICHD	34720//Nutrition//PSY	384759009//Nutrition//SNOMEDCT_US	0000001786//nutrition//AOD	CDR0000044698//nutrition//NCI_NCI-GLOSS	C15820//Nutritional Study//NCI
growth	U002048//Growth//LCH	D006128//Growth//MSH	0110//Growth//NOC	C18825//Generalized Growth//NCI	sh85057525//Growth//LCH_NW	13_1//Growth//NANDA-I	21910//Growth//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000005714//physical growth process//CHV	GO:0040007//growth//GO	1003950//GROWTH//CCPSS	MTHU000046//GROWTH//OMIM	Q000254//growth & development//MSH	C16648//Tissue Growth//NCI	C64379//Growth//NCI
ophthalmologic	C16939//Ophthalmology//NCI	G-B106//Ophthalmologic//SNMI	239005//Ophthalmologic//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	BI00642//ophthalmologic//BI	0000020617//ophthalmologic//CHV
manifestation	0000020498//manifestation of//CHV	0000057112//manifestation of//CHV
treatment	Q000628//therapy//MSH	C49236//Therapeutic Procedure//NCI	LP94823-9//Treatment//LNC	LP100632-1//Treatment//LNC	TCGA//Enterovirus//NCI	54190//Treatment//PSY	0373//Treatment//HL7V2.5	D013812//Therapeutics//MSH	0000016079//treatment//CHV	C70742//Treat//NCI	C25409//Administration//NCI	C43442//Biomaterial Treatment//NCI	SDTM-TTYPE//TREATMENT//NCI_CDISC	SDTM-TINDTP//TREATMENT//NCI_CDISC	C101526//TREATMENT//NCI_CDISC	TREAT//treatment//HL7V3.0
communication issues	0000012476//communication issues//AOD
and	C16289//Andorra//NCI	TCGA//Enterovirus//NCI	C37912//And//NCI	NOCODE//Developmental arithmetic disorder//MTH	AND//and//HL7V3.0	421829000//And//SNOMEDCT_US
craniofacial	4006-0029//craniofacial//CSP	0000041543//craniofacial//CHV
hypothyroidism	HYPOT//Hypothyroidism//AIR	T86009//hypothyroidism//ICPC2P	U002348//Hypothyroidism//LCH	10021114//Hypothyroidism//MDR	D007037//Hypothyroidism//MSH	X40IQ//Hypothyroidism//RCD	D-2200//Hypothyroidism//SNM	MTHU002670//Hypothyroidism//OMIM	N0000001654//Hypothyroidism [Disease/Finding]//NDFRT	MTHU020783//Hypothyroidism//LNC	sh85063828//Hypothyroidism//LCH_NW	C26800//Hypothyroidism//NCI_NICHD	E10334//Hypothyroidism//NCI_CTCAE	LA14303-4//Hypothyroidism//LNC	6175//Hypothyroidism//MEDLINEPLUS	HP:0000821//Hypothyroidism//HPO	02495//Hypothyroidism//NANDA-I	40930008//Hypothyroidism//SNOMEDCT_US	24120//Hypothyroidism//PSY	NOCODE//Developmental arithmetic disorder//MTH	1017778//HYPOTHYROIDISM//CCPSS	404//HYPOTHYROIDISM//COSTAR	HYPOTHYR//HYPOTHYROIDISM//CST	U002059//HYPOTHYROIDISM//DXP	0417//HYPOTHYROIDISM//WHO	0000005992//hypothyroidism//AOD	BI00015//hypothyroidism//BI	2928-6836//hypothyroidism//CSP	CDR0000489292//hypothyroidism//PDQ	0000006501//hypothyroidism//CHV	CDR0000044547//hypothyroidism//NCI_NCI-GLOSS	MTHU037239//hypothyroidism//ICPC2ICD10ENG	30524//hypothyroidism//MEDCIN
treatment is supportive	
forearm crutches or canes for gait stability	
special shoes, including those with good ankle support	
5 g/m2	
table 3	
considerations/other	
standard recommendations may vary from country to country	
ages 0-3 years	
ages 3-5 years	
ages 5-21 years	
all ages	
liver transplantation	311//Liver Transplantation//MEDLINEPLUS	C15271//Liver Transplantation//NCI	D016031//Liver Transplantation//MSH	1756-4994//liver transplantation//CSP	0000007508//liver transplantation//CHV	CDR0000474023//liver transplantation//PDQ	10024716//Liver transplantation//MDR
canes and walkers help prevent falls	
no specific therapy is available	
renal	T-71000//Kidney, NOS//SNMI	LP34712-7//Renal//LNC	LA18284-2//Renal//LNC	RENL//Renal//HL7V2.5	C25225//Renal//NCI	0000001845//renal//AOD	0000007085//kidney//CHV	1679-5191//kidney//CSP	0022293//RENAL//CCPSS
cardiomyopathy	7.2.2.1//Cardiomyopathy//CCS	I42//Cardiomyopathy//ICD10	K84041//cardiomyopathy//ICPC2P	G55..//Cardiomyopathy//RCD	D-7100//Cardiomyopathy//SNM	LP128708-7//Cardiomyopathy//LNC	3754//Cardiomyopathy//MEDLINEPLUS	MTHU036362//Cardiomyopathy//OMIM	MTHU040649//Cardiomyopathy//LNC	C34830//Cardiomyopathy//NCI_NICHD	1764//Cardiomyopathy//NCI_FDA	HP:0001638//Cardiomyopathy//HPO	10007636//Cardiomyopathy//MDR	D009202//Cardiomyopathies//MSH	425//Cardiomyopathy//ICD9CM	85898001//Cardiomyopathy//SNOMEDCT_US	1002024//CARDIOMYOPATHY//CCPSS	156//CARDIOMYOPATHY//COSTAR	CARDIOMYOPATHY//CARDIOMYOPATHY//CST	U000553//ENDOMETRIOSIS//DXP	0425//CARDIOMYOPATHY//WHO	0000005390//cardiomyopathy//AOD	BI00081//cardiomyopathy//BI	1393-3627//myocardium disorder//CSP	1393-3642//hypertrophic myocardiopathy//CSP	0000008422//heart muscle disease//CHV	MTHU014927//cardiomyopathy//ICPC2ICD10ENG	33263//cardiomyopathy//MEDCIN
intellectual disability	D008607//Intellectual Disability//MSH	N0000001995//Intellectual Disability [Disease/Finding]//NDFRT	C97250//Intellectual Disability//NCI	NOCODE//Developmental arithmetic disorder//MTH	MTHU035437//Intellectual disability//OMIM	HP:0001249//Intellectual disability//HPO	10067989//Intellectual disability//MDR	228156007//Intellectual functioning disability//SNOMEDCT_US	P28005//intellectual disability//ICPC2P	0000036317//intellectual disability//CHV
ataxia	N29011//ataxia//ICPC2P	U000411//Ataxia//LCH	10003591//Ataxia//MDR	D001259//Ataxia//MSH	X76q7//Ataxia//RCD	F-84580//Ataxia//SNM	N0000000502//Ataxia [Disease/Finding]//NDFRT	4359//Friedreich's Ataxia//MEDLINEPLUS	5919//Cerebellar Disorders//MEDLINEPLUS	619//Degenerative Nerve Diseases//MEDLINEPLUS	520//Movement Disorders//MEDLINEPLUS	MTHU036349//Ataxia//OMIM	sh85009080//Ataxia//LCH_NW	E12597//Ataxia//NCI_CTCAE	C26702//Ataxia//NCI_NICHD	20262006//Ataxia//SNOMEDCT_US	04250//Ataxia//PSY	NOCODE//Developmental arithmetic disorder//MTH	1014485//ATAXIA//CCPSS	U000053//ATAXIA//COSTAR	ATAXIA//ATAXIA//CST	0088//ATAXIA//WHO	0000005037//ataxia//AOD	2057-3228//ataxia//CSP	734//walk is wobbly or unsteady//MEDCIN	0000001550//ataxia//CHV	CDR0000043999//ataxia//NCI_NCI-GLOSS	MTHU008913//ataxia//ICPC2ICD10ENG	278526//ataxia//MEDCIN	HP:0001251//Ataxia//HPO
special education	D004519//Education, Special//MSH	48930//Special Education//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000012600//special education//AOD	0988-7567//remedial/special education//CSP	0000004285//special education//CHV	193301//special education//MEDCIN	sh85046212//Special education//LCH_NW
failure to thrive	D005183//Failure to Thrive//MSH	N0000001205//Failure to Thrive [Disease/Finding]//NDFRT	G17.1//Failure to Thrive//CCC	265//Growth Disorders//MEDLINEPLUS	C107587//Failure to Thrive//NCI	19105//Failure to Thrive//PSY	NOCODE//Developmental arithmetic disorder//MTH	1015628//FAILURE TO THRIVE//CCPSS	U000276//FAILURE TO THRIVE//COSTAR	1626//FAILURE TO THRIVE//WHO	T10//Failure to thrive//ICPC	T10002//failure to thrive//ICPC2P	10016165//Failure to thrive//MDR	XM07a//Failure to thrive//RCD	MTHU000081//Failure to thrive//OMIM	LP36298-5//Failure to thrive//LNC	MTHU019355//Failure to thrive//LNC	00736//Failure to thrive//NANDA-I	783.41//Failure to thrive//ICD9CM	54840006//Failure to thrive//SNOMEDCT_US	10022898//Failure To Thrive//ICNP	1354-8678//postnatal growth disorder//CSP	2403-8925//prenatal growth disorder//CSP	38610//failure to thrive//MEDCIN	0000004874//growth failure//CHV	3587//failure to thrive//MEDCIN	HP:0001508//Failure to thrive//HPO	C113099//Failure to Thrive//NCI_GAIA	C85038//Infant Failure to Thrive//NCI_NICHD
developmental delay	X76B7//Developmental delay//RCD	MTHU000185//Developmental delay//OMIM	10012559//Developmental delay//MDR	00382//Developmental delay//NANDA-I	248290002//Developmental delay//SNOMEDCT_US	0058649//DEVELOPMENTAL DELAY//CCPSS	1577//DEVELOPMENTAL DELAY//WHO	0000006238//developmental delay//AOD	0000033357//child developmental delay//CHV	C116942//Developmental Delay//NCI_NICHD	HP:0001263//Global developmental delay//HPO
1-0	
treatment is symptomatic and may include the following:	
dystonia	N08007//dystonia//ICPC2P	10013983//Dystonia//MDR	D004421//Dystonia//MSH	X76qI//Dystonia//RCD	F-81330//Dystonia//SNM	F-A0950//Dystonia//SNMI	HP:0001332//Dystonia//HPO	15695//Dystonia//PSY	NOCODE//Developmental arithmetic disorder//MTH	DYSTONIA//DYSTONIA//CST	730//involuntary twisting movements//MEDCIN	0000004220//abnormal muscle twitching or contraction//CHV	MTHU024557//dystonia//ICPC2ICD10ENG	8993//dystonia//MEDCIN	G24//Dystonia//ICD10	U001488//Dystonia//LCH	N0000001033//Dystonia [Disease/Finding]//NDFRT	1252//Dystonia//MEDLINEPLUS	MTHU036384//Dystonia//OMIM	sh85040348//Dystonia//LCH_NW	C34563//Dystonia//NCI_NICHD	15802004//Dystonia//SNOMEDCT_US	0057274//DYSTONIA//CCPSS	U001018//LARYNX, HERPES//DXP	0068//DYSTONIA//WHO	2057-3370//dystonia//CSP	0000032219//dystonic disorder//CHV	335098//dystonia//MEDCIN
in the united states:	
consider evaluation for alternative means of communication (e	
yes	HGNC:12841//YES proto-oncogene 1, Src family tyrosine kinase//HGNC	373066001//Yes//SNOMEDCT_US	Y//Evaluation completed//HL7V2.5	TCGA//Enterovirus//NCI	C49488//Y//NCI_CDISC	LA33-6//Yes//LNC
short stature	237836003//Short stature disorder//SNOMEDCT_US	0000004192//short stature//CHV	Xa0MN//Short stature//RCD	MTHU000145//Short stature//OMIM	HP:0004322//Short stature//HPO	10040600//Short stature//MDR	783.43//Short stature//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	0037420//SHORT STATURE//CCPSS	GROWTH RETARD//GROWTH RETARDED//CST	C118686//Short Stature//NCI_NICHD	0000031268//short stature//CHV	T10009//short stature//ICPC2P	6077//short stature//MEDCIN	320653//SHOX gene with short stature//MEDCIN	C55745//Short stature//NCI_CTCAE
endocrine	LP31396-2//Endocrine//LNC	T-B0000//Endocrine gland, NOS//SNMI	C41064//Endocrine//NCI	NOCODE//Developmental arithmetic disorder//MTH	CDR0000458098//endocrine//NCI_NCI-GLOSS	0000037951//endocrine//CHV	0057755//ENDOCRINE//CCPSS	SKINENDO//ENDOCRINE//CST	C53801//ENDOCRINE//NCI_CTCAE
neurologic manifestations	N0000002173//Neurologic Manifestations [Disease/Finding]//NDFRT	D009461//Neurologic Manifestations//MSH	0000008643//neurologic manifestations//CHV
pulmonary	0000007565//lung//CHV	2612-7088//lung//CSP	54542-6//Pulmonary:-:Pt:^Patient:-//LNC	MFLUN//Pulmonary//AIR	XC0L5//Pulmonary//RCD	T-28000//Lung, NOS//SNMI	LP89785-7//Pulmonary//LNC	LP32264-1//Pulmonary//LNC	MTHU031874//Pulmonary//LNC	OMFAQ//Anemia//NCI	LA18283-4//Pulmonary//LNC	C13304//Pulmonary//NCI	264164005//Pulmonary//SNOMEDCT_US	CDR0000045852//pulmonary//NCI_NCI-GLOSS	0042932//PULMONARY//CCPSS
cancer	A79001//cancer//ICPC2P	U006339//Cancer//LCH	X78ef//Malignant tumour//RCD	M-8000/3//Neoplasm, malignant//SNM	M-80003//Neoplasm, malignant//SNMI	LP100805-3//Cancer//LNC	LP7106-0//Cancer//LNC	25//Cancer//MEDLINEPLUS	MTHU010328//Cancer//LNC	sh85019492//Cancer//LCH_NW	LA10524-9//Cancer//LNC	3262//Cancer//NCI_FDA	C9305//Cancer//NCI_NICHD	HP:0002664//Neoplasm//HPO	10007050//Cancer//MDR	01968//Cancer//NANDA-I	MTHU051589//Cancer//LNC	363346000//Malignant neoplastic disease//SNOMEDCT_US	D009369//Neoplasms//MSH	1001968//CANCER//CCPSS	CARCINOMA//CARCINOMA//CST	U000537//ENCEPHALITIS, SAINT LOUIS//DXP	0000004520//cancer//AOD	0000002337//cancer//CHV	CDR0000045333//cancer//NCI_NCI-GLOSS	CDR0000041060//cancer//PDQ	2000-0173//neoplasm/cancer//CSP	31465//cancer//MEDCIN	4103//reported family history of cancer//MEDCIN	6754//Cancer//NCBI	86049000//Neoplasm, malignant (primary)//SNOMEDCT_US	CAN//Cancel. Used to cancel a query//HL7V2.5	54532-7//Cancer:-:Pt:^Patient:-//LNC
physical therapy	MTHU030048//physical therapy//ICPC2ICD10ENG	722138006//Physiotherapy//SNOMEDCT_US	0000044521//physical therapy//CHV	16.26//Physical therapy//CCS	U003663//Physical therapy//LCH	LP6449-5//Physical therapy//LNC	LP98456-4//Physical therapy//LNC	MTHU035236//Physical therapy//LNC	sh85101568//Physical therapy//LCH_NW	10050334//Physical therapy//MDR	NOCODE//Developmental arithmetic disorder//MTH	522//Rehabilitation//MEDLINEPLUS	C15302//Physical Therapy//NCI_NICHD	38590//Physical Therapy//PSY	0000007923//physical therapy//AOD	1385-4813//physical therapy//CSP	CDR0000044708//physical therapy//NCI_NCI-GLOSS	A57003//physical therapy//ICPC2P	0000053447//physical therapy//CHV	0044460//PHYSICAL THERAPY//CCPSS	PT//Patient external identifier//HL7V2.5
renal anomalies	MTHU010000//Renal anomalies//OMIM	HP:0000077//Abnormality of the kidney//HPO
deafness	NOCODE//Sepsis//COSTAR	H86003//deafness//ICPC2P	U001277//Deafness//LCH	D003638//Deafness//MSH	XE0s9//Hearing loss//RCD	F-X6000//Deafness//SNM	MTHU002823//Deafness//OMIM	N0000000901//Deafness [Disease/Finding]//NDFRT	204//Hearing Disorders and Deafness//MEDLINEPLUS	3693//Hearing Problems in Children//MEDLINEPLUS	15188001//Deafness//SNOMEDCT_VET	sh85036068//Deafness//LCH_NW	C27644//Deafness//NCI_NICHD	1801//Deafness//NCI_FDA	HP:0000365//Hearing impairment//HPO	10011878//Deafness//MDR	H86//Deafness//ICPC2EENG	1003290//DEAFNESS//CCPSS	DEAF//DEAFNESS//CST	DA-95000//Deafness, NOS//SNMI	0258//DEAFNESS//WHO	0000006099//deafness//AOD	BI00646//deafness//BI	0977-5812//deafness//CSP	345//Hearing Loss, Partial//MTH	0000040635//complete hearing loss//CHV	0000003627//deafness//CHV	MTHU023796//deafness//ICPC2ICD10ENG	314703//deafness//MEDCIN	0000005856//partial hearing loss//CHV
5-1	
treatment follows routine practices	
speech therapy	NBC//Speech therapy//ALT	D013070//Speech Therapy//MSH	49190//Speech Therapy//PSY	NOCODE//Developmental arithmetic disorder//MTH	U004412//Speech therapy//LCH	8E21.//Speech and language therapy//RCD	P-8840//Speech therapy//SNM	LP6526-0//Speech therapy//LNC	sh85126455//Speech therapy//LCH_NW	10051217//Speech therapy//MDR	5154007//Speech therapy//SNOMEDCT_US	1579-3394//speech therapy//CSP	0000011578//speech and language therapy//CHV	48848//speech therapy//MEDCIN	Z50.5//Speech therapy//ICD10AM	MTHU069178//speech therapy//ICPC2ICD10ENG
some individuals require forearm crutches or canes for gait stability	
cardiac	T-32000//Heart, NOS//SNMI	C12727//Heart//NCI	0000002500//cardiac//AOD	BI00027//cardiovascular//BI	0000005865//heart//CHV	1390-0233//heart//CSP	0002824//CARDIAC//CCPSS	LA27421-9//Cardiac//LNC	C13306//Cardiac//NCI	CDR0000045634//cardiac//NCI_NCI-GLOSS
caregivers	610//Caregivers//MEDLINEPLUS	sh88007577//Caregivers//LCH_NW	07715//Caregivers//PSY	D017028//Caregivers//MSH	0000015637//caregiver//CHV
heart defects	198//Congenital Heart Defects//MEDLINEPLUS
psychotropic medication may also be indicated	
constipation	9.12.1//Constipation//CCS	K59.0//Constipation//ICD10	D12//Constipation//ICPC	D12001//constipation//ICPC2P	U001143//Constipation//LCH	10010774//Constipation//MDR	D003248//Constipation//MSH	020402//Constipation//NOC	PRB_01000.06//Constipation//PCDS	Q0200081//Constipation//QMR	XE0rD//Constipation//RCD	F-62350//Constipation//SNM	D5-44010//Constipation//SNMI	040416//Constipation//NOC	050110//Constipation//NOC	050005//Constipation//NOC	MTHU001907//Constipation//OMIM	10000567//Constipation//ICNP	N0000000841//Constipation [Disease/Finding]//NDFRT	B03.6//Constipation//CCC	200//Constipation//MEDLINEPLUS	MTHU020768//Constipation//LNC	sh85031314//Constipation//LCH_NW	E10562//Constipation//NCI_CTCAE	C37930//Constipation//NCI_NICHD	3274//Constipation//NCI_FDA	HP:0002019//Constipation//HPO	00011//Constipation//NANDA-I	00249//Risk for pressure ulcer//NANDA-I	LA22282-0//Constipation//LNC	14760008//Constipation//SNOMEDCT_US	11440//Constipation//PSY	564.0//Constipation//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1015408//CONSTIPATION//CCPSS	CONSTIP//CONSTIPATION//CST	U000845//HIRSCHSPRUNG DISEASE//DXP	0204//CONSTIPATION//WHO	0000005514//constipation//AOD	BI00230//constipation//BI	1248-3977//constipation//CSP	444//constipation//MEDCIN	0000003300//constipation//CHV	CDR0000407757//constipation//NCI_NCI-GLOSS	MTHU018925//constipation//ICPC2ICD10ENG	230057//constipation//MEDCIN	C57141//Constipation//NCI_CTCAE	MSAS-SF//Almost Constantly//NCI	MSAS//Dry mouth//NCI
antiepileptic drugs	03150//Antiepileptic Drugs//PSY	D000927//Anticonvulsants//MSH	0000001284//antiepileptics//CHV
musculoskeletal	LP89781-6//Musculoskeletal//LNC	MTHU031870//Musculoskeletal//LNC	LA16972-4//Musculoskeletal//LNC	C25348//Musculoskeletal//NCI	NOCODE//Developmental arithmetic disorder//MTH	0047159//MUSCULOSKELETAL//CCPSS	L//MUSCULOSKELETAL//ICPC	BI00516//musculoskeletal//BI	CDR0000044938//musculoskeletal//NCI_NCI-GLOSS	0000037430//musculoskeletal//CHV	54538-4//Musculoskeletal:-:Pt:^Patient:-//LNC
spasticity	PRB_17010.05//Spasticity//PCDS	X76qL//Spasticity//RCD	091107//Spasticity//NOC	MTHU000300//Spasticity//OMIM	C79750//Spasticity//NCI	1518//Neuromuscular Disorders//MEDLINEPLUS	sh85126342//Spasticity//LCH_NW	E12820//Spasticity//NCI_CTCAE	HP:0001257//Spasticity//HPO	10041416//Spasticity//MDR	397790002//Spasticity//SNOMEDCT_US	221360009//Spasticity//SNOMEDCT_US	U003757//SPASTICITY//DXP	0000008355//spasticity//CHV	8943//spasticity//MEDCIN
global developmental disability / intellectual disability educational issues	
private supportive therapies based on the affected individual’s needs	
medications	0000004159//drug//CHV	31//Medicines//MEDLINEPLUS	LA20271-5//Medications//LNC	MTHU008870//Medications//LNC	19789-7//Medications:Prid:Stdy:^Patient:Nom//LNC	52471-0//Medications:-:Pt:^Patient:-//LNC	MTHU854705//Medications//LNC	NOCODE//Developmental arithmetic disorder//MTH
0-3	
developmental	Xa0ts//Developmental//RCD	278923009//Developmental//SNOMEDCT_US	0000036759//developmental//CHV	C17770//Maturation//NCI
8-2	
gerd = gastroesophageal reflux disease	
hydrocephalus	G91//Hydrocephalus//ICD10	U002272//Hydrocephalus//LCH	10020508//Hydrocephalus//MDR	D006849//Hydrocephalus//MSH	X00EG//Hydrocephalus//RCD	M-33320//Hydrocephalus//SNM	MTHU002499//Hydrocephalus//OMIM	N0000001566//Hydrocephalus [Disease/Finding]//NDFRT	607//Hydrocephalus//MEDLINEPLUS	sh85063378//Hydrocephalus//LCH_NW	C3111//Hydrocephalus//NCI_NICHD	E12682//Hydrocephalus//NCI_CTCAE	3272//Hydrocephalus//NCI_FDA	HP:0000238//Hydrocephalus//HPO	230745008//Hydrocephalus//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0045789//HYDROCEPHALUS//CCPSS	U000361//HYDROCEPHALUS//COSTAR	HYDROCEPHALUS//HYDROCEPHALUS//CST	U002006//VIRAL MYOSITIS//DXP	0692//HYDROCEPHALUS//WHO	0000006135//hydrocephalus//AOD	0485-8483//hydrocephalus//CSP	0000006343//hydrocephalus//CHV	CDR0000045498//hydrocephalus//NCI_NCI-GLOSS	MTHU035873//hydrocephalus//ICPC2ICD10ENG	31969//hydrocephalus//MEDCIN	C55401//Hydrocephalus//NCI_CTCAE
adrenal insufficiency	C26691//Adrenocortical Insufficiency//NCI	N0000000326//Adrenal Insufficiency [Disease/Finding]//NDFRT	1233//Addison Disease//MEDLINEPLUS	D000309//Adrenal Insufficiency//MSH	1000462//ADRENAL INSUFFICIENCY//CCPSS	030//ADRENAL INSUFFICIENCY//COSTAR	ADREN INSUFFIC//ADRENAL CORTEX INSUFFIENCY//CST	U000092//ANEMIA, HEMOLYTIC, G6PD DEFICIENCY//DXP	0410//ADRENAL INSUFFICIENCY//WHO	C154.//Corticoadrenal insufficiency//RCD	MTHU008542//Adrenal insufficiency//OMIM	E10298//Adrenal insufficiency//NCI_CTCAE	HP:0000846//Adrenal insufficiency//HPO	10001367//Adrenal insufficiency//MDR	386584007//Adrenal cortical hypofunction//SNOMEDCT_US	BI00331//adrenal insufficiency//BI	0060-4666//hypoadrenalism//CSP	0000000766//adrenal insufficiency//CHV	T99003//adrenal insufficiency//ICPC2P	312629//adrenal insufficiency//MEDCIN	0000032628//adrenal insufficiency//CHV	C55748//Adrenal insufficiency//NCI_CTCAE
hypertension	7.1//Hypertension//CCS	K86005//hypertension//ICPC2P	U002317//Hypertension//LCH	005//Hypotension//MTH	PRB_11000.06//Hypertension//PCDS	XE0Ub//Hypertension//RCD	F-70700//Hypertension//SNM	050419//Hypertension//NOC	070808//Hypertension//NOC	MTHU002068//Hypertension//OMIM	N0000001616//Hypertension [Disease/Finding]//NDFRT	997.91//Hypertension//MTHICD9	34//High Blood Pressure//MEDLINEPLUS	MTHU020789//Hypertension//LNC	sh85063723//Hypertension//LCH_NW	E13785//Hypertension//NCI_CTCAE	LA7444-8//Hypertension//LNC	1908//Hypertension//NCI_FDA	C3117//Hypertension//NCI_NICHD	HP:0000822//Hypertension//HPO	10020772//Hypertension//MDR	00905//Hypertension//NANDA-I	38341003//Hypertensive disorder//SNOMEDCT_US	23830//Hypertension//PSY	D006973//Hypertension//MSH	1017493//HYPERTENSION//CCPSS	397//HYPERTENSION//COSTAR	CVHYPERT//HYPERTENSION//CST	HYPERTENS//HYPERTENSION//CST	U002034//YAWS//DXP	0210//HYPERTENSION//WHO	0000005280//hypertension//AOD	BI00001//hypertension//BI	0571-5243//hypertension//CSP	0000006443//high blood pressure disorder//CHV	MTHU036479//hypertension//ICPC2ICD10ENG	CDR0000044038//hypertension//NCI_NCI-GLOSS	C55060//Hypertension//NCI_CTCAE
liver disease	0025497//LIVER DISEASE//CCPSS	U000418//MOBITZ TYPE 2 SECOND DEGREE HEART BLOCK//COSTAR	U002405//LIVER DISEASE//DXP	D008107//Liver Diseases//MSH	C3196//Liver and Intrahepatic Bile Duct Disorder//NCI	9.8//Liver disease//CCS	X306R//Disorder of liver//RCD	OMFAQ//Anemia//NCI	HP:0001392//Abnormality of the liver//HPO	LA25810-5//Liver disease//LNC	235856003//Disease of liver//SNOMEDCT_US	D97002//liver disease//ICPC2P	0000007501//liver disease//CHV	3493//reported prior liver disease//MEDCIN
hepatic disease	310//Liver Diseases//MEDLINEPLUS	10019650//Hepatic disease//MDR	235856003//Hepatic disease//SNOMEDCT_VET	0353//HEPATOCELLULAR DAMAGE//WHO	0000007501//liver disease//CHV
pulmonary disease	N0000001879//Lung Diseases [Disease/Finding]//NDFRT	C3198//Lung Disorder//NCI	D008171//Lung Diseases//MSH	628//PULMONARY DISEASE//COSTAR	U003269//PULMONARY DISEASE//DXP	0000007568//lung disease//CHV	236576//pulmonary disease//MEDCIN	LP97125-6//Pulmonary disease//LNC	19829001//Disorder of lung//SNOMEDCT_US	3497//reported previous pulmonary disease//MEDCIN
renal manifestations	
hyperlipidemia	U002308//Hyperlipidemia//LCH	X40Wy//Hyperlipidemia//RCDAE	MTHU002043//Hyperlipidemia//OMIM	N0000001592//Hyperlipidemias [Disease/Finding]//NDFRT	4277//Triglycerides//MEDLINEPLUS	26//Cholesterol//MEDLINEPLUS	sh85063704//Hyperlipidemia//LCH_NW	HP:0003077//Hyperlipidemia//HPO	10020667//Hyperlipidemia//MDR	02489//Hyperlipidemia//NANDA-I	D006949//Hyperlipidemias//MSH	10062060//Hyperlipidaemia//MDR	55822004//Hyperlipidemia//SNOMEDCT_US	C34707//Hyperlipidemia//NCI	NOCODE//Developmental arithmetic disorder//MTH	1006712//HYPERLIPIDEMIA//CCPSS	395//HYPERLIPIDEMIA//COSTAR	HYPERLIPEM//HYPERLIPEMIA//CST	U002027//WISKOTT-ALDRICH SYNDROME//DXP	0000005732//hyperlipidemia//AOD	BI00109//hyperlipidemia//BI	1744-2444//hyperlipidemia//CSP	0000006419//excessive fat in the blood//CHV	T93008//hyperlipidaemia//ICPC2P	MTHU036253//hyperlipidemia//ICPC2ICD10ENG	214032//hyperlipidemia//MEDCIN	166816003//Hyperlipemia//SNOMEDCT_VET
bleeding	A10001//bleeding//ICPC2P	Xa9I7//Bleeding//RCD	M-37000//Hemorrhage//SNM	C26791//Hemorrhage//NCI	110018//Bleeding//NOC	040902//Bleeding//NOC	N0000001481//Hemorrhage [Disease/Finding]//NDFRT	6039//Bleeding//MEDLINEPLUS	LA7418-2//Bleeding//LNC	1888//Hemorrhage//NCI_FDA	10005103//Bleeding//MDR	00152//Risk for powerlessness//NANDA-I	MTHU053652//Bleeding//OMIM	131148009//Bleeding//SNOMEDCT_US	50960005//Hemorrhage//SNOMEDCT_US	D006470//Hemorrhage//MSH	110//BLEEDING//COSTAR	U000382//COLON, DIVERTICULOSIS//DXP	0000006008//bleeding//CHV	0571-4198//hemorrhage//CSP	MTHU034211//bleeding//ICPC2ICD10ENG	282941//bleeding//MEDCIN
dialysis	U001377//Dialysis//LCH	LP32538-8//Dialysis//LNC	LP20688-5//Dialysis//LNC	LP6226-7//Dialysis//LNC	MTHU026059//Dialysis//LNC	sh85037540//Dialysis//LCH_NW	D003956//Dialysis//MSH	0000001524//dialysis//AOD	2323-1315//dialysis//CSP	3789//Dialysis//MEDLINEPLUS	LA7216-0//Dialysis//LNC	10061105//Dialysis//MDR	14020//Dialysis//PSY	C15221//Dialysis//NCI	0000052369//dialysis//CHV	0000003858//dialysis//CHV	CDR0000045485//dialysis//NCI_NCI-GLOSS	CDR0000042471//dialysis//PDQ	MTHU022883//dialysis//ICPC2ICD10ENG	41810//dialysis//MEDCIN	1015724//DIALYSIS//CCPSS	124307//Dialysis//NCBI	NOCODE//administration devices//MMSL
surgical stabilization of the spine may be required	
pectus excavatum can be severe	
optic atrophy	NOCODE//Sepsis//COSTAR	D009896//Optic Atrophy//MSH	N0000002226//Optic Atrophy [Disease/Finding]//NDFRT	C34863//Optic Atrophy//NCI	0047751//OPTIC ATROPHY//CCPSS	ATROPHY OPTIC//OPTIC ATROPHY//CST	0135//OPTIC ATROPHY//WHO	H47.2//Optic atrophy//ICD10	10030910//Optic atrophy//MDR	F4H1.//Optic atrophy//RCD	M-58000//Atrophy//SNM	MTHU036360//Optic atrophy//OMIM	HP:0000648//Optic atrophy//HPO	377.1//Optic atrophy//ICD9CM	76976005//Optic atrophy//SNOMEDCT_US	2042-6601//optic nerve disorder//CSP	0000008978//optic atrophy//CHV	36835//optic atrophy//MEDCIN
appropriate treatment includes the following:	
diabetes mellitus	D003920//diabetes mellitus//MSHCZE	10012601//Diabetes mellitus//MDRCZE	T90//Diabetes mellitus//ICPCDAN	U000263//Brassica napus//MTH	N0000000950//Diabetes Mellitus [Disease/Finding]//NDFRT	4//Diabetes//MEDLINEPLUS	45//Diabetes Mellitus//MEDLINEPLUS	TCGA//Enterovirus//NCI	C2985//Diabetes Mellitus//NCI_NICHD	13970//Diabetes Mellitus//PSY	NOCODE//Developmental arithmetic disorder//MTH	1018264//DIABETES MELLITUS//CCPSS	230//DIABETES MELLITUS//COSTAR	DIABETES MELL//DIABETES MELLITUS//CST	U000960//JAUNDICE, OBSTRUCTIVE//DXP	R0121582//DIABETES MELLITUS//QMR	0371//DIABETES MELLITUS//WHO	DIABT//Diabetes mellitus//AIR	E10-E14.9//Diabetes mellitus//ICD10	T90002//diabetes mellitus//ICPC2P	C10..//Diabetes mellitus//RCD	D-2381//Diabetes mellitus//SNM	MTHU036798//Diabetes mellitus//OMIM	MTHU020781//Diabetes mellitus//LNC	LA14291-1//Diabetes mellitus//LNC	HP:0000819//Diabetes mellitus//HPO	00385//Diabetes mellitus//NANDA-I	250//Diabetes mellitus//ICD9CM	73211009//Diabetes mellitus//SNOMEDCT_US	0000005999//diabetes mellitus//AOD	BI00008//diabetes mellitus//BI	0862-6160//diabetes mellitus//CSP	0000003834//diabetes//CHV	CDR0000044129//diabetes mellitus//NCI_NCI-GLOSS	30479//diabetes mellitus//MEDCIN
for ages 0-3 years	
for ages 3-5 years	
for ages 5-21 years	
for all ages	
social/behavioral difficulties	
05-0	
weight control to avoid obesity	
feeding difficulties	MTHU001721//Feeding difficulties//OMIM	R63.3//Feeding difficulties//ICD10CM	338368//Feeding difficulties//MEDCIN	HP:0011968//Feeding difficulties//HPO	NOCODE//Developmental arithmetic disorder//MTH	0000022945//feeding problems//CHV
osteopenia	D001851//Choroby kości metaboliczne//MSHPOL	L95002//osteopenia//ICPC2P	10049088//Osteopenia//MDR	XaE5D//Osteopenia//RCD	M-59180//Osteopenia//SNM	M-59070//Osteopenia//SNMI	C50910//Osteopenia//NCI	MTHU000031//Osteopenia//OMIM	5935//Bone Density//MEDLINEPLUS	sh85095982//Osteopenia//LCH_NW	2651//Osteopenia//NCI_FDA	HP:0000938//Osteopenia//HPO	312894000//Osteopenia//SNOMEDCT_US	78441005//Osteopenia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0045116//OSTEOPENIA//CCPSS	0000005166//osteopenia//AOD	4001-0098//osteopenia//CSP	0000009092//bone loss//CHV	CDR0000538637//osteopenia//NCI_NCI-GLOSS	32589//osteopenia//MEDCIN
management is supportive	
development	13_2//Development//NANDA-I	Q000254//growth & development//MSH	C17770//Maturation//NCI	C18732//Development//NCI	GO:0032502//developmental process//GO	C84377//Development//NCI	13830//Development//PSY	NOCODE//Developmental arithmetic disorder//MTH	C96110//Development//NCI_FDA
exocrine pancreatic insufficiency	D5-90550//Exocrine pancreatic insufficiency//SNMI	MTHU010290//Exocrine pancreatic insufficiency//OMIM	HP:0001738//Exocrine pancreatic insufficiency//HPO	K86.81//Exocrine pancreatic insufficiency//ICD10CM	363695//Exocrine pancreatic insufficiency//MEDCIN	47367009//Exocrine pancreatic insufficiency//SNOMEDCT_US	U000150//Exocrine pancreatic insufficiency//MTH	C84316//Pancreatic Insufficiency//NCI	N0000011093//Exocrine Pancreatic Insufficiency [Disease/Finding]//NDFRT	D010188//Exocrine Pancreatic Insufficiency//MSH
anemia	4.1//Anemia//CCS	U000235//Anemia//LCH	D000740//Anemia//MSH	U000161//Anemia//MTH	U000164//Poisoning by antiviral drug//MTH	XM05A//Anemia//RCDAE	D-4010//Anemia//SNM	050423//Anemia//NOC	MTHU002606//Anemia//OMIM	N0000000384//Anemia [Disease/Finding]//NDFRT	139//Anemia//MEDLINEPLUS	MTHU020823//Anemia//LNC	sh85004940//Anemia//LCH_NW	OMFAQ//Anemia//NCI	E10010//Anemia//NCI_CTCAE	C2869//Anemia//NCI_NICHD	LA18969-8//Anemia//LNC	1706//Anemia//NCI_FDA	HP:0001903//Anemia//HPO	10002272//Anemia//MDR	01904//Anemia//NANDA-I	10002034//Anaemia//MDR	271737000//Anemia//SNOMEDCT_US	02450//Anemia//PSY	NOCODE//Developmental arithmetic disorder//MTH	1017210//ANEMIA//CCPSS	051//ANEMIA//COSTAR	ANEMIA//ANEMIA//CST	U000172//ATAXIA, CEREBELLAR, ACUTE//DXP	0000005870//anemia//AOD	BI00026//anemia//BI	0427-0313//anemia//CSP	30.06//anemia//OMS	0000001118//anemia//CHV	CDR0000045360//anemia//NCI_NCI-GLOSS	CDR0000041382//anemia//PDQ	MTHU005706//anemia//ICPC2ICD10ENG	B82005//anaemia//ICPC2P	30320//anemia//MEDCIN	0544//ANEMIA//WHOPOR	12939//Anemia//NCBI
malignancy	MALIG//Malignancy//AIR	M-8000/3//Neoplasm, malignant//SNM	M-80003//Neoplasm, malignant//SNMI	LP20701-6//Malignancy//LNC	LP128794-7//Malignancy//LNC	25//Cancer//MEDLINEPLUS	MTHU040703//Malignancy//LNC	C9305//Cancer//NCI_NICHD	02867//Malignancy//NANDA-I	D009369//Neoplasms//MSH	1017904//MALIGNANCY//CCPSS	RETICMALIG//MALIGNANCY//CST	465//MALIGNANCY//COSTAR	CDR0000045771//malignancy//NCI_NCI-GLOSS	BB02.//Malignant tumour morphology//RCD	86049000//Neoplasm, malignant (primary)//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH
exercise within the individual's capability	
fewer than 5% need wheelchairs	
symptomatic treatment	
5-0	
0 g/m2	
audiologic	
fitting with appropriate hearing aids	
enrollment in an appropriate educational program for the hearing impaired	
growth hormone deficiency	10056438//Growth hormone deficiency//MDR	Xa9Ap//Growth hormone deficiency//RCD	MTHU004822//Growth hormone deficiency//OMIM	397827003//Growth hormone deficiency//SNOMEDCT_US	2715-1517//pituitary dwarfism//CSP	0000026643//growth hormone deficiency//CHV	HP:0000824//Growth hormone deficiency//HPO	C112835//Growth Hormone Deficiency//NCI_NICHD	34030//growth hormone deficiency//MEDCIN
tolerance to different primary layers varies	
nonstick products (e	
silicone-based products without adhesive (e	
rolls of gauze (e	
cleft palate	NOCODE//Sepsis//COSTAR	D002972//Cleft Palate//MSH	C87069//Cleft Palate//NCI	N0000000793//Cleft Palate [Disease/Finding]//NDFRT	191//Cleft Lip and Palate//MEDLINEPLUS	09480//Cleft Palate//PSY	CLEFT PALATE//CLEFT PALATE//CST	U000774//HEART FAILURE, HIGH OUTPUT//DXP	0680//CLEFT PALATE//WHO	Q35//Cleft palate//ICD10	U001048//Cleft palate//LCH	10009269//Cleft palate//MDR	P90..//Cleft palate//RCD	MTHU000511//Cleft palate//OMIM	sh85026926//Cleft palate//LCH_NW	LA14412-3//Cleft palate//LNC	02033//Cleft palate//NANDA-I	749.0//Cleft palate//ICD9CM	87979003//Cleft palate//SNOMEDCT_US	0000004973//cleft palate//AOD	0725-9049//cleft palate//CSP	0000003027//cleft palate//CHV	30403//cleft palate//MEDCIN	119540//CLEFT PALATE, ISOLATED//OMIM	6826//cleft palate on exam//MEDCIN	M-21510//Congenital fissure//SNM	HP:0000175//Cleft palate//HPO
table 5	
neutropenia	LEUKOPENIA//LEUKOPENIA//CST	NOCODE//Sepsis//COSTAR	B84008//neutropenia//ICPC2P	10029354//Neutropenia//MDR	D009503//Neutropenia//MSH	M-59100//Cytopenia//SNM	288.0//Neutropenia//ICD9CM	D70//Neutropenia//ICD10CM	N0000002182//Neutropenia [Disease/Finding]//NDFRT	0045739//NEUTROPENIA//CCPSS	U002790//NEUTROPENIA//DXP	0572//GRANULOCYTOPENIA//WHO	BI00317//neutropenia//BI	5000-0035//neutropenia//CSP	0000008679//neutropenia//CHV	CDR0000041387//neutropenia//PDQ	MTHU052896//neutropenia//ICPC2ICD10ENG	30301//neutropenia//MEDCIN	42J2.//Neutropenia//RCD	MTHU001686//Neutropenia//OMIM	C80520//Neutropenia//NCI	HP:0001875//Neutropenia//HPO	165517008//Neutropenia//SNOMEDCT_US	CDR0000045361//neutropenia//NCI_NCI-GLOSS
physical therapy is recommended to maximize mobility	
no specific treatment is available	
prevention of secondary manifestations	
ketogenic diet	D055423//Diet, Ketogenic//MSH	NOCODE//Developmental arithmetic disorder//MTH	U005709//Ketogenic diet//LCH	Ub02Z//Ketogenic diet//RCD	C-F2730//Ketogenic diet//SNMI	10073855//Ketogenic diet//MDR	sh85072093//Ketogenic diet//LCH_NW	226108007//Ketogenic diet//SNOMEDCT_US	0000025270//ketogenic diet//CHV
7-2	
pediatric issues	
liver	U002724//Liver//LCH	D008099//Liver//MSH	U000466//Liver//SNM	T-56000//Liver//SNM	7197//Liver//UWDA	MTHU000220//Liver//OMIM	LP29289-3//Liver//LNC	LP7400-7//Liver//LNC	MTHU002039//Liver//LNC	sh85077748//Liver//LCH_NW	TCGA//Enterovirus//NCI	LA4584-4//Liver//LNC	LP199933-5//Liver//LNC	10200004//Liver structure//SNOMEDCT_US	28620//Liver//PSY	C12392//Liver//NCI	LIVER//Liver//HL7V2.5	U002051//Liver//MTH	0050526//LIVER//CCPSS	T-62000//Liver, NOS//SNMI	0000002569//liver//AOD	1754-0095//liver//CSP	CDR0000046312//liver//NCI_NCI-GLOSS	0000007494//liver//CHV	N0000145839//LIVER//NDFRT	4017451//LIVER//VANDF	NOCODE//administration devices//MMSL	0000045892//Liver brand//CHV	14013//Liver//MMSL	7N330//Liver//RCD	C73399//LIVER//NCI_FDA
sodium benzoate	C66541//Sodium Benzoate//NCI	5206//LVP solution Ringers Injection intravenous solution//MMSL	56455//Sodium Benzoate//RXNORM	N0000006712//Sodium Benzoate [Chemical/Ingredient]//NDFRT	OJ245FE5EU//Sodium Benzoate//MTHSPL	D020160//Sodium Benzoate//MSH	d03096//sodium benzoate//MMSL	5472//beta-carotene 25000 units oral capsule//MMSL	0000016501//sodium benzoate//CHV	001243//POTASSIUM ACETATE MISCELL GRANULES (GRAM)//NDDF	003194//ESTRADIOL CYPIONATE 1 mg/mL INTRAMUSC VIAL (ML)//NDDF	A16AX11//sodium benzoate//ATC	U005211//Sodium benzoate//LCH	X79Ed//Sodium benzoate//RCD	LP62281-8//Sodium benzoate//LNC	sh85124256//Sodium benzoate//LCH_NW	398718007//Sodium benzoate//SNOMEDCT_US	125706008//Sodium benzoate//SNOMEDCT_US	N0000146158//SODIUM BENZOATE//NDFRT	4017797//SODIUM BENZOATE//VANDF
table 4	
orthopedic	D009985//Orthopedics//MSH	LP100610-7//Orthopedic//LNC	C16942//Orthopedics//NCI	0000009051//orthopedic surgery//CHV
supportive therapy includes the following:	
use of respiratory aids when indicated	
genitourinary abnormalities	N0000003083//Urogenital Abnormalities [Disease/Finding]//NDFRT	D014564//Urogenital Abnormalities//MSH
epilepsy	6.4.1//Epilepsy//CCS	G40//Epilepsy//ICD10	N88006//epilepsy//ICPC2P	U001630//Epilepsy//LCH	D004827//Epilepsy//MSH	F25..//Epilepsy//RCD	F-87000//Seizure//SNM	MTHU022799//Epilepsy//OMIM	N0000001126//Epilepsy [Disease/Finding]//NDFRT	244//Epilepsy//MEDLINEPLUS	MTHU020586//Epilepsy//LNC	sh85044401//Epilepsy//LCH_NW	C3020//Epilepsy//NCI_NICHD	OMFAQ//Anemia//NCI	LA16985-6//Epilepsy//LNC	HP:0001250//Seizures//HPO	10015037//Epilepsy//MDR	LP248725-6//Epilepsy//LNC	84757009//Epilepsy//SNOMEDCT_US	N88//Epilepsy//ICPC2EENG	17680//Epilepsy//PSY	NOCODE//Developmental arithmetic disorder//MTH	283//EPILEPSY//COSTAR	CONVULS//CONVULSION//CST	U001142//MEASLES//DXP	0093//CONVULSIONS//WHO	0000006149//epilepsy//AOD	BI00559//seizure disorder//BI	0485-6986//epilepsy//CSP	0000004556//epilepsy//CHV	CDR0000044028//epilepsy//NCI_NCI-GLOSS	MTHU026633//epilepsy//ICPC2ICD10ENG	313582//epilepsy//MEDCIN
see hereditary hearing loss and deafness	
supportive and symptomatic management is indicated	
9-2	
2(1	
0(1	
5-2	
7-4	
surgery	sh85130766//Surgery//LCH_NW	TCGA//Enterovirus//NCI	C17173//Surgery//NCI	SUR//Summary product experience report//HL7V2.5	426//Surgery//MEDLINEPLUS	Q000601//surgery//MSH	U004538//Surgery//LCH	X79q6//Surgery//RCD	LP97910-1//Surgery//LNC	LP32925-7//Surgery//LNC	LP173473-2//Surgery//LNC	MTHU007597//Surgery//LNC	1003143//Surgery//CPT	LA14620-1//Surgery//LNC	10042609//Surgery//MDR	MTHU051579//Surgery//LNC	MTHU854701//Surgery//LNC	50790//Surgery//PSY	C15329//Surgical Procedure//NCI	257556004//Surgery//SNOMEDCT_US	2846-3981//surgery//CSP	0000038661//surgery//CHV	CDR0000045570//surgery//NCI_NCI-GLOSS	CDR0000042869//surgery//PDQ	41559//surgery//MEDCIN	0038373//SURGERY//CCPSS	D013502//General Surgery//MSH	MTHU055642//surgery//ICPC2ICD10ENG	S//Stat (do immediately)//HL7V2.5	C49611//SG//NCI_CDISC
dysphagia	D003680//Slikaandoening//MSHDUT	9.12.2//Dysphagia//CCS	R13//Dysphagia//ICD10	D21004//dysphagia//ICPC2P	10013950//Dysphagia//MDR	MT160004//Dysphagia//MTHMST	XM08J//Dysphagia//RCD	F-61020//Dysphagia//SNM	787.2//Dysphagia//ICD9CM	R13.1//Dysphagia//ICD10CM	N0000000910//Deglutition Disorders [Disease/Finding]//NDFRT	1309//Swallowing Disorders//MEDLINEPLUS	MTHU036443//Dysphagia//OMIM	E10621//Dysphagia//NCI_CTCAE	C2980//Dysphagia//NCI_NICHD	1815//Dysphagia//NCI_FDA	HP:0002015//Dysphagia//HPO	40739000//Dysphagia//SNOMEDCT_US	15654//Dysphagia//PSY	1014574//DYSPHAGIA//CCPSS	265//DYSPHAGIA//COSTAR	DYSPHAGIA//DYSPHAGIA//CST	U001012//LARYNX, CARCINOMA, INTRINSIC//DXP	0280//DYSPHAGIA//WHO	0000005507//dysphagia//AOD	BI00239//dysphagia//BI	5000-0052//dysphagia//CSP	CDR0000524080//dysphagia//PDQ	399//difficulty swallowing//MEDCIN	0000003662//swallowing difficulty//CHV	CDR0000044666//dysphagia//NCI_NCI-GLOSS	MTHU024378//dysphagia//ICPC2ICD10ENG	312702//dysphagia//MEDCIN
vision	U004965//Vision//LCH	091302//Vision//NOC	F-X0000//Visual function//SNM	20//Vision//OMS	C38533//Sight//NCI	LP30560-4//Vision//LNC	MTHU014733//Vision//LNC	sh85143872//Vision//LCH_NW	D014785//Vision, Ocular//MSH	MTHU051591//Vision//LNC	55820//Vision//PSY	NOCODE//Developmental arithmetic disorder//MTH	0034996//VISION//CCPSS	F-F0000//Vision, NOS//SNMI	0000002747//vision//AOD	1113-5071//vision//CSP	GO:0007601//visual perception//GO	0000013030//vision//CHV	54543-4//Vision:-:Pt:^Patient:-//LNC	562//Vision//SOP
hypogonadism	T99032//hypogonadism//ICPC2P	U002330//Hypogonadism//LCH	10058359//Hypogonadism//MDR	D007006//Hypogonadism//MSH	X40Ov//Hypogonadism//RCD	C9227//Hypogonadism//NCI	MTHU000132//Hypogonadism//OMIM	N0000001636//Hypogonadism [Disease/Finding]//NDFRT	sh85063790//Hypogonadism//LCH_NW	HP:0000135//Hypogonadism//HPO	48130008//Hypogonadism//SNOMEDCT_US	24000//Hypogonadism//PSY	NOCODE//Developmental arithmetic disorder//MTH	1013140//HYPOGONADISM//CCPSS	U000373//HYPOGONADISM//COSTAR	U002049//HYPOGONADISM//DXP	0000005865//hypogonadism//AOD	2586-8835//hypogonadism//CSP	0000006477//hypogonadism//CHV	30700//hypogonadism//MEDCIN
care by a pediatric endocrinologist is recommended	
standard management	
craniosynostosis	Q75.0//Craniosynostosis//ICD10	10049889//Craniosynostosis//MDR	XE1Lz//Craniosynostosis//RCD	M-22650//Congenital ossification of sutures//SNM	D4-00C00//Craniosynostosis syndrome//SNMI	MTHU002205//Craniosynostosis//OMIM	C84655//Craniosynostosis//NCI	N0000000870//Craniosynostoses [Disease/Finding]//NDFRT	5757//Craniofacial Abnormalities//MEDLINEPLUS	HP:0001363//Craniosynostosis//HPO	D003398//Craniosynostoses//MSH	57219006//Craniosynostosis syndrome//SNOMEDCT_US	756.0//Craniosynostosis//MTHICD9	N85006//craniosynostosis//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	U000901//HYPOGLYCEMIA, REACTIVE FUNCTIONAL//DXP	0726-0275//craniosynostosis//CSP	0000003432//craniosynostosis//CHV	MTHU019901//craniosynostosis//ICPC2ICD10ENG	37675//craniosynostosis//MEDCIN
org)	
obesity	3.11.2//Obesity//CCS	E66//Obesity//ICD10	U003312//Obesity//LCH	10029883//Obesity//MDR	D009765//Obesity//MSH	545//Obesity//MTH	C380.//Obesity//RCD	M-71800//Obesity//SNM	MTHU000250//Obesity//OMIM	N0000002200//Obesity [Disease/Finding]//NDFRT	61//Obesity//MEDLINEPLUS	sh85093646//Obesity//LCH_NW	E12361//Obesity//NCI_CTCAE	LA6301-1//Obesity//LNC	HP:0001513//Obesity//HPO	00232//Obesity//NANDA-I	02972//Obesity//NANDA-I	T82//Obesity//ICPC2EENG	34780//Obesity//PSY	C3283//Obesity//NCI	414916001//Obesity//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1003545//OBESITY//CCPSS	529//OBESITY//COSTAR	OBESITY//OBESITY//CST	U002906//OBESITY//DXP	R0121694//OBESITY//QMR	0397//OBESITY//WHO	155541//MELANOCORTIN 4 RECEPTOR//OMIM	601665//OBESITY//OMIM	0000004374//obesity//AOD	BI00002//obesity//BI	0467-3154//obesity//CSP	CDR0000467910//obesity//PDQ	0000008861//obesity//CHV	CDR0000527371//obesity//NCI_NCI-GLOSS	MTHU053527//obesity//ICPC2ICD10ENG	33649//obesity//MEDCIN	C55334//Obesity//NCI_CTCAE
obstructive sleep apnea	X0084//Obstructive sleep apnea//RCDAE	MTHU001467//Obstructive sleep apnea//OMIM	HP:0002870//Obstructive sleep apnea//HPO	78275009//Obstructive sleep apnea syndrome//SNOMEDCT_US	0000037771//obstructive sleep apnea//CHV	4003-0054//sleep apnea//CSP	270273//obstructive sleep apnea//MEDCIN	N0000004021//Sleep Apnea, Obstructive [Disease/Finding]//NDFRT	C116337//Obstructive Sleep Apnea//NCI	D020181//Sleep Apnea, Obstructive//MSH
ocular	C12401//Eye//NCI	0000004810//eye//CHV	C38533//Sight//NCI	371398005//Ocular//SNOMEDCT_VET	T-AA000//Eye, NOS//SNMI	C87163//Ocular//NCI	0045304//OCULAR//CCPSS
cleft lip/palate	D81005//cleft lip/palate//ICPC2P	MTHU015010//Cleft lip/palate//OMIM	HP:0000202//Oral cleft//HPO
chronic treatment	
hypogonadotropic hypogonadism	C34752//Klinefelter Syndrome//NCI	226//chromosome XXY syndrome//JABL	0000007121//klinefelter's syndrome//CHV	DB-12710//Hypogonadotropic hypogonadism//SNMI	MTHU004823//Hypogonadotropic hypogonadism//OMIM	E23.0//Hypopituitarism//ICD10CM	33927004//Hypogonadotropic hypogonadism//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000026650//hypogonadotropic hypogonadism//CHV	C113347//Hypogonadotropic Hypogonadism//NCI	D007006//Hypogonadism//MSH
other treatments	
movement disorder	0042860//MOVEMENT DISORDER//CCPSS	MOVEMENT DIS//MOVEMENT DISORDER//CST	NOCODE//Sepsis//COSTAR	D009069//Movement Disorders//MSH	C116757//Movement Disorder//NCI	2057-3596//neuromuscular disorder//CSP	2057-3603//degenerative motor system disease//CSP	0000008293//movement disorders//CHV	276423//movement disorder//MEDCIN	MTHU044333//Movement disorder//OMIM	HP:0100022//Abnormality of movement//HPO	10028035//Movement disorder//MDR	60342002//Movement disorder//SNOMEDCT_US
lung disease	D008171//Lung Diseases//MSH	LA10531-4//Lung Disease//LNC	0027432//LUNG DISEASE//CCPSS	10051054//Lung disease//MDR	HP:0002088//Abnormality of lung morphology//HPO	0000007568//lung disease//CHV	R99024//lung disease//ICPC2P	236576//pulmonary disease//MEDCIN
no definitive treatments for the limb-girdle muscular dystrophies exist	
thrombocytopenia	4.2.2//Thrombocytopenia//CCS	U004668//Thrombocytopenia//LCH	10043554//Thrombocytopenia//MDR	D013921//Thrombocytopenia//MSH	XE24o//Thrombocytopenia//RCD	M-59100//Cytopenia//SNM	MTHU000212//Thrombocytopenia//OMIM	N0000002932//Thrombocytopenia [Disease/Finding]//NDFRT	5218//Platelet Disorders//MEDLINEPLUS	sh85135069//Thrombocytopenia//LCH_NW	C3408//Thrombocytopenia//NCI_NICHD	HP:0001873//Thrombocytopenia//HPO	302215000//Thrombocytopenic disorder//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1015045//THROMBOCYTOPENIA//CCPSS	731//THROMBOCYTOPENIA//COSTAR	THROMBOCYTOPENIA//THROMBOCYTOPENIA//CST	U004003//THROMBOCYTOPENIA//DXP	0594//THROMBOCYTOPENIA//WHO	0000005934//thrombocytopenia//AOD	BI00327//thrombocytopenia//BI	0446-5652//thrombocytopenia//CSP	U000208//Musculosketally mobile//MTH	0000012221//reduced platelet count//CHV	CDR0000045365//thrombocytopenia//NCI_NCI-GLOSS	CDR0000041408//thrombocytopenia//PDQ	MTHU075511//thrombocytopenia//ICPC2ICD10ENG	B83012//thrombocytopaenia//ICPC2P	30298//thrombocytopenia//MEDCIN
reducing the risk of neurologic damage	
see deafness and hereditary hearing loss overview, management	
immunodeficiency	MTHU007447//Immunodeficiency//OMIM	HP:0002721//Immunodeficiency//HPO	10061598//Immunodeficiency//MDR	C39725//Immunodeficiency//NCI_NICHD	02515//Immunodeficiency//NANDA-I	MTHU054768//Immunodeficiency//LNC	LP231628-1//Immunodeficiency//LNC	234532001//Immunodeficiency disorder//SNOMEDCT_US	0000004832//immunodeficiency//AOD	1560-5885//immunodeficiency//CSP	0000006602//immunodeficiency syndrome//CHV	CDR0000046357//immunodeficiency//NCI_NCI-GLOSS	MTHU037620//immunodeficiency//ICPC2ICD10ENG	C3131//Immunodeficiency Syndrome//NCI	1007151//IMMUNODEFICIENCY//CCPSS	82757-6//Immunodeficiency:Type:Pt:^Patient:Nom//LNC
some symptoms (e	
bone marrow transplantation	D016026//Bone Marrow Transplantation//MSH	1457//Bone Marrow Transplantation//MEDLINEPLUS	TCGA//Enterovirus//NCI	C15194//Bone Marrow Transplantation//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	P-1429//Transplantation, allogeneic//SNM	0432-1339//bone marrow transplantation//CSP	0000002077//bone marrow transplant (BMT)//CHV	CDR0000045263//bone marrow transplantation//NCI_NCI-GLOSS	CDR0000039793//bone marrow transplantation//PDQ
symptoms typically resolve within days	
bone marrow transplantation (bmt)	
education of parents regarding common seizure presentations is appropriate	
, contractures, scoliosis, hip dislocation)	
parkinsonism	N87//Parkinsonism//ICPC	N87003//parkinsonism//ICPC2P	10034010//Parkinsonism//MDR	X003Z//Disorders presenting primarily with parkinsonism//RCD	D-8450//Paralysis agitans//SNM	MTHU000764//Parkinsonism//OMIM	N0000004168//Parkinsonian Disorders [Disease/Finding]//NDFRT	C116922//Parkinsonism//NCI	HP:0001300//Parkinsonism//HPO	32798002//Parkinsonism//SNOMEDCT_US	36715//Parkinsonism//PSY	D020734//Parkinsonian Disorders//MSH	U000510//PARKINSONISM//COSTAR	EXTRAPYR SYND//EXTRAPYRAMIDAL SYNDROME//CST	U003023//PARKINSONISM//DXP	0106//EXTRAPYRAMIDAL DISORDER//WHO	BI00554//parkinson's disease//BI	0000024819//parkinsonism//CHV	MTHU057914//parkinsonism//ICPC2ICD10ENG	312997//parkinsonism//MEDCIN
other features	
ovarian insufficiency	C113351//Ovarian Failure//NCI	5804//Ovarian Disorders//MEDLINEPLUS	3684//Premature Ovarian Failure//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH
infertility	U002427//Infertility//LCH	D007246//Infertility//MSH	Q0200152//Infertility//QMR	X76Lv//Infertility//RCD	F-30710//Infertility//SNM	MTHU006969//Infertility//OMIM	N0000001684//Infertility [Disease/Finding]//NDFRT	250//Infertility//MEDLINEPLUS	8619003//Infertility//SNOMEDCT_VET	sh85066087//Infertility//LCH_NW	HP:0000789//Infertility//HPO	10021926//Infertility//MDR	25210//Infertility//PSY	C3836//Infertility//NCI	NOCODE//Developmental arithmetic disorder//MTH	1007691//INFERTILITY//CCPSS	416//INFERTILITY//COSTAR	U002093//INFERTILITY//DXP	0000005861//infertility//AOD	BI00389//infertility//BI	1138-0208//fertility//CSP	47.06//infertility//OMS	1085//inability to conceive//MEDCIN	0000006699//infertility//CHV	CDR0000046348//infertility//NCI_NCI-GLOSS	CDR0000040782//fertility assessment/management//PDQ	283389//infertility//MEDCIN
cardiac defects are managed in a routine manner	
the following are recommended:	
precocious puberty	C79704//Precocious Puberty//NCI	N0000002535//Puberty, Precocious [Disease/Finding]//NDFRT	D011629//Puberty, Precocious//MSH	NOCODE//Developmental arithmetic disorder//MTH	E30.1//Precocious puberty//ICD10	10058084//Precocious puberty//MDR	XE10t//Precocious puberty//RCD	F-96410//Precocious puberty//SNM	MTHU037101//Precocious puberty//OMIM	sh89003319//Precocious puberty//LCH_NW	E10340//Precocious puberty//NCI_CTCAE	HP:0000826//Precocious puberty//HPO	400179000//Precocious puberty//SNOMEDCT_US	0000005969//precocious puberty//AOD	2586-8869//precocious puberty//CSP	0000010360//precocious puberty//CHV	T99051//precocious puberty//ICPC2P	30589//precocious puberty//MEDCIN
physical therapy and rehabilitation to improve motor function	
they can tolerate carbohydrates, fats, and protein	
oral motor dysfunction with persistent vomiting	
consultation with a gastroenterologist and nutritionist is often necessary	
"infantile catastrophic phase	
strabismus	D013285//strabismus//MSHCZE	10042159//Strabismus//MDRCZE	F95//Strabismus//ICPCDUT	F95002//strabismus//ICPC2P	U004482//Strabismus//LCH	X75dL//Ocular dissociation//RCD	Xa9Bh//Disorder of binocular eye movements//RCD	F-X1320//Strabismus//SNM	MTHU000389//Strabismus//OMIM	N0000002836//Strabismus [Disease/Finding]//NDFRT	5873//Eye Movement Disorders//MEDLINEPLUS	sh85128443//Strabismus//LCH_NW	C35040//Strabismus//NCI_NICHD	HP:0000486//Strabismus//HPO	MTHU051221//Strabismus//LNC	LP200651-0//Strabismus//LNC	22066006//Strabismus//SNOMEDCT_US	50140//Strabismus//PSY	NOCODE//Developmental arithmetic disorder//MTH	1004827//STRABISMUS//CCPSS	704//STRABISMUS//COSTAR	STRABISMUS//STRABISMUS//CST	U003832//STRABISMUS//DXP	0256//STRABISMUS//WHO	BI00859//strabismus//BI	1115-2310//eye coordination disorder//CSP	0000011750//crossed eye//CHV	MTHU070561//strabismus//ICPC2ICD10ENG	30753//strabismus//MEDCIN	HGNC:15511//VANGL planar cell polarity protein 2//HGNC	6547//strabismus on exam//MEDCIN	LA16300-8//Strabismus//LNC
stroke-like episodes	MTHU013464//Stroke-like episodes//OMIM	HP:0002401//Stroke-like episode//HPO
coagulopathy	10009802//Coagulopathy//MDR	D30..//Coagulation disorder//RCD	D-4400//Blood coagulation disorder, disease or syndrome//SNM	MTHU008649//Coagulopathy//OMIM	1779//Coagulopathy//NCI_FDA	HP:0003256//Abnormality of the coagulation cascade//HPO	C2902//Coagulation Disorder//NCI_NICHD	64779008//Blood coagulation disorder//SNOMEDCT_US	0027739//COAGULOPATHY//CCPSS	U000185//DEVIATED NASAL SEPTUM//COSTAR	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0000005929//coagulopathy//AOD	0000001990//bleeding tendency//CHV	MTHU017004//coagulopathy//ICPC2ICD10ENG
deep venous thrombosis (dvt)	
independent living issues	
0-2	
ocular manifestations	
aeruginosa in airway cultures	
bronchodilator	2599-2967//bronchodilator//CSP	CDR0000476099//bronchodilator//NCI_NCI-GLOSS	0000002190//bronchodilator//CHV	Xa7kI//Bronchodilator//RCD	LP31460-6//Bronchodilator//LNC	TCGA//Enterovirus//NCI	C319//Bronchodilator//NCI	372580007//Bronchodilator//SNOMEDCT_US
hypertonic saline	E-8727//Sodium chloride//SNM	C-70880//Hypertonic saline//SNMI	51103004//Hypertonic saline//SNOMEDCT_US	373766008//Hypertonic saline//SNOMEDCT_US	0000011003//hypertonic saline//CHV	CDR0000467928//hypertonic saline//PDQ	C60814//Hypertonic Saline//NCI
dornase alfa	337623//Dornase Alfa//RXNORM	C81664//Dornase Alfa//NCI	NOCODE//Developmental arithmetic disorder//MTH	d03173//dornase alfa//MMSL	4633//magnesium lactate 84 mg oral tablet, extended release//MMSL	45935//dornase alfa//MEDCIN	0000054886//dornase alpha//CHV	004413//SALICYLAMIDE/ATROPINE/SCOPOLAMINE/HYOSCYAMINE/BUTABARBITAL ORAL TABLET//NDDF	C568813//dornase alfa//MSH	cd2..//Dornase alfa//RCD	DB00003//Dornase alfa//DRUGBANK	386882003//Dornase alfa//SNOMEDCT_US	108630006//Dornase alfa//SNOMEDCT_US	953A26OA1Y//DORNASE ALFA//NCI_FDA
airway clearance	
fertility	U001764//Fertility//LCH	D005298//Fertility//MSH	X76Lt//Fertility//RCD	F-30700//Fertility//SNM	C94191//Fertile//NCI	4455//Preconception Care//MEDLINEPLUS	250//Infertility//MEDLINEPLUS	sh85047895//Fertility//LCH_NW	19618//Fertility//PSY	C16578//Fertility//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000002589//fertility//AOD	1138-0208//fertility//CSP	CDR0000046399//fertility//NCI_NCI-GLOSS	0000004977//fertility//CHV	MTHU000074//Fertility//LNC	C95089//FE//NCI_CDISC
refractive errors may be managed with spectacles or contact lenses	
to improve alignment in primary gaze position	
colitis	D003092//Colitis//MSHDUT	10009887//colitis//MDRDUT	D99045//colitis//ICPC2P	U001091//Colitis//LCH	X303f//Colitis//RCD	M-40000//Inflammation//SNM	N0000000806//Colitis [Disease/Finding]//NDFRT	MTHU036324//Colitis//OMIM	446//Ulcerative Colitis//MEDLINEPLUS	sh85027957//Colitis//LCH_NW	E10521//Colitis//NCI_CTCAE	C26723//Colitis//NCI_NICHD	HP:0002583//Colitis//HPO	64226004//Colitis//SNOMEDCT_US	10220//Colitis//PSY	009.0//Colitis//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	0059526//COLITIS//CCPSS	190//COLITIS//COSTAR	COLITIS//COLITIS//CST	U000794//HEMOGLOBIN E DISEASE//DXP	0271//COLITIS//WHO	0000005557//colitis//AOD	BI00225//colitis//BI	1248-5200//colitis//CSP	0000003154//colitis//CHV	CDR0000044318//colitis//NCI_NCI-GLOSS	MTHU017132//colitis//ICPC2ICD10ENG	313223//colitis//MEDCIN	C57134//Colitis//NCI_CTCAE
antidepressants are often required to treat concurrent depression	
ocular abnormalities	
services provided vary based on age and needs	
physical and occupational therapy	
ventilatory support	
daily heel cord stretching exercises to prevent achilles tendon shortening	
orthopedic surgery	0000009051//orthopedic surgery//CHV	C16942//Orthopedics//NCI	D009985//Orthopedics//MSH	0000017846//orthopedic surgery//CHV	41730//orthopedic surgical procedures//MEDCIN	02985//Orthopedic surgery//NANDA-I	LP97123-1//Orthopedic surgery//LNC	0054510//ORTHOPEDIC SURGERY//CCPSS
fewer than 5% of individuals need wheelchairs	
respiratory dysfunction	0000056356//abnormal breathing//CHV
odontoid hypoplasia	MTHU003440//Odontoid hypoplasia//OMIM	HP:0003311//Hypoplasia of the odontoid process//HPO	C86969//Odontoid Hypoplasia//NCI	613628//ODONTOID HYPOPLASIA//OMIM
exercise within the individual's capability to remain physically active	
hearing aids as needed	
management includes the following:	
0 mm in diameter	
pharmacologic treatment	
central nervous system	V09A//CENTRAL NERVOUS SYSTEM DIAGNOSTIC RADIOPHARMACEUTICALS//ATC	NER/CNS//Central Nervous System//CST	D002490//Central Nervous System//MSH	TCGA//Enterovirus//NCI	LA4174-4//Central Nervous System//LNC	08100//Central Nervous System//PSY	C12438//Central Nervous System//NCI	NOCODE//Developmental arithmetic disorder//MTH	U000879//Central nervous system//LCH	Xa0eL//Central nervous system//RCD	T-X0090//Central nervous system//SNM	T-A0090//Central nervous system//SNMI	MTHU000058//Central nervous system//OMIM	55675//Neuraxis//FMA	sh85021906//Central nervous system//LCH_NW	21483005//Structure of central nervous system//SNOMEDCT_US	0000017844//central nervous system//AOD	2049-9515//central nervous system//CSP	CDR0000046481//central nervous system//NCI_NCI-GLOSS	854//central nervous system//NEU
cognitive	C37926//Cognitive//NCI
endocrinopathies	0000004447//hormonal disorder//CHV	D004700//Maladies endocriniennes//MSHFRE
spine	U004435//Spine//LCH	X74Xc//Spine//RCD	T-10500//Vertebral column//SNM	13478//Vertebral column//UWDA	MTHU000142//Spine//AOT	MTHU000034//Spine//OMIM	LP7596-2//Spine//LNC	MTHU003055//Spine//LNC	sh85126694//Spine//LCH_NW	LA4340-1//Spine//LNC	LP200016-6//Spine//LNC	C12998//Vertebral Column//NCI	D013131//Spine//MSH	0000017079//spine//AOD	2715-6251//spine//CSP	CDR0000415914//spine//NCI_NCI-GLOSS	0000011627//spine//CHV	0045295//SPINE//CCPSS	GO:0044309//neuron spine//GO
sodium benzoate: 250 mg/kg or 5	
sodium phenylacetate: 250 mg/kg or 5	
10% arginine hcl: 600 mg/kg or 12	
reversal of catabolism	
gastroesophageal reflux should be addressed in a standard manner	
ophthalmologic abnormalities are treated in the standard manner	
skeletal abnormalities (e	
hearing loss is treated with a trial of hearing aids	
infants benefit from enrollment in an early-intervention program	
pulmonary fibrosis	D011658//Pulmonary Fibrosis//MSH	N0000002544//Pulmonary Fibrosis [Disease/Finding]//NDFRT	378//Pulmonary Fibrosis//MEDLINEPLUS	C26869//Pulmonary Fibrosis//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	0042976//PULMONARY FIBROSIS//CCPSS	U000569//PULMONARY FIBROSIS//COSTAR	FIBRO LUNG//LUNG FIBROSIS//CST	0532//PULMONARY FIBROSIS//WHO	U003945//Pulmonary fibrosis//LCH	10037383//Pulmonary fibrosis//MDR	X102u//Pulmonary fibrosis//RCD	D2-61310//Fibrosis of lung, NOS//SNMI	MTHU007791//Pulmonary fibrosis//OMIM	LP128703-8//Pulmonary fibrosis//LNC	MTHU040644//Pulmonary fibrosis//LNC	sh85109004//Pulmonary fibrosis//LCH_NW	E13527//Pulmonary fibrosis//NCI_CTCAE	HP:0002206//Pulmonary fibrosis//HPO	51615001//Fibrosis of lung//SNOMEDCT_US	0000005464//pulmonary fibrosis//AOD	2596-8265//pulmonary fibrosis/granuloma//CSP	0000010390//pulmonary fibrosis//CHV	R99010//pulmonary fibrosis//ICPC2P	33019//pulmonary fibrosis//MEDCIN
thiamine	D013831//Thiamine//MSH	X80RQ//Vitamin B1//RCD	F-16210//Thiamine//SNM	F-BB310//Thiamine//SNMI	10454//Thiamine//RXNORM	N0000007147//Thiamine [Chemical/Ingredient]//NDFRT	X66NSO3N35//Thiamine//MTHSPL	LP15886-2//Thiamine//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU008943//Thiamine//LNC	C874//Thiamin//NCI_CRCH	05001//Thiamine//NCI_DCP	DB00152//Thiamine//DRUGBANK	30866//Thiamine//CPM	259659006//Vitamin B1//SNOMEDCT_US	U002296//Thiamine//MTH	0000004766//thiamine//AOD	3147-2928//thiamine//CSP	41296//thiamine//MEDCIN	0000012172//thiamine//CHV	A11DA01//thiamine//ATC	CDR0000556404//thiamine//NCI_NCI-GLOSS	CDR0000037856//thiamine//PDQ	d03130//thiamine//MMSL	N0000145862//THIAMINE//NDFRT	4017474//THIAMINE//VANDF	10058787//thiamine//MDRDUT	U002824//Radiolabelled sucralfate scan//MTH	C74896//Thiamine//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	N0000029453//[VT105] THIAMINE//NDFRT	4021900//THIAMINE//VANDF
riboflavin	D012256//riboflavin//MSHCZE	5062//morphine 100 mg/24 hours oral capsule, extended release//MMSL	X80RU//Vitamin B2//RCD	F-16220//Riboflavin//SNM	F-BB320//Riboflavin//SNMI	9346//Riboflavin//RXNORM	N0000005897//Riboflavin [Chemical/Ingredient]//NDFRT	TLM2976OFR//Riboflavin//MTHSPL	LP15853-2//Riboflavin//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU007595//Riboflavin//LNC	C74898//Riboflavin//NCI_CDISC	C808//Riboflavin//NCI_CRCH	02185//Riboflavin//NCI_DCP	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	DB00140//Riboflavin//DRUGBANK	13235001//Riboflavin//SNOMEDCT_US	U002226//Riboflavin//MTH	0000018237//riboflavin//AOD	3147-2745//riboflavin//CSP	d00409//riboflavin//MMSL	5422//levoFLOXacin 500 mg/100 mL intravenous solution//MMSL	41298//riboflavin//MEDCIN	0000010877//riboflavin//CHV	A11HA04//riboflavin//ATC	CDR0000556406//riboflavin//NCI_NCI-GLOSS	CDR0000038330//riboflavin//PDQ	N0000146013//RIBOFLAVIN//NDFRT	NSC0033298//RIBOFLAVIN//NCI_DTP	4017633//RIBOFLAVIN//VANDF	10058790//Riboflavin//MDRCZE	U002823//Histology Procedure//MTH	0000031661//riboflavin//CHV	N0000029454//[VT106] RIBOFLAVIN//NDFRT	4021901//RIBOFLAVIN//VANDF
initial treatment	
long-term medical management	
levodopa	D007980//levodopa//MSHCZE	1804//lidocaine 5%-0.8% injectable solution//MMSL	dq1..//Levodopa//RCD	E-7741//Dihydroxyphenylalanine//SNM	C-B70E0//Levodopa//SNMI	6375//Levodopa//RXNORM	46627O600J//Levodopa//MTHSPL	N0000006700//Levodopa [Chemical/Ingredient]//NDFRT	LP16328-4//Levodopa//LNC	MTHU015998//Levodopa//LNC	DB01235//Levodopa//DRUGBANK	15383004//Levodopa//SNOMEDCT_US	387086006//Levodopa//SNOMEDCT_US	28290//Levodopa//PSY	C611//Levodopa//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000020119//levodopa//AOD	5000-0053//levodopa//CSP	d00277//levodopa//MMSL	4971//naphazoline-zinc ophthalmic 0.02%-0.25% ophthalmic solution//MMSL	0000007378//levodopa//CHV	001639//FERROUS SULFATE 220 mg/5 mL ORAL ELIXIR//NDDF	N04BA01//levodopa//ATC	CDR0000042622//levodopa//PDQ	N0000146151//LEVODOPA//NDFRT	4017790//LEVODOPA//VANDF
treatment of psychiatric problems with appropriate psychotropic medications	
adaptation of environment and care to the level of dementia	
individuals with severe heart block may require pacemaker implantation	
growth retardation	GRDST//Growth retardation//AIR	U006451//Growth retardation//LCH	10053759//Growth retardation//MDR	M-70110//Growth retardation//SNM	MTHU000166//Growth retardation//OMIM	444896005//Growth retardation//SNOMEDCT_US	HP:0001510//Growth delay//HPO	59576002//Growth retardation//SNOMEDCT_US	783.43//Growth retardation//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	0055830//GROWTH RETARDATION//CCPSS	U001751//SJOGREN SYNDROME//DXP	Q0200129//Growth Retardation//QMR	C78328//Growth Retardation//NCI	0000005009//growth retardation//AOD	T10010//growth retardation//ICPC2P	0000017034//growth retardation//CHV
feeding therapy	
oral medications are usually tried first:	
baclofen (lioresal®)	
benzodiazepines	U000538//Benzodiazepines//LCH	D001569//Benzodiazepines//MSH	N0000007542//Benzodiazepines [Chemical/Ingredient]//NDFRT	LP15014-1//Benzodiazepines//LNC	MTHU001123//Benzodiazepines//LNC	sh85013239//Benzodiazepines//LCH_NW	MTHU002730//Benzodiazepines//USPMG	32097//Benzodiazepines//CPM	05824//Benzodiazepines//PSY	U001735//Benzodiazepines//MTH	0000018905//benzodiazepines//AOD	41395//benzodiazepines//MEDCIN	1022254//Benzodiazepines//CPT	C-64500//Benzodiazepine, NOS//SNMI	0000001794//benzodiazepine//CHV
primary layers include the following:	
, telfa®, n-terface®)	
, mepitel®, mepilex®)	
, kerlix®) are commonly used	
hypotrichosis	D007039//Hypotrichosis//MSHDUT	10021126//Hypotrichosis//MDR	X509L//Hypotrichosis//RCD	MTHU002744//Hypotrichosis//OMIM	N0000001655//Hypotrichosis [Disease/Finding]//NDFRT	HP:0001006//Hypotrichosis//HPO	53602002//Hypotrichosis//SNOMEDCT_US	C34720//Hypotrichosis//NCI	U001999//Hypotrichosis//MTH	ALOPECIA//ALOPECIA//CST	0828//HYPOTRICHOSIS//WHO	MTHU037279//hypotrichosis//ICPC2ICD10ENG	0000006503//hypotrichosis//CHV
see prevention of primary manifestations	
hematologic	C16673//Hematology//NCI	G-B113//Hematologic//SNMI	C62780//Hematologic//NCI	TCGA//Enterovirus//NCI	57407000//Hematologic//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000020623//hematologic//CHV	0053403//HEMATOLOGIC//CCPSS
treatment of manifestations in individuals with ethylmalonic encephalopathy	
gorman et al [2016]	
enrollment in developmental disabilities administration (dda) is recommended	
hernia	D006547//hernie//MSHCZE	10019909//hernia//MDRDUT	K40-K46.9//Hernia//ICD10	D91001//hernia//ICPC2P	U002183//Hernia//LCH	J3...//Hernia of abdominal cavity//RCD	M-31600//Hernia//SNM	MTHU012924//Hernia//OMIM	N0000001516//Hernia [Disease/Finding]//NDFRT	283//Hernia//MEDLINEPLUS	sh85060424//Hernia//LCH_NW	C34685//Hernia//NCI_NICHD	2240//Hernia//NCI_FDA	HP:0100790//Hernia//HPO	52515009//Hernia of abdominal cavity//SNOMEDCT_US	414403008//Hernia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1006190//HERNIA//CCPSS	360//HERNIA//COSTAR	HERNIA//HERNIA//CST	0000004460//hernia//AOD	BI00271//hernia//BI	0944-5779//hernia//CSP	0000006079//hernia//CHV	CDR0000630906//hernia//NCI_NCI-GLOSS	MTHU034462//hernia//ICPC2ICD10ENG	96160//hernia//MEDCIN
arterial abnormalities	HP:0011004//Abnormality of the systemic arterial tree//HPO
acute photosensitivity	
grey or smoke-colored filters provide only partial protection	
topical sunscreens are typically not useful	
close monitoring is warranted	
treatment of thrombosis in children	
antoun et al [2016]	
huemer et al [2015]	
the following measures are appropriate:	
referral of the family to support groups and other resources	
cryptorchidism	D003456//Cryptorchidism//MSH	PC50.//Cryptorchism//RCD	D4-85110//Undescended testis//SNMI	MTHU000066//Cryptorchidism//OMIM	N0000000881//Cryptorchidism [Disease/Finding]//NDFRT	HP:0000028//Cryptorchidism//HPO	10056600//Cryptorchidism//MDR	C12326//Cryptorchidism//NCI_NICHD	204878001//Undescended testicle//SNOMEDCT_US	U001835//Cryptorchidism//MTH	0059144//CRYPTORCHIDISM//CCPSS	U000019//CRYPTORCHIDISM//COSTAR	U000914//HYPOVITAMINOSIS A//DXP	146738//INSULIN-LIKE 3//OMIM	2586-8788//cryptorchidism//CSP	0000003493//cryptorchidism//CHV	CDR0000046458//cryptorchidism//NCI_NCI-GLOSS	7506//cryptorchidism//MEDCIN
dental problems	HP:0000164//Abnormality of the dentition//HPO	0000040304//dental problem//CHV
pain	D001939//Pain//MSHFRE	A29020//pain//ICPC2P	U003436//Pain//LCH	D010146//Pain//MSH	306//Abdominal Pain//MTH	120324//Pain//NOC	Xa07F//Pain//RCD	F-82600//Pain//SNM	200714//Pain//NOC	110407//Pain//NOC	110021//Pain//NOC	230324//Pain//NOC	24//Pain//OMS	10023130//Pain//ICNP	N0000002278//Pain [Disease/Finding]//NDFRT	Q63.0//Pain//CCC	MTHU033713//Pain//OMIM	351//Pain//MEDLINEPLUS	MTHU029813//Pain//LNC	sh85096617//Pain//LCH_NW	C3303//Pain//NCI_NICHD	E11167//Pain//NCI_CTCAE	ESAS//Pain//NCI	LASA//Pain//NCI	LA7460-4//Pain//LNC	1994//Pain//NCI_FDA	HP:0012531//Pain//HPO	10033371//Pain//MDR	01394//Pain//NANDA-I	22253000//Pain//SNOMEDCT_US	36150//Pain//PSY	NOCODE//Developmental arithmetic disorder//MTH	0035760//PAIN//CCPSS	548//PAIN//COSTAR	PAIN//PAIN//CST	0730//PAIN//WHO	338-338.99//PAIN//ICD9CM	0000002779//pain//AOD	BI00754//pain//BI	2683-4824//pain//CSP	0000009185//pain//CHV	CDR0000041399//pain//PDQ	MTHU059479//pain//ICPC2ICD10ENG	283263//pain//MEDCIN	MSAS//Dry mouth//NCI	SDS//Bowel//NCI	PT//Patient external identifier//HL7V2.5	C53794//PAIN//NCI_CTCAE	C53837//Pain//NCI_CTCAE	52500-6//Pain:-:Pt:^Patient:-//LNC	MSAS-SF//Almost Constantly//NCI
thus, good sleep hygiene should be encouraged	
corticosteroids	x002V//Corticosteroids//RCD	N0000011309//Adrenal Cortex Hormones [Chemical/Ingredient]//NDFRT	LP20687-7//Corticosteroids//LNC	4557//Steroids//MEDLINEPLUS	79440004//Corticoid preparation//SNOMEDCT_US	12000//Corticosteroids//PSY	C211//Therapeutic Corticosteroid//NCI	D000305//Adrenal Cortex Hormones//MSH	0000028357//corticosteroids//AOD	0000000762//corticosteroid//CHV	R01AD//Corticosteroid nasal preparations for topical use//ATC	S02BA//Corticosteroids//ATC	S02B//Corticosteroid otologicals//ATC	S03BA//Corticosteroids//ATC	S03B//Corticosteroid ophthalmologic and otologic preparations//ATC	C05AA//Corticosteroids, topical for treatment of hemorrhoids and anal fissures//ATC
immunoglobulins	U002384//Immunoglobulins//LCH	D007136//Immunoglobulins//MSH	U000207//Immunoglobulins//SNM	N0000007920//Immunoglobulins [Chemical/Ingredient]//NDFRT	LP31769-0//Immunoglobulins//LNC	sh85064568//Immunoglobulins//LCH_NW	24580//Immunoglobulins//PSY	C572//Immunoglobulin//NCI	U002003//Immunoglobulins//MTH	F-C8000//Immunoglobulin, NOS//SNMI	4021646//IMMUNOGLOBULINS//VANDF	N0000029199//[IM500] IMMUNOGLOBULINS//NDFRT	J06B//IMMUNOGLOBULINS//ATC	0000020386//immunoglobulins//AOD	0000006598//immunoglobulin//CHV	10021496//Immunoglobulins//MDR
educational programming directed to the specific disabilities identified	
cardiac manifestations	
intramuscular injections should be avoided unless under factor coverage	
dermatologic	G-B114//Dermatologic//SNMI	C41128//Dermatologic//NCI	64947008//Dermatologic//SNOMEDCT_US	BI00622//dermatologic//BI	0000020624//dermatologic//CHV	0017118//DERMATOLOGIC//CCPSS
cataract	F92//Cataract//ICPCDUT	D002386//Cataract//MSHDUT	10007739//cataract//MDRDUT	6.7.1//Cataract//CCS	86//Cataract//CCS	F92001//cataract//ICPC2P	U000841//Cataract//LCH	622//Cataract//MTH	F46..//Cataract//RCD	M-51100//Cataract//SNM	MTHU004637//Cataract//OMIM	N0000000698//Cataract [Disease/Finding]//NDFRT	LP128693-1//Cataract//LNC	116//Cataract//MEDLINEPLUS	MTHU040525//Cataract//LNC	sh85020947//Cataract//LCH_NW	E10350//Cataract//NCI_CTCAE	C26713//Cataract//NCI_NICHD	1766//Cataract//NCI_FDA	HP:0000518//Cataract//HPO	128306009//Cataract//SNOMEDCT_US	193570009//Cataract//SNOMEDCT_US	366//Cataract//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1017415//CATARACT//CCPSS	162//CATARACT//COSTAR	CATARACT//CATARACT SPECIFIED//CST	0235//CATARACT//WHO	0000006040//cataract//AOD	BI00628//cataract//BI	1114-9096//cataract//CSP	30745//cataract//MEDCIN	0000015953//cataract//CHV	CDR0000440102//cataract//NCI_NCI-GLOSS	MTHU015169//cataract//ICPC2ICD10ENG	MTHU007394//cataract//OMIM	6620//cataract on exam//MEDCIN	C55830//Cataract//NCI_CTCAE
250 mg/kg/day	
sodium phenylacetate	48N6U1781G//sodium phenylacetate//MTHSPL	56510//sodium phenylacetate//RXNORM	C025136//phenylacetic acid//MSH	001244//POTASSIUM BICARBONATE 100 % MISCELL POWDER (GRAM)//NDDF	d05460//sodium phenylacetate//MMSL	19292//sodium phenylacetate//MMSL	NOCODE//Developmental arithmetic disorder//MTH	N0000147675//SODIUM PHENYLACETATE//NDFRT	4019576//SODIUM PHENYLACETATE//VANDF	NSC0003039//Sodium phenylacetate//NCI_DTP	398818001//Sodium phenylacetate//SNOMEDCT_US	125705007//Sodium phenylacetate//SNOMEDCT_US	31742//Sodium Phenylacetate//NCI_DCP	C66723//Sodium Phenylacetate//NCI
mechanisms of drug action in treatment of hyperammonemia	
raises insulin levels	
induces anabolic state	
causes protein sparing effect from skeletal muscle amino acids	
stimulates secretion of insulin	
eliminates one amino group in the urine	
eliminates two amino groups in the urine	
a non-essential amino acid in humans	
surgical management	C16080//Surgical Management//NCI
renal and liver function	
full blood count	424..//Full blood count//RCD	10017411//Full blood count//MDR	0000003246//complete blood count test (CBC)//CHV	A34011//full blood count//ICPC2P	C28133//Blood Cell Count//NCI
psychological support	Ua1Nf//Emotional support//RCD	342386//Psychological support//MEDCIN	133921002//Emotional support//SNOMEDCT_US	0000042145//emotional support//CHV
table 7	
principles of treatment for individuals with hokpp	
add 0	
3 meq/kg/h	
(2) in the work setting	
myopathy	L99023//myopathy//ICPC2P	10028641//Myopathy//MDR	D009135//Muscular Diseases//MSH	X708s//Myopathy//RCD	D-8004//Muscle disease or syndrome//SNM	MTHU003653//Myopathy//OMIM	510//Muscle Disorders//MEDLINEPLUS	C101216//Myopathy//NCI	HP:0003198//Myopathy//HPO	129565002//Disorder of muscle//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0045912//MYOPATHY//CCPSS	U000457//MYOPATHY//COSTAR	MYOPATHY//MYOPATHY//CST	U002703//MYOPATHY//DXP	0074//MYOPATHY//WHO	590075//TRANSFER RNA, MITOCHONDRIAL, PROLINE//OMIM	590030//TRANSFER RNA, MITOCHONDRIAL, GLUTAMINE//OMIM	0000005066//myopathy//AOD	BI00507//myopathy//BI	0000008361//muscle disease//CHV	MTHU051138//myopathy//ICPC2ICD10ENG
behavior	D001519//Behavior//MSH	U000232//Behavior//SNM	F-94000//Behavior//SNM	LP89757-6//Behavior//LNC	LP28433-8//Behavior//LNC	MTHU031771//Behavior//LNC	MTHU013956//Behavior//LNC	C16326//Behavior//NCI_NICHD	05670//Behavior//PSY	NOCODE//Developmental arithmetic disorder//MTH	0000000085//behavior//AOD	2483-0090//behavior//CSP	GO:0007610//behavior//GO	0000001751//behavior//CHV	MTHU000008//BEHAVIOR//OMS	54511-1//Behavior:-:Pt:^Patient:-//LNC
drugs to reduce muscle spasticity (e	
, oxybutynin)	
cd46	1556-6810//CD antigen//CSP	F-C7A10//Membrane cofactor protein//SNMI	LP20089-6//CD46//LNC	MTHU022288//CD46//LNC	D051916//Antigènes CD46//MSHFRE	HGNC:6953//CD46 molecule//HGNC	C126977//CD46 Gene//NCI	120920//CD46 ANTIGEN//OMIM
cfh	C97209//CFH Gene//NCI	HGNC:4883//complement factor H//HGNC	134370//COMPLEMENT FACTOR H//OMIM
dgke	HGNC:2852//diacylglycerol kinase epsilon//HGNC	601440//DIACYLGLYCEROL KINASE, EPSILON, 64-KD//OMIM
thbd	HGNC:11784//thrombomodulin//HGNC	C101378//THBD Gene//NCI	188040//THROMBOMODULIN//OMIM
hyperuricemia/gout	
lifelong therapy with allopurinol may be required	
the transplanted kidney does not develop the disease	
current recommended drug therapies for adults with fh	
15% 1, 3	
50% 5	
often ineffective in hofh	
kastelein et al [2008]	
rader et al [2003]	
approved only for adults with hofh	
cuchel et al [2014]	
raal & santos [2012]	
physical therapy to improve motor function	
pharmacologic treatment of spasticity and seizures	
maintenance therapy	314122007//Maintenance therapy//SNOMEDCT_US	CDR0000045768//maintenance therapy//NCI_NCI-GLOSS	0000042690//maintenance therapy//CHV	TCGA//Enterovirus//NCI	29142//Maintenance Therapy//PSY	C15688//Maintenance Therapy//NCI
genital anomalies	MTHU053771//Genital anomalies//OMIM	HP:0000078//Abnormality of the genital system//HPO
surgery as required	
routine management	
thyroid hormone replacement as needed	
treatment of manifestations in individuals with kcnk9 imprinting syndrome	
standard treatment for scoliosis	
developmental disabilities administration (dda) enrollment is recommended	
social/behavioral issues	
therapeutic management of the sleep disorder	
management of seizures in accordance with standard practice	
auditory amplification if hearing loss is identified	
gonadotropin therapy	
spastic paraplegia	NOCODE//Sepsis//COSTAR	D010264//Paraplegia//MSH	U003756//SPASTIC PARAPLEGIA//DXP	605//spastic paraplegia//JABL	0000011557//spastic paraplegia//CHV	G82.1//Spastic paraplegia//ICD10	MTHU000470//Spastic paraplegia//OMIM	HP:0001258//Spastic paraplegia//HPO	10048792//Spastic paraplegia//MDR	364126//Spastic paraplegia//MEDCIN	192967009//Spastic paraplegia//SNOMEDCT_US
general guidelines can be followed	
antiepileptic drugs (aed) if epileptic seizures are present	
acidosis	NOCODE//Sepsis//COSTAR	E87.2//Acidosis//ICD10	U000036//Acidosis//LCH	D000138//Acidosis//MSH	U000118//Compensation as a Defense Mechanism//MTH	C362.//Acidosis//RCD	C83504//Acidosis//NCI	N0000000283//Acidosis [Disease/Finding]//NDFRT	338589//Acidosis//MEDCIN	sh85000531//Acidosis//LCH_NW	HP:0001941//Acidosis//HPO	10000486//Acidosis//MDR	51387008//Acidosis//SNOMEDCT_US	276.2//Acidosis//ICD9CM	0063443//ACIDOSIS//CCPSS	METACIDOSIS//ACIDOSIS//CST	ACIDOSIS//ACIDOSIS//CST	U000077//AMNESTIC SYNDROME//DXP	0363//ACIDOSIS//WHO	0000005821//acidosis//AOD	0465-0952//acidosis//CSP	MTHU002955//acidosis//ICPC2ICD10ENG	0000000634//acidosis//CHV	E12237//Acidosis//NCI_CTCAE
psychological support for the affected individual and family is essential	
feeding	Xa4Hu//Feeding//RCD	1050//Feeding//NIC	75118006//Feeding patient//SNOMEDCT_US	0000001801//feeding//AOD	133435//feeding of newborn//MEDCIN	LA19832-7//Feeding//LNC	C88198//Feeding//NCI	129007004//Feeding//SNOMEDCT_US	309102//feeding//MEDCIN	Barthel//Bladder//NCI
psychomotor development	65401001//Psychomotor development//SNOMEDCT_US	41780//Psychomotor Development//PSY
gerd	D005764//gastroezofageální reflux//MSHCZE	N0000001319//Gastroesophageal Reflux [Disease/Finding]//NDFRT	109350//GASTROESOPHAGEAL REFLUX//OMIM	512//GERD//MEDLINEPLUS	10018203//GERD//MDR	C26781//Gastroesophageal Reflux Disease//NCI_NICHD	HP:0002020//Gastroesophageal reflux//HPO	BI00251//gastroesophageal reflux//BI	0000005382//gastroesophageal reflux disease (GERD)//CHV
neurobehavioral symptoms	
the choice should be left to personal preference	
dural ectasia is usually asymptomatic	
no effective therapies for symptomatic dural ectasia currently exist	
hernias tend to recur after surgical intervention	
long-term treatment	0000024957//long-term treatment//AOD	0000007534//long term care//CHV
genitourinary	T-70200//Genitourinary system, NOS//SNMI	BI00472//genitourinary//BI	0000035689//genitourinary system//CHV	54535-0//Genitourinary:-:Pt:^Patient:-//LNC	C38214//Genitourinary Route of Administration//NCI	LP89778-2//Genitourinary//LNC	MTHU031868//Genitourinary//LNC	TCGA//Enterovirus//NCI	LA16969-0//Genitourinary//LNC	C25350//Genitourinary//NCI	NOCODE//Developmental arithmetic disorder//MTH	MTHU000003//GENITOURINARY//OMIM
joint contractures	MTHU000680//Joint contractures//OMIM	HP:0001371//Flexion contracture//HPO
developmental delay/cognitive impairment	
specialized learning programs to meet individual needs	
no specific antiepileptic or antipsychotic medications are indicated	
cardiac malformations	MTHU052238//Cardiac malformations//OMIM
treatment should follow standard practice	
see hereditary hearing loss and deafness overview	
congenital heart defects	N0000001431//Heart Defects, Congenital [Disease/Finding]//NDFRT	198//Congenital Heart Defects//MEDLINEPLUS	D006330//Heart Defects, Congenital//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000005874//congenital heart defect//CHV	MTHU013668//Congenital heart defects//OMIM	HP:0001627//Abnormal heart morphology//HPO
stretching exercises are ineffective and painful	
the following treatment is appropriate:	
joints	U002546//Joints//LCH	D007596//Joints//MSH	NOCODE//Developmental arithmetic disorder//MTH	73023//Set of joints//FMA	sh85070658//Joints//LCH_NW	C13044//Joint//NCI	0000007022//joint//CHV	s7701//Joints//ICF	81087007//Articular system structure//SNOMEDCT_US	0000032186//joint//CHV
reasons for 28 hospitalizations in 15 infants with msud	
strauss et al [2010]	
4(2	
3(1	
1(1	
5-6	LA14354-7//5-6//LNC
3-9	
3-1	
0(3	
7(3	
7-7	
2(5	
50(0	
43-0	
58)	
from strauss et al [2010]	
with permission from elsevier	
acute pancreatitis	K85//Acute pancreatitis//ICD10DUT	10000971//acute pancreatitis//MDRDUT	9.9.1//Acute pancreatitis//CCS	MT180012//Acute pancreatitis//MTHMST	J670.//Acute pancreatitis//RCD	D5-90110//Acute pancreatitis//SNMI	HP:0001735//Acute pancreatitis//HPO	577.0//Acute pancreatitis//ICD9CM	197456007//Acute pancreatitis//SNOMEDCT_US	NOCODE//Sepsis//COSTAR	5876//Pancreatitis//MEDLINEPLUS	C95437//Acute Pancreatitis//NCI	0000005654//acute pancreatitis//AOD	BI00281//acute pancreatitis//BI	0000000688//acute pancreatitis//CHV	30029//acute pancreatitis//MEDCIN
infection	N0000001681//Infection [Disease/Finding]//NDFRT	1930//Infection//NCI_FDA	02120//Infection//NANDA-I	C26726//Infectious Disorder//NCI	40733004//Disorder due to infection//SNOMEDCT_US	4000-0216//infection//CSP	C53791//INFECTION//NCI_CTCAE	U002423//Infection//LCH	D007239//Infection//MSH	PRB_07010.00//Infection//PCDS	X79pw//Infection//RCD	D-0070//Infection//SNM	031102//Infection//NOC	251113//Infection//NOC	10023032//Infection//ICNP	K25.6//Infection//CCC	LP130385-0//Infection//LNC	MTHU041099//Infection//LNC	sh85066076//Infection//LCH_NW	LA7446-3//Infection//LNC	10021789//Infection//MDR	11_1//Infection//NANDA-I	C128320//Infection//NCI_NICHD	A78051//infection//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	1018029//INFECTION//CCPSS	413//INFECTION//COSTAR	PATHINFECT//INFECTION//CST	PULMINFECT//INFECTION//CST	INFECT//INFECTION//CST	U002090//INFECTION//DXP	0736//INFECTION//WHO	0000004491//infection//AOD	50.01//infection//OMS	0000006691//infection//CHV	CDR0000045364//infection//NCI_NCI-GLOSS	CDR0000041393//infection//PDQ	MTHU038002//infection//ICPC2ICD10ENG	363071//infection//MEDCIN
see hirschsprung disease overview	
cataracts	NOCODE//Sepsis//COSTAR	D002386//Cataract//MSH	U000341//Cataracts//SNM	MTHU000155//Cataracts//OMIM	MTHU020817//Cataracts//LNC	10007771//Cataracts//MDR	07890//Cataracts//PSY	HP:0000518//Cataract//HPO	DA-73500//Cataract, NOS//SNMI	0000015953//cataract//CHV	LA16306-5//Cataracts//LNC	95722004//Bilateral cataracts//SNOMEDCT_US
deep brain stimulation (dbs)	
cataracts can be removed if they impair vision	
other tumors	
photodysphoria (discomfort in bright light	
orthopedic treatment	
dental treatment	10061813//Dental treatment//MDR	0000003709//dental care//CHV	13550//Dental Treatment//PSY
treatment of decreased visual acuity is symptomatic (e	
, low-vision aids)	
250 mg/kg	
5,500 mg/m2	
batshaw et al [2001]	
loading dose given over 90 to 120 minutes	
maintenance dose given over 24 hours	
the typical dilution is 1:10	
arginine infusion not to exceed 150mg/kg/h	
surgery has been reported to be helpful by many patients	
fecal elastase-1 analysis (schebo® biotech ag	
, cck-8) or receptor agonists (e	
their nature (e	
blocking of pancreatic lipase (e	
diseases of the intestinal mucosa	
diffusion-weighted mri	C111116//Diffusion Weighted Imaging//NCI
monitoring for glucose intolerance	
hypoventilation	NOCODE//Sepsis//COSTAR	10021133//Hypoventilation//MDR	D007040//Hypoventilation//MSH	U000115//Mental tolerance//MTH	F-76570//Hypoventilation//SNM	C50594//Hypoventilation//NCI	N0000001656//Hypoventilation [Disease/Finding]//NDFRT	MTHU041452//Hypoventilation//OMIM	1916//Hypoventilation//NCI_FDA	HP:0002791//Hypoventilation//HPO	31515003//Hypoventilation//SNOMEDCT_US	0003592//HYPOVENTILATION//CCPSS	HYPOVENTIL//HYPOVENTILATION//CST	U002061//HYPOVENTILATION//DXP	0518//HYPOVENTILATION//WHO	0000005443//hypoventilation//AOD	2602-3621//hypoventilation//CSP	MTHU037284//hypoventilation//ICPC2ICD10ENG	0000032373//hypoventilation//CHV
consider aspirin treatment	
severe atp8b1 deficiency	
mild atp8b1 deficiency	
reduction of calcium oxalate supersaturation	
organ transplantation	D016377//Organ Transplantation//MSH	1462//Organ Transplantation//MEDLINEPLUS	35660//Organ Transplantation//PSY	C15289//Organ Transplantation//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000008151//organ transplantation//AOD	0000009013//organ transplantation//CHV	CDR0000474022//organ transplantation//PDQ
only if affected person is known to be b6 responsive	
from cochat et al [2012]	
recommendations assume the availability of facilities	
pox= plasma oxalate	
see note	
visual impairment	HP:0000505//Visual impairment//HPO	D014786//Vision Disorders//MSH	55964//Visual Impairment//PSY	NOCODE//Developmental arithmetic disorder//MTH	VISION ABNORM//ABNORMAL VISION//CST	0257//VISION ABNORMAL//WHO	XE16L//Impaired vision//RCD	MTHU002513//Visual impairment//OMIM	10047571//Visual impairment//MDR	397540003//Visual impairment//SNOMEDCT_US	BI00637//impaired vision//BI	0000013036//cannot see properly//CHV	0000025347//vision problem//CHV	F28006//visual impairment//ICPC2P	36646//visual impairment//MEDCIN
cys282tyr / p	
treatment of medical manifestations in individuals with ptls	
standard treatment as recommended by dentist/orthodontist	
poor weight gain / failure to thrive	
global developmental delay / intellectual disability educational issues	
, orthotics, adaptive strollers)	
chemotherapy	D004358//Drug Therapy//MSH	Q000188//drug therapy//MSH	02005//Chemotherapy//NANDA-I	0000032192//cancer chemotherapy//CHV	2.15.2//Chemotherapy//CCS	A50009//chemotherapy//ICPC2P	U005481//Chemotherapy//LCH	X71bL//Chemotherapy//RCD	P-5110//Chemotherapy//SNM	464//Cancer Chemotherapy//MEDLINEPLUS	MTHU010425//Chemotherapy//LNC	sh85023041//Chemotherapy//LCH_NW	TCGA//Enterovirus//NCI	LA6172-6//Chemotherapy//LNC	10044583//Chemotherapy//ICNP	10061758//Chemotherapy//MDR	367336001//Chemotherapy//SNOMEDCT_US	08580//Chemotherapy//PSY	C15632//Chemotherapy//NCI	NOCODE//Developmental arithmetic disorder//MTH	0000024419//chemotherapy//AOD	0962-5748//chemotherapy//CSP	0000004154//drug therapy//CHV	CDR0000045214//chemotherapy//NCI_NCI-GLOSS	CDR0000039455//chemotherapy//PDQ	MTHU016113//chemotherapy//ICPC2ICD10ENG	342594//chemotherapy//MEDCIN	1017439//CHEMOTHERAPY//CCPSS
5 years	
joint pain	N0000003851//Arthralgia [Disease/Finding]//NDFRT	2355//Arthralgia//NCI_FDA	C50464//Arthralgia//NCI_NICHD	D018771//Arthralgia//MSH	U000033//ANISOCORIA//COSTAR	ARTHRALGIA//ARTHRALGIA//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0063//ARTHRALGIA//WHO	XE1EY//Joint pain//RCD	F-13100//Joint pain//SNMI	070629//Joint pain//NOC	MTHU002712//Joint pain//OMIM	MTHU020863//Joint pain//LNC	HP:0002829//Arthralgia//HPO	10023222//Joint pain//MDR	57676002//Joint pain//SNOMEDCT_US	BI00473//arthralgia//BI	L20005//joint pain//ICPC2P	0000001465//joint pain//CHV	C56095//Joint pain//NCI_CTCAE	C125623//Level of Joint Pain//NCI
see published guidelines/consensus statements	
treatment of manifestations in individuals with pura-related neurodevelopmental disorders	
scoliosis	M41//Scoliosis//ICD10	U004240//Scoliosis//LCH	10039722//Scoliosis//MDR	Xa6vS//Scoliosis deformity of spine//RCD	M-31510//Scoliosis//SNM	MTHU000036//Scoliosis//OMIM	C78603//Scoliosis//NCI	N0000002703//Scoliosis [Disease/Finding]//NDFRT	395//Scoliosis//MEDLINEPLUS	sh85118750//Scoliosis//LCH_NW	E12521//Scoliosis//NCI_CTCAE	76631//Scoliosis//UWDA	298382003//Scoliosis deformity of spine//SNOMEDCT_US	D012600//Scoliosis//MSH	668//SCOLIOSIS//COSTAR	U003455//SCOLIOSIS//DXP	1684//SCOLIOSIS//WHO	BI00512//scoliosis//BI	2715-3059//scoliosis//CSP	0000011122//scoliosis//CHV	MTHU066716//scoliosis//ICPC2ICD10ENG	34520//scoliosis//MEDCIN	X789G//Congenital scoliosis//RCD	L85002//scoliosis//ICPC2P	X70D3//Acquired scoliosis//RCD	HP:0002650//Scoliosis//HPO
sleep	U004339//Sleep//LCH	D012890//Sleep//MSH	0004//Sleep//NOC	X7A2s//Sleep//RCD	F-85800//Sleep//SNM	C73425//Sleep//NCI	sh85123396//Sleep//LCH_NW	HFRDIS//Leisure Activities//NCI	LA18125-7//Sleep//LNC	258158006//Sleep//SNOMEDCT_US	47820//Sleep//PSY	U002247//Sleep//MTH	0000003419//sleep//AOD	2482-1824//sleep//CSP	GO:0030431//sleep//GO	0000011413//sleep//CHV	7461//Sleep//MMSL
skeletal abnormalities	HP:0000924//Abnormality of the skeletal system//HPO
treatments include the following:	
standard treatment with antiepileptic drugs for seizures	
physical, occupational, and speech therapies, if necessary	
standard treatment is indicated	
treatment of manifestations in individuals with trio-related intellectual disability	
treatment of manifestations in individuals with unc80 deficiency	
see retinitis pigmentosa overview, management	
educational support	
hearing impairment	0000005856//partial hearing loss//CHV	H28002//hearing impairment//ICPC2P	NOCODE//Developmental arithmetic disorder//MTH	HEARL//Hearing impairment//AIR	XE0s9//Hearing loss//RCD	MTHU038541//Hearing impairment//OMIM	LA16989-8//Hearing impairment//LNC	HP:0000365//Hearing impairment//HPO	02421//Hearing impairment//NANDA-I	15188001//Hearing loss//SNOMEDCT_US	U001869//THYROID, ECTOPIC//DXP	C50576//Hearing Impairment//NCI	N0000011013//Hearing Loss [Disease/Finding]//NDFRT	1881//Hearing Impairment//NCI_FDA	D034381//Hearing Loss//MSH	0000023586//hearing impairment//AOD
medical measures	
early use of antibiotics for bacterial infections	
insertion	P-1270//Implantation//SNM	X79w8//Insertion//RCD	_Insertion//Insertion//HL7V3.0	C48685//Insertion//NCI	71861002//Implantation//SNOMEDCT_US	0000034855//insertion procedure//CHV	C19295//Insertion Mutation//NCI	2.16.840.1.113883.1.11.14687//Insertion//HL7V3.0	LA6687-3//Insertion//LNC	C45518//Insert//NCI	LP111537-9//insertion//LNC
physiotherapy including hydrotherapy to avoid strain on the joints	
use of a wheelchair if necessary	
orthopedic intervention if necessary	
special shoes may help with ankle and foot support	
therefore, ventriculocaval shunts are preferred	
educational opportunities/social considerations	
use of sign language in individuals with significant hearing loss	
early educational intervention for development of social skills	
speech therapy to improve speech	
special education to maximize learning	
planning housing for possible future wheelchair use	
hbh disease	
cortisol deficiency	10078563//Cortisol deficiency//MDR
genital abnormalities	HP:0000078//Abnormality of the genital system//HPO
hypospadias and cryptorchidism may be corrected with surgery	
vaginal reconstruction may be performed in females with vaginal hypoplasia	
ovarian cysts	D010048//Ovarian Cysts//MSH	N0000002272//Ovarian Cysts [Disease/Finding]//NDFRT	349//Ovarian Cysts//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	BI00396//ovarian cysts//BI	0000009119//ovarian cyst//CHV	MTHU016093//Ovarian cysts//OMIM
nasal stints or tracheotomy may be required	
joint contractures and elbow synostosis	
early developmental/educational intervention is appropriate for cognitive delays	
low-dose neuroleptics may be useful for psychiatric manifestations	
referral for psychiatric evaluation is appropriate	
low vision aids include high-powered magnifiers for reading	
achromat	
provide palliative care for viable newborns	
only modest effects on adult stature seem to accrue	
measures to avoid obesity should start in early childhood	
craniocervical junction constriction	
the best predictors of need for suboccipital decompression include:	
lower-limb hyperreflexia or clonus	
central hypopnea demonstrated by polysomnography	
treatment may include the following:	
adenotonsillectomy	10001256//Adenotonsillectomy//MDR	75306//Tonsillectomy and adenoidectomy//RCD	28913000//Tonsillectomy and adenoidectomy//SNOMEDCT_US	0000019518//adenotonsillectomy//CHV
weight reduction	N0000010968//Weight Loss [Disease/Finding]//NDFRT	D015431//Weight Loss//MSH	0000013130//weight loss//CHV
continuous positive airway pressure	D045422//Airway Pressure Release Ventilation//MSHDUT	C124040//Continuous Positive Airway Pressure//NCI	NOCODE//Developmental arithmetic disorder//MTH	2592-7337//positive pressure breathing//CSP	LA6176-7//Continuous positive airway pressure//LNC	10052934//Continuous positive airway pressure//MDR
tracheostomy for extreme cases	
middle ear dysfunction	
varus deformity	M-31570//Varus deformity//SNM	257756001//Varus deformity//SNOMEDCT_VET	127562007//Varus deformity//SNOMEDCT_US	0000038713//varus deformity//CHV	0000035336//varus deformity//CHV
various interventions may be elected (e	
kyphosis	L85004//kyphosis//ICPC2P	U002597//Kyphosis//LCH	10023509//Kyphosis//MDR	Xa6vT//Kyphosis deformity of spine//RCD	M-31530//Kyphosis//SNM	MTHU000681//Kyphosis//OMIM	N0000001768//Kyphosis [Disease/Finding]//NDFRT	414564002//Kyphosis deformity of spine//SNOMEDCT_US	1505//Spine Injuries and Disorders//MEDLINEPLUS	sh85073583//Kyphosis//LCH_NW	E12447//Kyphosis//NCI_CTCAE	HP:0002808//Kyphosis//HPO	C34754//Kyphosis//NCI_NICHD	737.1//Acquired kyphosis//MTHICD9	D007738//Kyphosis//MSH	U002296//KYPHOSIS//DXP	0000007144//hunchback//CHV	MTHU042267//kyphosis//ICPC2ICD10ENG	335709//kyphosis//MEDCIN	N371.//Acquired kyphosis//RCD	XE1M4//Congenital kyphosis//RCD	0000025940//inborn hunchback//CHV	7992//kyphosis//MEDCIN	NOCODE//Developmental arithmetic disorder//MTH
spinal stenosis	SPI//Spinal Stenosis//AIR	DXSPI//Spinal Stenosis//AIR	D013130//Spinal Stenosis//MSH	N0000002801//Spinal Stenosis [Disease/Finding]//NDFRT	412//Spinal Stenosis//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	1003773//SPINAL STENOSIS//CCPSS	696//SPINAL STENOSIS//COSTAR	M48.0//Spinal stenosis//ICD10	X70Co//Spinal stenosis//RCD	MTHU038291//Spinal stenosis//OMIM	76107001//Spinal stenosis//SNOMEDCT_US	BI00513//spinal stenosis//BI	0000011626//spinal narrowing//CHV	L86011//spinal stenosis//ICPC2P	35861//spinal stenosis//MEDCIN	HP:0003416//Spinal canal stenosis//HPO
socialization	U004371//Socialization//LCH	C88512//Socialization//NCI	sh85124152//Socialization//LCH_NW	48470//Socialization//PSY	D012951//Socialization//MSH	0000009691//socialization//AOD	2727-6778//socialization//CSP	0000011471//socialization//CHV
desferrioxamine	x01GJ//Desferrioxamine//RCD	N0000007065//Deferoxamine [Chemical/Ingredient]//NDFRT	NSC0527604//Desferal//NCI_DTP	DB00746//Deferoxamine//DRUGBANK	372825006//Deferoxamine//SNOMEDCT_US	70702006//Deferoxamine//SNOMEDCT_US	C416//Deferoxamine//NCI	D003676//Deferoxamine//MSH	0000003658//deferoxamine//CHV	1629-5423//deferoxamine//CSP
treatment with iron chelating agents (i	
deferasirox	614373//deferasirox//RXNORM	CDR0000435986//deferasirox//PDQ	302332//deferasirox//MEDCIN	N0000171608//deferasirox [Chemical/Ingredient]//NDFRT	011097//deferasirox//NDDF	V03AC03//deferasirox//ATC	CDR0000514444//deferasirox//NCI_NCI-GLOSS	d05659//deferasirox//MMSL	20643//deferasirox//MMSL	C415250//deferasirox//MSH	4024936//DEFERASIROX//VANDF	N0000023118//DEFERASIROX//NDFRT	V8G4MOF2V9//DEFERASIROX//NCI_FDA	C48384//Deferasirox//NCI	50595//Deferasirox//NCI_DCP	MTHU003565//Deferasirox//USPMG	DB01609//Deferasirox//DRUGBANK	419985007//Deferasirox//SNOMEDCT_US	417910004//Deferasirox//SNOMEDCT_US
deferiprone	11645//deferiprone//RXNORM	0000013302//deferiprone//CHV	007561//BETAMETHASONE DIPROPIONATE/PROPYLENE GLYCOL 0.05 % TOPICAL CREAM (GRAM)//NDDF	d04976//deferiprone//MMSL	18035//deferiprone//MMSL	V03AC02//deferiprone//ATC	C044919//deferiprone//MSH	NOCODE//Developmental arithmetic disorder//MTH	N0000183921//DEFERIPRONE//NDFRT	4031179//DEFERIPRONE//VANDF	2BTY8KH53L//DEFERIPRONE//NCI_FDA	C73030//Deferiprone//NCI	MTHU003566//Deferiprone//USPMG	DB08826//Deferiprone//DRUGBANK	396011004//Deferiprone//SNOMEDCT_US	329482000//Deferiprone//SNOMEDCT_US
fresh-frozen human plasma	
if the serum potassium concentration is low (<3	
treatment for actg2-related disorders remains supportive	
urologic manifestations	
management of bladder dysfunction by an urologist is recommended	
gastrointestinal manifestations	
however, bladder catheterization was still required	
prophylaxis for pneumocystis jiroveci	
intravenous immunoglobulin (ivig)	
cutaneous/cranial	
wounds without calvarial involvement	
plastic wrap (e	
, duoderm®)	
other less preferred, less costly dressings are:	
wounds with calvarial defects: acute care	
wounds with calvarial defects: late calvarial reconstruction	
limb	D005121//Extremities//MSH	X74Yt//Limb//RCD	T-Y1800//Extremity//SNM	7182//Limb//UWDA	TCGA//Enterovirus//NCI	C12429//Limb//NCI	66019005//Limb structure//SNOMEDCT_US	0000004703//limb//AOD	0000004807//arms and legs//CHV	2715-5305//limb//CSP
early physiotherapy can maximize motor function and range of motion	
management of seizures is per routine	
if typical signs (e	
medication has been variably effective in suppressing debilitating symptoms	
j friedman, personal observation]	
fm hisama, personal observation]	
stress management	Ub014//Stress management//RCD	441151000124104//Stress management//SNOMEDCT_US	sh88004681//Stress management//LCH_NW	226060000//Stress management//SNOMEDCT_US	4006-0088//stress management//CSP	56//stress management//OMS	0000016930//stress management//CHV	79650//stress management//MEDCIN	50175//Stress Management//PSY
intrafamilial variation in pharmaco-responsiveness occurs	
therefore, all appropriate aeds should be tried	
speech, occupational, and physical therapy	
specialized learning programs depending on individual needs	
nutritional support if necessary	
routine treatment of cardiac and ophthalmologic findings	
ankyloblepharon filiforme adnatum	MTHU019531//Ankyloblepharon filiforme adnatum//OMIM	HP:0009755//Ankyloblepharon//HPO	C536373//Ankyloblepharon filiforme adnatum//MSH	400952003//Ankyloblepharon filiforme adnatum//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	HGNC:310//ankyloblepharon filiforme adnatum//HGNC
larger ones may require surgical separation by an ophthalmologist	
ectodermal defects	
skin erosions	MTHU009028//Skin erosions//OMIM
empiric treatment (i	
clefting should be addressed as soon as developmentally possible	
chest physiotherapy and vigorous treatment of respiratory complications	
management of seizures using standard protocols	
acute episodes	
correction of hyperkalemia may be needed	
, solu-cortef®)	
adequate sodium must be provided	
treatment during stress	
, intercurrent illness, surgery, trauma)	
glucose and sodium may be needed	
parents should have access to rapid medical advice	
guidelines for hospital admission should be clear	
acth levels should normalize when replacement therapy is adequate	
acute neurovisceral attack	
clinical assessment should include a full neurologic evaluation	
investigations should include:	
full blood count (fbc)	
serum and urine osmolality	
urine sodium concentration if hyponatremic	
, crp, blood cultures, ck, magnesium	
mri should be considered if cns symptoms are present	
general measures	
see agents/circumstances to avoid	
restore energy balance using an enteral route if possible	
treat intercurrent infections and other diseases promptly	
supportive treatment	
pain relief	10033487//Pain relief//MDR	182970005//Pain relief//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000036051//pain relief//CHV	BPI-Short Form//Pain at its Worst//NCI	C112216//Pain Relief//NCI	0000046073//Pain Relief brand//CHV	6725//candesartan 8 mg oral tablet//MMSL
nausea and vomiting	17.1.6//Nausea and vomiting//CCS	250//Nausea and vomiting//CCS	R11//Nausea and vomiting//ICD10	Xa1pJ//Nausea and vomiting//RCD	F-61640//Nausea and vomiting//SNM	F-52840//Nausea and vomiting//SNMI	HP:0002017//Nausea and vomiting//HPO	16932000//Nausea and vomiting//SNOMEDCT_US	787.0//Nausea and vomiting//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	NAUSEA VOMIT//NAUSEA AND VOMITING//CST	CDR0000041395//nausea and vomiting//PDQ	C3259//Nausea and Vomiting//NCI	489//Nausea and Vomiting//MEDLINEPLUS
prochloperazine, promazine or ondansetron are considered safe	
beta blockers are considered safe	
fluid balance and electrolytes	
dextrose saline is preferred	
specific treatment	
it is infused over at least 30 minutes	
recurrent acute attacks	
gynecological review and bone density monitoring are recommended	
prophylactic hemin infusion	
however, evidence for clinical efficacy remains elusive	
, medicalert® or similar)	
see resources	
liver transplantation for end-stage liver disease has an 80	
cardiac involvement is treated in a standard manner	
renal anomalies are treated in a standard manner	
vascular accidents should be treated in a standard manner	
head injuries and neurologic symptoms should be evaluated aggressively	
ophthalmologic abnormalities rarely need intervention	
vertebral anomalies are rarely symptomatic	
no specific therapy is currently available for alexander disease	
neuroblastoma and ganglioneuroblastoma	
aortic stenosis may necessitate valve replacement	
treatment is limited to symptom management and supportive care	
alpers-huttenlocher syndrome	D002549//Diffuse Cerebral Sclerosis of Schilder//MSH	203700//MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE)//OMIM
family education is critical	
supportive therapies	
hepatic	T-62000//Liver, NOS//SNMI	LP92703-5//Hepatic//LNC	TCGA//Enterovirus//NCI	C13308//Hepatic//NCI	U000508//Hepatic//MTH	1754-0095//liver//CSP	CDR0000045709//hepatic//NCI_NCI-GLOSS
treatment with cpap or bipap as indicated is appropriate	
seizure control is a goal of treatment	
other phenotypes	
gastrostomy may be required to provide adequate nutrition	
surgery for ptosis may provide symptomatic relief for some	
, influenza and pneumococcal)	
controls	
recommend intravenous aat augmentation therapy for individuals with established emphysema	
, fev1 35%-60% predicted)	
2 months post-liver transplant and not achieving statistical significance	
panniculitis	D015434//panniculitis//MSHCZE	10033675//panniculitis//MDRDUT	10033674//panniculitis//MDRDUT	NOCODE//Sepsis//COSTAR	L99083//panniculitis//ICPC2P	X707z//Panniculitis//RCD	M-40000//Inflammation//SNM	N0000003238//Panniculitis [Disease/Finding]//NDFRT	MTHU032395//Panniculitis//OMIM	C112112//Panniculitis//NCI	HP:0012490//Panniculitis//HPO	22125009//Panniculitis//SNOMEDCT_US	0039159//PANNICULITIS//CCPSS	CELLULITIS//CELLULITIS//CST	1416//PANNICULITIS//WHO	0000005146//panniculitis//AOD	0000009236//panniculitis//CHV	MTHU057236//panniculitis//ICPC2ICD10ENG	211130//panniculitis//MEDCIN
hypertensive individuals should receive appropriate management	
male relative without hematuria	
male relative with hematuria	
female relative without hematuria	
female relative with hematuria (i	
, heterozygous female)	
cochlear	C12395//Cochlea//NCI
hearing aids should be prescribed when appropriate	
some individuals develop cataracts that interfere with vision	
these should be extracted when necessary	
diffuse leiomyomatosis	HP:0006756//Diffuse leiomyomatosis//HPO
symptomatic leiomyomas may require surgical intervention	
monitoring for and treatment of lymphoproliferation and hypersplenism	
however, sirolimus is not without side effects	
treatment of lymphoma is according to conventional protocols	
treatment of cytopenias and other autoimmune diseases	
caregiver and patient support groups are valuable	
options include:	
ssris	4146//Antidepressants//MEDLINEPLUS	D000068760//СЕРОТОНИНА И НОРАДРЕНАЛИНА ОБРАТНОГО ЗАХВАТА ИНГИБИТОРЫ//MSHRUS
venlafaxine	5002-0025//venlafaxine//CSP	d03181//venlafaxine//MMSL	39786//venlafaxine//RXNORM	0000015055//venlafaxine//CHV	004428//MAGNESIUM SALICYLATE/PHENYLTOLOXAMINE CITRATE 325 mg-30 mg ORAL TABLET//NDDF	340497//venlafaxine//MEDCIN	N06AX16//venlafaxine//ATC	CDR0000046117//venlafaxine//NCI_NCI-GLOSS	GRZ5RCB1QG//venlafaxine//MTHSPL	CDR0000043238//venlafaxine//PDQ	NOCODE//Developmental arithmetic disorder//MTH	da7..//Venlafaxine//RCD	LP17950-4//Venlafaxine//LNC	MTHU004272//Venlafaxine//LNC	N0000006524//Venlafaxine [Chemical/Ingredient]//NDFRT	DB00285//Venlafaxine//DRUGBANK	108432009//Venlafaxine//SNOMEDCT_US	372490001//Venlafaxine//SNOMEDCT_US	55450//Venlafaxine//PSY	C1278//Venlafaxine//NCI	MTHU000317//Venlafaxine//USPMG	D000069470//Venlafaxine Hydrochloride//MSH	4023901//VENLAFAXINE//VANDF	N0000021906//VENLAFAXINE//NDFRT
however, weakness and lethargy are common side effects	
low-tech (e	
, alphabet board) and high-tech (i	
no therapy exists to prevent the progressive organ involvement	
rod-cone dystrophy	N0000002614//Retinitis Pigmentosa [Disease/Finding]//NDFRT	D012174//Retinitis Pigmentosa//MSH	0000010812//Retinitis pigmentosa (RP)//CHV	MTHU030127//Rod-cone dystrophy//OMIM	HP:0000510//Rod-cone dystrophy//HPO
progressive sensorineural hearing loss	
hearing can be maximized with bilateral digital hearing aids	
exercise	D015444//Exercise//MSH	X79ON//Exercise//RCD	LP61581-2//Exercise//LNC	sh85046328//Exercise//LCH_NW	LA22651-6//Exercise//LNC	LP207667-9//Exercise//LNC	256235009//Exercise//SNOMEDCT_US	18390//Exercise//PSY	C16567//Exercise//NCI	NOCODE//Developmental arithmetic disorder//MTH	1101-5144//exercise//CSP	0000004762//exercise//CHV	C26387//Exercise Pain Management//NCI
and metformin	
hypertriglyceridemia	D015228//Hypertriglyceridemia//MSH	U000352//Ammonia measurement//MTH	Xa9At//Hypertriglyceridemia//RCDAE	N0000003210//Hypertriglyceridemia [Disease/Finding]//NDFRT	4277//Triglycerides//MEDLINEPLUS	sh91000712//Hypertriglyceridemia//LCH_NW	10020870//Hypertriglyceridemia//MDR	10020869//Hypertriglyceridaemia//MDR	302870006//Hypertriglyceridemia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	1006866//HYPERTRIGLYCERIDEMIA//CCPSS	399//HYPERTRIGLYCERIDEMIA//COSTAR	HYPERLIPEM//HYPERLIPEMIA//CST	U002037//ZINC CHLORIDE POISONING//DXP	0000005733//hypertriglyceridemia//AOD	BI00121//hypertriglyceridemia//BI	1744-2731//hypertriglyceridemia//CSP	0000006455//high triglycerides//CHV	T93005//hypertriglyceridaemia//ICPC2P	166848004//Hypertriglyceridemia//SNOMEDCT_VET	MTHU002090//Hypertriglyceridemia//OMIM	E12299//Hypertriglyceridemia//NCI_CTCAE	C37971//Hypertriglyceridemia//NCI_NICHD	HP:0002155//Hypertriglyceridemia//HPO
pancreatitis should be treated as in the general population	
urologic	G-B104//Urologic//SNMI	C17243//Urology//NCI	77926000//Urologic//SNOMEDCT_US	0000020615//urologic//CHV
prevention of primary complications	
depression and seizures should be treated with appropriate medications	
the first such drug was tacrine	
however, this agent is also hepatotoxic	
antidepressant medication may improve associated depression	
seizures have occurred in some affected infants	
assignment of sex of rearing	
even in cais this may not always be easy	
cais	C120191//Complete Androgen Insensitivity Syndrome//NCI
however, the issue of gonadectomy is controversial	
pais with predominantly female genitalia (incomplete ais)	
pais with ambiguous genitalia or predominantly male genitalia	
gynecomastia that develops in puberty eventually requires reduction mammoplasty	
mais	D003313//КУКУРУЗА//MSHRUS
the customary medical treatment (i	
sometimes fundoplication as required	
no one drug has proven superior	
medications used for minor motor seizures (e	
hypermotoric behaviors are typically resistant to behavioral therapies	
unstable or nonambulatory children may benefit from physical therapy	
individualization and flexibility in the school are important educational strategies	
administration of 0	
strabismus may require surgical correction	
aniridia	10002532//Aniridia//MDR	D015783//Aniridia//MSH	P343.//Aniridia//RCD	M-21000//Absence, congenital//SNM	D4-A0310//Aniridia//SNMI	MTHU007655//Aniridia//OMIM	C84563//Aniridia//NCI	Q13.1//Absence of iris//ICD10CM	N0000003313//Aniridia [Disease/Finding]//NDFRT	HP:0000526//Aniridia//HPO	743.45//Aniridia//ICD9CM	69278003//Congenital aniridia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	U000184//BACILLUS CEREUS DIARRHEA//DXP	0689//EYE MALFORMATION//WHO	607108//PAIRED BOX GENE 6//OMIM	0000001211//aniridia//CHV	297655//aniridia//MEDCIN	MTHU006498//aniridia//ICPC2ICD10ENG	38547//aniridia//MEDCIN
simple measures are often the most important:	
regular eye examinations and correction of refractive errors	
occlusion therapy for anisometropic amblyopia or strabismic amblyopia in childhood	
advice and help with schooling	
social support	220307//Social support//NOC	U002253//Social support//MTH	1504//Social Support//NOC	48416//Social Support//PSY	D012944//Social Support//MSH	0000009753//social support//AOD	0000011465//social support//CHV	CDR0000440116//social support//NCI_NCI-GLOSS	315042007//Social support//SNOMEDCT_US	250805//Social support//NOC	441141000124101//Social support//SNOMEDCT_US
lens	NOCODE//Developmental arithmetic disorder//MTH	7N160//Lens//RCD	T-XX700//Crystalline lens//SNM	58241//Lens//UWDA	LA25447-6//Lens//LNC	C12743//Lens//NCI	LENS//Lens//HL7V2.5	78076003//Lens clear//SNOMEDCT_US	1110-6890//lens//CSP	CDR0000572035//lens//NCI_NCI-GLOSS	SDTM-LOC//PERIPANCREATIC LYMPH NODE//NCI_CDISC	D007908//Øyets linse//MSHNOR	D007909//Lens//MSHDUT	0000007303//lens//CHV	3863//Lens//NCBI	D027806//Lens//MSHCZE	YF//LENS//NDDF	6619//examination of lens//MEDCIN	C50030//Lens Device Component//NCI
children rarely require surgery (lens aspiration or lensectomy)	
in adults, phacoemulsification can be successful	
intraocular pressure	D007429//Intraocular Pressure//MSH	U002489//Intraocular pressure//LCH	X77Nd//Intraocular pressure//RCD	F-X3290//Intraocular pressure//SNM	LP96294-1//Intraocular pressure//LNC	MTHU034775//Intraocular pressure//LNC	sh85067624//Intraocular pressure//LCH_NW	41633001//Intraocular pressure//SNOMEDCT_US	0000006874//pressure in eye//CHV	1110-3144//intraocular pressure//CSP	10022801//Intraocular pressure//MDR	0000057830//pressure in eye//CHV	6670//intraocular pressure//MEDCIN	C87143//Intraocular Pressure//NCI_CDISC	SDTM-OETEST//Color//NCI_CDISC	SS/EYE/IOP//intraocular pressure//CST	0000041433//pressure in eye//CHV	OPHIOP//INTRAOCULAR PRESSURE//CST
glaucoma is usually initially treated with topical anti-glaucoma medication	
trabeculectomy with or without antimetabolites (e	
medical treatment is generally ineffective and surgery is required	
cornea	D003315//rohovka//MSHCZE	U001163//Cornea//LCH	7N151//Cornea//RCD	T-XX200//Cornea//SNM	58238//Cornea//UWDA	s2201//Cornea//ICF	LP32986-9//Cornea//LNC	MTHU010519//Cornea//LNC	sh85032796//Cornea//LCH_NW	28726007//Corneal structure//SNOMEDCT_US	11830//Cornea//PSY	C12342//Cornea//NCI	CORN//Cornea//HL7V2.5	U001828//Cornea//MTH	SDTM-LOC//PERIPANCREATIC LYMPH NODE//NCI_CDISC	0000017573//cornea//AOD	1109-3779//cornea//CSP	LP91416-5//cornea//LNC	0000003354//outer coat of the eyeball//CHV	CDR0000044199//cornea//NCI_NCI-GLOSS	90095//corneal disorder//MEDCIN	CRN//Cornea//HL7V3.0
aniridic fibrosis syndrome	
wilms tumor	10047985//Wilms tumor//MDRDUT	C3267//Wilms Tumor//NCI	N0000171666//Wilms Tumor [Disease/Finding]//NDFRT	3075//Wilms Tumor//MEDLINEPLUS	D009396//Wilms Tumor//MSH	0048278//WILMS TUMOR//CCPSS	CARCINOMA//CARCINOMA//CST	U002025//WILMS TUMOR//DXP	600185//BRCA2 GENE//OMIM	0000023021//Wilms tumor//AOD	MTHU006873//Wilms tumor//OMIM	HP:0002667//Nephroblastoma//HPO	CDR0000042957//Wilms' tumor and other childhood kidney tumors//PDQ	302849000//Nephroblastoma//SNOMEDCT_US	0000008581//wilms tumor//CHV	D030321//Denys-Drash' syndrom//MSHNOR	C103086//Wilms Tumor//NCI_CTEP-SDC
see wilms tumor overview	
the need for orthoses or other assistive devices varies individually	
most patients remain ambulatory without assistance for decades	
provide palliative care for the viable newborn	
educational support (e	
, behavioralists) who can provide the following:	
gait safety devices including canes and wheel chairs	
behavioral modification and cognitive aids as needed	
there are no formal management guidelines for apoe p	
leu167del-related lipid disorders	
in patients with fasting triglyceride levels:	
splenomegaly	SPLEN//Splenomegaly//AIR	B87//Splenomegaly//ICPC	B87003//splenomegaly//ICPC2P	10041660//Splenomegaly//MDR	XM096//Splenomegaly//RCD	M-71000//Hypertrophy//SNM	MTHU001744//Splenomegaly//OMIM	N0000002808//Splenomegaly [Disease/Finding]//NDFRT	414//Spleen Diseases//MEDLINEPLUS	HP:0001744//Splenomegaly//HPO	16294009//Splenomegaly//SNOMEDCT_US	C3384//Splenomegaly//NCI	789.2//Splenomegaly//ICD9CM	D013163//Splenomegaly//MSH	1012345//SPLENOMEGALY//CCPSS	U000635//SPLENOMEGALY//COSTAR	SPLENOMEGALY//SPLENOMEGALY//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0569//SPLENOMEGALY//WHO	0000005960//splenomegaly//AOD	0427-9482//splenomegaly//CSP	0000011648//enlarged spleen//CHV	CDR0000373017//splenomegaly//NCI_NCI-GLOSS	360329//splenomegaly//MEDCIN	MTHU068980//splenomegaly//ICPC2ICD10ENG	7434//splenomegaly//MEDCIN
splenectomy should be avoided as it may worsen hyperlipidemia	
liver function abnormalities	
persistent nausea	03039//Persistent nausea//NANDA-I
vomiting	D10//Vomiting//ICPC	D10004//vomiting//ICPC2P	U004996//Vomiting//LCH	D014839//Vomiting//MSH	XE0rA//Vomiting//RCD	F-61570//Vomiting//SNM	070813//Vomiting//NOC	250928//Vomiting//NOC	040609//Vomiting//NOC	040507//Vomiting//NOC	230322//Vomiting//NOC	230204//Vomiting//NOC	070622//Vomiting//NOC	210519//Vomiting//NOC	040410//Vomiting//NOC	251025//Vomiting//NOC	422400008//Vomiting//SNOMEDCT_US	MTHU000225//Vomiting//OMIM	b5106//Vomiting//ICF-CY	10025981//Vomiting//ICNP	R11.1//Vomiting//ICD10CM	N0000003141//Vomiting [Disease/Finding]//NDFRT	B04.2//Vomiting//CCC	489//Nausea and Vomiting//MEDLINEPLUS	MTHU013530//Vomiting//LNC	sh85144382//Vomiting//LCH_NW	E11068//Vomiting//NCI_CTCAE	C3442//Vomiting//NCI_NICHD	LA15099-7//Vomiting//LNC	2144//Vomiting//NCI_FDA	HP:0002013//Vomiting//HPO	10047700//Vomiting//MDR	01771//Vomiting//NANDA-I	56340//Vomiting//PSY	NOCODE//Developmental arithmetic disorder//MTH	793//VOMITING//COSTAR	VOMIT//VOMITING//CST	U004425//VOMITING//DXP	0228//VOMITING//WHO	0000005506//vomiting//AOD	BI00287//vomiting//BI	415//vomiting//MEDCIN	0000013085//vomiting//CHV	MTHU012494//vomiting//ICPC2ICD10ENG	1248-4787//emesis//CSP	293335//vomiting//MEDCIN	C57896//Vomiting//NCI_CTCAE	MSAS-SF//Almost Constantly//NCI	MSAS//Dry mouth//NCI	BCPTSS//Night sweats//NCI
abdominal pain	D015746//Abdominal Pain//MSH	306//Abdominal Pain//MTH	N0000003309//Abdominal Pain [Disease/Finding]//NDFRT	3061//Abdominal Pain//MEDLINEPLUS	1685//Pain, Abdominal//NCI_FDA	C26682//Abdominal Pain//NCI_NICHD	MPN-SAF//Problem//NCI	10043953//Abdominal Pain//ICNP	NOCODE//Developmental arithmetic disorder//MTH	004//ABDOMINAL PAIN//COSTAR	PAIN ABDO//ABDOMINAL PAIN//CST	U000023//ACID PHOSPHATASE, LYSOSOMAL, DEFICIENCY//DXP	0268//ABDOMINAL PAIN//WHO	17.1.7//Abdominal pain//CCS	251//Abdominal pain//CCS	1969.//Abdominal pain//RCD	F-50860//Abdominal pain//SNMI	250912//Abdominal pain//NOC	040408//Abdominal pain//NOC	MTHU036407//Abdominal pain//OMIM	MTHU013636//Abdominal pain//LNC	sh85000111//Abdominal pain//LCH_NW	E10460//Abdominal pain//NCI_CTCAE	LA15468-4//Abdominal pain//LNC	HP:0002027//Abdominal pain//HPO	10000081//Abdominal pain//MDR	00005//Risk for imbalanced body temperature//NANDA-I	789.0//Abdominal pain//ICD9CM	21522001//Abdominal pain//SNOMEDCT_US	0000005516//abdominal pain//AOD	BI00206//abdominal pain//BI	0000000535//abdominal pain//CHV	D01006//abdominal pain//ICPC2P	475//abdominal pain//MEDCIN
yellow discoloration of the skin	
bruising	XM0AW//Bruise//RCD	M-14200//Contusion, NOS//SNMI	C37921//Bruise//NCI	040903//Bruising//NOC	E11666//Bruising//NCI_CTCAE	10006504//Bruising//MDR	125667009//Contusion//SNOMEDCT_US	308492005//Contusion - lesion//SNOMEDCT_US	0032910//BRUISING//CCPSS	0000003331//bruise//CHV	26.08//bruising//OMS	124703//reported bruising//MEDCIN
any new petechial rash	
allopurinol	1816//heparin 20000 units/mL injectable solution//MMSL	j61..//Allopurinol//RCD	E-8987//Allopurinol//SNM	C-B7020//Allopurinol//SNMI	519//Allopurinol//RXNORM	63CZ7GJN5I//Allopurinol//MTHSPL	N0000005830//Allopurinol [Chemical/Ingredient]//NDFRT	LP17988-4//Allopurinol//LNC	MTHU024809//Allopurinol//LNC	DB00437//Allopurinol//DRUGBANK	25246002//Allopurinol//SNOMEDCT_US	387135004//Allopurinol//SNOMEDCT_US	C224//Allopurinol//NCI	MTHU000412//Allopurinol//USPMG	D000493//Allopurinol//MSH	0875-2372//allopurinol//CSP	d00023//allopurinol//MMSL	4150//calcium carbonate-magnesium carbonate 520 mg-400 mg oral tablet//MMSL	0000000917//allopurinol//CHV	001084//CHLORPHENIRAMINE MALEATE/PHENYLPROPANOLAMINE HCL 8 mg-75 mg ORAL TABLET, EXTENDED RELEASE//NDDF	M04AA01//allopurinol//ATC	CDR0000045052//allopurinol//NCI_NCI-GLOSS	CDR0000038452//allopurinol//PDQ	0062165//ALLOPURINOL//CCPSS	N0000146247//ALLOPURINOL//NDFRT	4017895//ALLOPURINOL//VANDF
febuxostat	D000069465//febuxostat//MSHCZE	73689//febuxostat//RXNORM	101V0R1N2E//febuxostat//MTHSPL	26212//febuxostat//MMSL	d07397//febuxostat//MMSL	M04AA03//febuxostat//ATC	012966//febuxostat//NDDF	NOCODE//Developmental arithmetic disorder//MTH	N0000171777//FEBUXOSTAT//NDFRT	4025245//FEBUXOSTAT//VANDF	C65629//Febuxostat//NCI	441610003//Febuxostat//SNOMEDCT_US	441743008//Febuxostat//SNOMEDCT_US	304534//Febuxostat//MEDCIN	MTHU002406//Febuxostat//USPMG	N0000179385//Febuxostat [Chemical/Ingredient]//NDFRT	DB04854//Febuxostat//DRUGBANK
treatment of esrd	
kidney transplantation	D016030//Kidney Transplantation//MSH	1299//Kidney Transplantation//MEDLINEPLUS	C15265//Kidney Transplantation//NCI	NOCODE//Developmental arithmetic disorder//MTH	P-1429//Transplantation, allogeneic//SNM	70536003//Transplant of kidney//SNOMEDCT_US	1683-2651//kidney transplantation//CSP	0000007098//kidney transplant//CHV	CDR0000354477//kidney transplantation//PDQ
arginine supplementation is obviously contraindicated	
rapidly reducing plasma ammonia concentration	
pharmacologic management to allow alternative pathway excretion of excess nitrogen	
in early treatment, feeding 1	
0 to 1	
older children require and tolerate lower protein intake	
seizures are easily treated by phenobarbital or carbamazepine	
discontinuing oral protein intake	
intravenous nitrogen scavenging therapy	
ammonia levels usually normalize with therapy	
nitrogen scavenging therapy needs to be continued during hemodialysis	
curative therapy is not available	
clinical history studies are limited	
aneurysms and focal stenoses are amenable to surgical intervention	
hernias may recur after surgical repair	
emphysema is treated symptomatically	
, swimming) performed in moderation	
no treatment is available	
see hereditary ataxias, management	
beta blockers are considered first line therapy	
however, individual responses to specific medications (e	
(see also therapies under investigation	
speech therapy may benefit persons with dysarthria	
one of the following vitamin e preparations is used:	
the naturally occurring form, rrr-α-tocopherol	
thalassemia major	D017086//beta-Thalassemia//MSH	0046795//THALASSEMIA MAJOR//CCPSS	730//THALASSEMIA MAJOR//COSTAR	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	D-4181//beta Thalassemia, homozygous//SNM	282.44//Cooley's anemia//MTHICD9	314996//Thalassemia major//MEDCIN	D56.1//Beta thalassemia//ICD10CM	10054661//Thalassemia major//MDR	75451007//Thalassemia major//SNOMEDCT_US	0000001121//cooley's anemia//CHV	1418-5761//thalassemia//CSP
transfusions are usually given every two to three weeks	
thalassemia intermedia	10062923//thalassemia intermedia//MDRDUT	10062921//thalassemia intermedia//MDRDUT	D017086//beta-Thalassemia//MSH	0000026688//thalassemia intermedia//CHV	141900//HEMOGLOBIN--BETA LOCUS//OMIM	D56.1//Beta thalassemia//ICD10CM	282.44//Cooley's anemia//MTHICD9	934007//Thalassemia intermedia//SNOMEDCT_US
cord blood transplantation	CDR0000042637//umbilical cord blood transplantation//PDQ	C15640//Cord Blood Transplantation//NCI_NICHD
uveal melanoma	MTHU035642//Uveal melanoma//OMIM	309341000009105//Melanoma of uvea//SNOMEDCT_VET	HP:0007716//Intraocular melanoma//HPO	C536494//Uveal melanoma//MSH	0000021169//intraocular melanoma//CHV	CDR0000038817//intraocular melanoma//PDQ	C7712//Uveal Melanoma//NCI
malignant mesothelioma	BBP1.//Malignant mesothelioma//RCD	4014//Mesothelioma//MEDLINEPLUS	HP:0100001//Malignant mesothelioma//HPO	109378008//Mesothelioma (malignant, clinical disorder)//SNOMEDCT_US	62064005//Mesothelioma, malignant//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000031033//malignant mesothelioma//CHV	CDR0000044992//malignant mesothelioma//NCI_NCI-GLOSS	CDR0000038142//malignant mesothelioma//PDQ	C4456//Malignant Mesothelioma//NCI
thus, a cure is unlikely	
there is no specific treatment of bwcff syndrome	
symptomatic management involves the following	
ptosis may require surgical treatment	
hearing loss may require routine care including hearing aids	
epilepsy is treated using standard protocols	
management of heart failure	
management of neutropenia	
78 ± 0	
45-12	
8 years, with an average exposure of 7	
3 years	
educational support in school	
, renal or hepatic dysfunction)	
indicators are functional interference and poorly fitting footwear	
dental extractions are appropriate as required for dental crowding	
insertion of grommets is commonplace	
manifestations should be treated by specialists (e	
keratocysts usually require surgical excision	
systemic treatment with retinoids (e	
bethlem myopathy	718572004//Bethlem myopathy//SNOMEDCT_US	C535436//Bethlem myopathy//MSH	158810//BETHLEM MYOPATHY 1//OMIM
ullrich cmd	
contractures tend to be aggressive and may require surgery	
kcnq2-bfne	
refractory seizures are uncommon in kcnq2-related bfne	
kcnq2-nee	
augmentative communication techniques can be valuable for many patients	
antiepileptic treatment for seizures	
symptomatic treatment for headaches	
biotin and thiamine therapy	
biotin and thiamine need to be given lifelong	
in the acute stage empiric treatment with antimicrobial/antiviral agents	
fever control	
antiepileptic drugs for effective control of seizures	
symptomatic treatment of dystonia, including administration of l-dopa	
rehabilitation, physiotherapy, occupational therapy, and speech therapy	
educational programs adapted to individual needs	
therefore, renal tumors greater than 3	
no treatment for bcd currently exists	
psychosocial	NOCODE//Developmental arithmetic disorder//MTH	BI00025//psychosocial//BI	0000038590//psychosocial//CHV	0043148//PSYCHOSOCIAL//CCPSS	CDR0000648685//psychosocial//NCI_NCI-GLOSS
milunsky et al [2011] provided management guidelines	
see table iii)	
they should not be cauterized	
most larger skin defects require surgical excision	
recommended treatment:	
second branchial arch anomalies	
excise branchial cleft cysts/fistulae	
otologic anomalies	
fit with appropriate aural habilitation as indicated	
enroll in an appropriate educational program for the hearing impaired	
consider canaloplasty to correct an atretic canal	
treat urologic and renal abnormalities in the standard manner	
if renal anomalies (e	
if esrd develops, consider renal transplantation	
global developmental disability/intellectual disability	
disordered sleep	
ophthalmologic findings	
eye findings are treated in a routine manner	
regular pulmonary hygiene to manage risk for pulmonary complications	
tracheostomy as indicated when secretions are difficult to manage	
eyelid surgery	
timing of eyelid surgery is controversial	
however, it remains controversial	
hormone replacement therapy (hrt)	0000027580//hormone replacement therapy (HRT)//CHV
it is important to:	
controversy exists regarding the treatment of asymptomatic individuals	
treatment of craniofacial manifestations (e	
there are no reports on the use of aflibercept	
the cnv regressed and the subretinal hemorrhage resolved	
genetic counseling and occupational counseling should be offered	
abdominal wall repair for omphalocele soon after birth	
generally, this surgery is well tolerated	
management of difficulties arising from macroglossia:	
some children benefit from tongue reduction surgery	
orthodontic intervention as needed in later childhood/adolescence	
assessment of speech difficulties	
management of cleft palate following standard protocols	
referral to a craniofacial surgeon if facial hemihyperplasia is significant	
treatment of neoplasias following standard pediatric oncology protocols	
, nephrocalcinosis)	
management of cardiac problems following standard protocols	
during acute episodes	
restrict protein intake if plasma ammonia is elevated	
without carglumic acid, hyperammonemia persisted longer (i	
, an additional 1-2 days)	
there is no treatment of proven efficacy for cadasil	
classic 21-ohd cah	
glucocorticoid replacement therapy	
the use of oral hydrocortisone suspension is discouraged	
during periods of stress (e	
affected individuals should carry medical information regarding emergency steroid dosing	
mineralocorticoid replacement therapy	
sodium chloride supplementation may not be necessary after infancy	
feminizing genitoplasty	
the systematic evidence for this belief is lacking	
testicular adrenal rest tumors	
transition from adolescence to adulthood	
women with classic cah had increased diastolic blood pressure	
subjective health status was significantly impaired and fertility compromised	
adrenalectomy	119//Adrenalectomy//ICD10AM	U000086//Adrenalectomy//LCH	7122.//Adrenalectomy//RCD	P-1100//Excision, NOS (-ectomy)//SNM	sh85001006//Adrenalectomy//LCH_NW	10061622//Adrenalectomy//MDR	31904001//Adrenalectomy//SNOMEDCT_US	01050//Adrenalectomy//PSY	C15177//Adrenalectomy//NCI	D000315//Adrenalectomy//MSH	0038762//ADRENALECTOMY//CCPSS	U000094//ANEMIA, HEMOLYTIC, MICROANGIOPATHIC//DXP	0000008376//adrenalectomy//AOD	0062-1836//adrenalectomy//CSP	0000000772//adrenalectomy//CHV	CDR0000458096//adrenalectomy//NCI_NCI-GLOSS	CDR0000038849//adrenalectomy//PDQ	41691//adrenalectomy//MEDCIN
non-classic 21-ohd cah	
most survivors with cd require orthopedic care	
club feet require surgical correction	
the hips should be checked for luxation	
bracing is usually not helpful	
neonatal/infantile canavan disease	
seizures may be treated with antiepileptic drugs (aeds)	
diamox® seems to reduce intracranial pressure	
botox® injections may be used to relieve spasticity	
mild/juvenile canavan disease	
scoliosis may require bracing or surgical correction	
personality change may require antipsychotic medication	
a wig or hairpiece may be helpful for alopecia	
the following interventions are routine:	
cardiac myxoma	10061005//Cardiac myxoma//MDR	C7748//Cardiac Myxoma//NCI	0000056522//cardiac myxoma//CHV	HP:0011672//Cardiac myxoma//HPO	35888//myxoma of heart//MEDCIN
open-heart surgery	
cutaneous and mammary myxoma	
surgical excision	X79vD//Surgical excision//RCD	0000046660//removal//CHV
cushing syndrome	D003480//Cushing Syndrome//MSH	C2969//Cushing Syndrome//NCI	N0000000883//Cushing Syndrome [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	0059645//CUSHING SYNDROME//CCPSS	U000916//HYPOVOLEMIC SHOCK//DXP	U000424//CUSHING SYNDROME//DXP	0000003509//cushing's syndrome//CHV	CDR0000626500//Cushing syndrome//NCI_NCI-GLOSS	MTHU016145//Cushing syndrome//OMIM	237735008//Adrenal Cushing's syndrome//SNOMEDCT_US	HP:0003118//Increased circulating cortisol level//HPO
bilateral adrenalectomy	Xa8OV//Bilateral adrenalectomy//RCD	P1-60342//Total adrenalectomy, NOS//SNMI	07.3//Bilateral adrenalectomy//ICD9CM	302340005//Bilateral adrenalectomy//SNOMEDCT_US	41693//bilateral adrenalectomy//MEDCIN
pituitary adenoma	C3329//ADENOMA, ANTERIOR LOBE PITUITARY GLAND, BENIGN//NCI_CDISC	D010911//Pituitary Neoplasms//MSH	NOCODE//Developmental arithmetic disorder//MTH	0039068//PITUITARY ADENOMA//CCPSS	584//PITUITARY ADENOMA//COSTAR	X78aD//Pituitary adenoma//RCD	MTHU016150//Pituitary adenoma//OMIM	354687//Pituitary adenoma//MEDCIN	HP:0002893//Pituitary adenoma//HPO	10035079//Pituitary adenoma//MDR	254956000//Pituitary adenoma//SNOMEDCT_US	128664001//Pituitary adenoma//SNOMEDCT_US	T73010//pituitary adenoma//ICPC2P	0000009757//pituitary adenoma//CHV
transsphenoidal surgery	C93344//Transsphenoidal Surgery//NCI	CDR0000476651//transsphenoidal surgery//NCI_NCI-GLOSS
thyroid adenomas	D013964//Thyroid Neoplasms//MSH
surgery if cancerous	
lccsct	
pms	D006064//ГОНАДОТРОПИНЫ СЫВОРОТКИ ЖЕРЕБЫХ КОБЫЛ//MSHRUS	D011293//premenstruační syndrom//MSHCZE	1138-6312//premenstrual syndrome//CSP	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	D7-76000//Premenstrual tension syndrome, NOS//SNMI	1504//PREMENSTRUAL TENSION//WHO	0000010085//premenstrual syndrome (PMS)//CHV	3793//Premenstrual Syndrome//MEDLINEPLUS	39185//PMS//PSY	82639001//Premenstrual tension syndrome//SNOMEDCT_US	BI00402//premenstrual syndrome//BI	180989//PROLINE-RICH PROTEIN, BstNI SUBFAMILY, 1//OMIM	HGNC:9337//proline rich protein BstNI subfamily 1//HGNC	174310//POLYDACTYLY, POSTAXIAL, WITH PROGRESSIVE MYOPIA//OMIM
surgery to remove primary and/or metastatic lesions	
no specific treatment is currently available for caveolinopathies	
management should include the following:	
infants are started with daily 1	
0 mg intramuscular or subcutaneous injections	
acute metabolic decompensation	MTHU023740//Acute metabolic decompensation//OMIM
long-term management	
these are accomplished by:	
parenteral ohcbl	
0 mg (~0	
betaine	E-8709//Betaine//SNM	C-85310//Betaine//SNMI	1512//Betaine//RXNORM	413645006//Betaine preparation//SNOMEDCT_US	N0000006734//Betaine [Chemical/Ingredient]//NDFRT	3SCV180C9W//Betaine//MTHSPL	C81038//Betaine//NCI	sh2005007337//Betaine//LCH_NW	DB06756//Glycine betaine//DRUGBANK	43356007//Betaine//SNOMEDCT_US	MTHU001174//Betaine//USPMG	D001622//Betaine//MSH	N0000147725//BETAINE//NDFRT	4019632//BETAINE//VANDF	258267//betaine//MEDCIN	0000001833//betaine//CHV	006281//betaine//NDDF	A16AA06//betaine//ATC	004543//PRIMIDONE 250 mg ORAL TABLET//NDDF	d04875//betaine//MMSL	11810//betaine//MMSL
optimal dosing and monitoring have not been adequately established	
folate and folinic acid	
the adult dose of folate is 1	
5 mg for maintenance	
dietary management	67//dietary management//OMS	Q000178//diet therapy//MSH
other therapeutic considerations that have not been fully validated:	
methionine supplementation	
pyridoxine	0000018236//pyridoxine//AOD	3147-5673//pyridoxine//CSP	d00412//pyridoxine//MMSL	684879//pyridoxine//RXNORM	41299//vitamin B6//MEDCIN	0000010456//pyridoxine//CHV	004538//DIVALPROEX SODIUM 125 mg ORAL TABLET, DELAYED RELEASE (ENTERIC COATED)//NDDF	KV2JZ1BI6Z//pyridoxine//MTHSPL	A11HA02//pyridoxine//ATC	CDR0000468776//pyridoxine//NCI_NCI-GLOSS	NOCODE//Developmental arithmetic disorder//MTH	6601//sildenafil 50 mg oral tablet//MMSL	X80RV//Vitamin B6//RCD	F-16250//Vitamin B6//SNM	F-BB350//Vitamin B6//SNMI	C62619//Pyridoxine//NCI	430469009//Pyridoxine//SNOMEDCT_US	N0000006060//Pyridoxine [Chemical/Ingredient]//NDFRT	LP32568-5//Pyridoxine//LNC	LP15842-5//Pyridoxine//LNC	MTHU012245//Pyridoxine//LNC	DB00165//Pyridoxine//DRUGBANK	D011736//Pyridoxine//MSH	N0000148007//PYRIDOXINE//NDFRT	4019922//PYRIDOXINE//VANDF	C74901//Pyridoxine//NCI_CDISC	N0000029452//[VT104] PYRIDOXINE//NDFRT	4021899//PYRIDOXINE//VANDF
levocarnitine	42955//Levocarnitine//RXNORM	0G389FZZ9M//Levocarnitine//MTHSPL	D002331//Carnitine//MSH	DB00583//L-Carnitine//DRUGBANK	C26657//Levocarnitine//NCI	372601001//L-Carnitine//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	d00491//levOCARNitine//MMSL	10540//LevOCARNitine//MMSL	48737//levocarnitine//MEDCIN	4970//naphazoline-zinc ophthalmic 0.12%-0.25% ophthalmic solution//MMSL	0000016097//l-carnitine//CHV	003576//PHENOBARBITAL SODIUM 30 mg/mL INJECTION SYRINGE (ML)//NDDF	A16AA01//levocarnitine//ATC	CDR0000321378//levocarnitine//NCI_NCI-GLOSS	CDR0000301896//levocarnitine//PDQ	N0000147225//LEVOCARNITINE//NDFRT	4018934//LEVOCARNITINE//VANDF
indicated for low plasma carnitine levels	
supportive therapy includes the following as needed:	
treatment of headache	
guidance for visual impairment	
classic cca	
this type of therapy is best instituted in childhood	
surgical release of contractures may be necessary	
consultation with an orthopedist is encouraged	
severe/lethal cca	
no general recommendations exist	
speech therapy may be required during periods of dental treatment	
sinus and middle ear infections require aggressive and timely treatment	
helmets may be advised for high-risk activities	
the treatment of cataracts is surgical	
regular rehabilitation can prevent or postpone osteoporosis	
recurrent hemorrhage or mass effect	
neuropsychological testing may be considered prior to any neurosurgical procedure	
microsurgical techniques rely on intraoperative examination for precise localization	
headaches	NOCODE//Sepsis//COSTAR	10019231//Headaches//MDR	D006261//Headache//MSH	120321//Headaches//NOC	091022//Headaches//NOC	210513//Headaches//NOC	121303//Headaches//NOC	090915//Headaches//NOC	240417//Headaches//NOC	MTHU036635//Headaches//OMIM	MTHU053651//Headaches//LNC	LP217220-5//Headaches//LNC	HP:0002315//Headache//HPO	BI00020//headache//BI	0000005820//headache//CHV
neurologic deficits	D009461//Neurologic Manifestations//MSH	0000038008//neurological deficit//CHV
hypotonia and weakness	
patients may benefit from physical therapy	
scoliosis and joint contractures	
patients with more severe symptoms may require respiratory support	
peginterferon-α2b has also been given once a week	
the mechanism behind this response is unknown	
splenectomy is of unproved value	
orthopedic issues—thorax shortening, scoliosis/kyphosis	
occasionally, surgical treatment of spinal curvature is warranted	
others may have a more refractory course	
renal issues	
immunologic status	
most individuals affected with cdgs have functional immune systems	
additional management issues of adults with cdg	
orthopedic issues — thorax shortening, scoliosis/kyphosis	
recently, therapy may start in the prenatal period	
postnatal treatment	
emphasis must be on preventing secondary lung injury	
it is unclear whether ecmo improves survival in cdh	
prenatal treatment	
surgical correction of intestinal malrotation if present	
alternative communicative methods (e	
standard treatment for hearing loss	
standard interventions for cardiac defects	
appropriate treatment for seizures	
antibiotic prophylaxis and follow up for vesicoureteral reflux	
orchiopexy if cryptorchidism is present	
standard intervention for bicornuate uterus, if present	
cervical spine stenosis may require decompression	
thoracic and lumbar spine (for scoliosis)	
l-carnitine supplementation	
l-carnitine supplementation has relatively few side effects:	
hypoglycemic episodes are treated with intravenous dextrose infusion	
cardiomyopathy requires management by specialists in cardiology	
correction of polydactyly (optional)	
orthopedic care as required (e	
, for hip dysplasia)	
dental care	223//Dental Care//MTH	D003729//Dental Care//MSH	U001306//Dental care//LCH	10056723//Dental care//MDR	sh85036869//Dental care//LCH_NW	108306002//Dental-oral procedure AND/OR service//SNOMEDCT_US	225362009//Dental care//SNOMEDCT_US	0000003709//dental care//CHV	0000032401//dental care//CHV
standard treatment for renal and liver abnormalities	
pneumonia should be treated with antibiotics	
asthma can be treated with steroids	
standard treatment for cardiac abnormalities	
no consensus management guidelines have been developed to date	
improving gait, exercise tolerance, and flexion contractures	
unsuccessful steroid therapy was reported in one adult	
less symptomatic individuals can be started on 0	
0 mg/kg every other day	
higher-dose steroids may help with acute pain crises	
calcitonin	U000739//Calcitonin//LCH	D002116//Calcitonin//MSH	XM0lH//Calcitonin//RCD	F-26960//Calcitonin//SNM	F-B3140//Calcitonin//SNMI	83348//Calcitonin//FMA	N0000006509//Calcitonin [Chemical/Ingredient]//NDFRT	LP14649-5//Calcitonin//LNC	DF35I47HCM//Calcitonin//MTHSPL	1311287//Calcitonin//RXNORM	MTHU003443//Calcitonin//LNC	sh85018767//Calcitonin//LCH_NW	30451//Calcitonin//CPM	63730009//Calcitonin//SNOMEDCT_US	U001773//Calcitonin//MTH	0000018771//calcitonin//AOD	2929-0286//calcitonin//CSP	0000002289//calcitonin//CHV	005019//METHOXYPHENAMINE HCL 100 mg ORAL TABLET//NDDF	CDR0000039292//calcitonin//PDQ	d00598//calcitonin//MMSL	N0000022460//CALCITONIN//NDFRT	4018749//CALCITONIN//VANDF	82308//Calcitonin//CPT	C74848//Calcitonin//NCI_CDISC	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	10006940//Calcitonin//MDR	CDR0000045207//calcitonin//NCI_NCI-GLOSS	114130//CALCITONIN/CALCITONIN-RELATED POLYPEPTIDE, ALPHA//OMIM	HGNC:1437//calcitonin related polypeptide alpha//HGNC	C2281//Calcitonin Gene-Related Peptide 1//NCI	00630//Calcitonin//NCI_DCP	C329//Calcitonin Salmon//NCI	N0000175942//Calcitonin [EPC]//NDFRT	22657006//Calcitonin preparation//SNOMEDCT_US	41026//calcitonin//MEDCIN
losartan	D019808//losartan//MSHCZE	bk3..//Losartan//RCD	C-81310//Losartan//SNMI	52175//Losartan//RXNORM	C66869//Losartan//NCI	N0000005774//Losartan [Chemical/Ingredient]//NDFRT	LP171619-2//Losartan//LNC	JMS50MPO89//Losartan//MTHSPL	DB00678//Losartan//DRUGBANK	373567002//Losartan//SNOMEDCT_US	96309000//Losartan//SNOMEDCT_US	MTHU001043//Losartan//USPMG	0000018751//losartan//AOD	4009-0050//losartan//CSP	d03821//losartan//MMSL	0000016349//losartan//CHV	C09CA01//losartan//ATC	CDR0000560966//losartan//NCI_NCI-GLOSS	004991//AMPHETAMINE SULFATE/DEXTROAMPHETAMINE 20 mg ORAL CAPSULE//NDDF	N0000148401//LOSARTAN//NDFRT	4020913//LOSARTAN//VANDF
pain in the tibia resolved completely following the surgery	
corticosteroids may delay skull hyperostosis and cranial nerve impingement	
three underwent internal auditory canal decompression with mixed results	
celiac disease	D002446//Celiac Disease//MSH	N0000000704//Celiac Disease [Disease/Finding]//NDFRT	897//Celiac Disease//MEDLINEPLUS	LA15156-5//Celiac Disease//LNC	C26714//Celiac Disease//NCI	NOCODE//Developmental arithmetic disorder//MTH	0032735//CELIAC DISEASE//CCPSS	U000111//CELIAC DISEASE//COSTAR	U000577//EPIDIDYMOORCHITIS//DXP	K90.0//Celiac disease//ICD10AE	U000862//Celiac disease//LCH	MT210023//Celiac disease//MTHMST	XE0bK//Celiac disease//RCDAE	D-6218//Celiac disease//SNM	D5-47100//Celiac disease//SNMI	MTHU018114//Celiac disease//OMIM	sh85021632//Celiac disease//LCH_NW	HP:0002608//Celiac disease//HPO	10007864//Celiac disease//MDR	10009839//Coeliac disease//MDR	579.0//Celiac disease//ICD9CM	396331005//Celiac disease//SNOMEDCT_US	0000005573//celiac disease//AOD	1248-3893//celiac disease//CSP	0000002574//celiac disease//CHV	CDR0000377726//celiac disease//NCI_NCI-GLOSS	D99003//coeliac disease//ICPC2P	30192//celiac disease//MEDCIN
a dietitian experienced in treating celiac disease should be involved	
, 100 mg) can damage the small intestine	
note that a slice of bread contains approximately 2	
5 grams of gluten	
some hidden sources of gluten:	
non-starchy foods such as soy sauce and beer	
, lipstick)	
refractory sprue or celiac disease	
cutaneous photosensitivity	MTHU035822//Cutaneous photosensitivity//OMIM	HP:0000992//Cutaneous photosensitivity//HPO
reflectant sunscreens containing zinc oxide or titanium dioxide	
skin trauma should be avoided	
wound care is essential to prevent infection of opened blisters	
laser hair removal can be used to treat facial hypertrichosis	
topical antibiotics for corneal ulcers, scleritis, and blepharitis	
bone manifestations	
hemolytic anemia	U002151//Hemolytic anemia//LCH	D1...//Hemolytic anemia//RCDAE	D-4020//Hemolytic anemia//SNM	MTHU006276//Hemolytic anemia//OMIM	sh85060210//Hemolytic anemia//LCH_NW	HP:0001878//Hemolytic anemia//HPO	10019493//Hemolytic anemia//MDR	10018916//Haemolytic anaemia//MDR	61261009//Hemolytic anemia//SNOMEDCT_US	U000342//HEMOLYTIC ANEMIA//COSTAR	ANEMIA HEMOL//HEMOLYTIC ANEMIA//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	0000005908//hemolytic anemia//AOD	0427-1005//hemolytic anemia//CSP	0000001123//hemolytic anemia//CHV	B82008//haemolytic anaemia//ICPC2P	30339//hemolytic anemia//MEDCIN	N0000000387//Anemia, Hemolytic [Disease/Finding]//NDFRT	C34376//Hemolytic Anemia//NCI_NICHD	2279//Hemolytic Anemia//NCI_FDA	D000743//Anemia, Hemolytic//MSH
consider blood transfusions when hemolysis is significant	
cystic fibrosis (cf)	0000003553//cystic fibrosis//CHV
inhaled dornase alfa in all individuals age ≥6 years	
inhaled hypertonic saline in all individuals age ≥6 years	
recommended sequence for inhaled medications:	
an aerosolized antibiotic	
gly551asp and other specific pathogenic variants	
phe508del	
lung or heart/lung transplantation	
an option for some individuals with severe disease	
oral pancreatic enzyme replacement with meals	
congenital absence of the vas deferens (cavd)	
prevention of primary manifestations – cystic fibrosis	
aerosolized antibiotic	
all routine immunizations should be given at the recommended times	
pancreatic enzyme replacement and supplementation of fat-soluble vitamins	
high-calorie, high-fat nutritional supplements	
consultation with a nutritionist specializing in cf	
surveillance – cystic fibrosis	
culture respiratory tract secretions at least four times yearly	
75 g/kg, or 75 g maximum	
evaluate bone mineral density in adolescence	
agents/circumstances to avoid – cystic fibrosis	
avoid the following:	
respiratory irritants (e	
, smoke, dust)	
individuals with respiratory infections	
dehydration	T11//Dehydration//ICPC	T11001//dehydration//ICPC2P	10012174//Dehydration//MDR	D003681//Dehydration//MSH	Q0200088//Dehydration//QMR	XM00s//Dehydration//RCD	F-01790//Dehydration//SNM	D6-20650//Dehydration//SNMI	251229//Dehydration//NOC	080111//Dehydration//NOC	080014//Dehydration//NOC	MTHU000177//Dehydration//OMIM	E86.0//Dehydration//ICD10CM	N0000000911//Dehydration [Disease/Finding]//NDFRT	6051//Dehydration//MEDLINEPLUS	C26740//Dehydration//NCI_NICHD	E12258//Dehydration//NCI_CTCAE	HP:0001944//Dehydration//HPO	10041882//Dehydration//ICNP	02151//Dehydration//NANDA-I	34095006//Dehydration//SNOMEDCT_US	13285//Dehydration//PSY	276.51//Dehydration//ICD9CM	NOCODE//Developmental arithmetic disorder//MTH	1015105//DEHYDRATION//CCPSS	220//DEHYDRATION//COSTAR	DEHYDRAT//DEHYDRATION//CST	U000936//INNOMINATE ARTERY, ANOMALOUS ORIGIN//DXP	0370//DEHYDRATION//WHO	0000005833//dehydration//AOD	0000003663//loss of body water//CHV	MTHU022122//dehydration//ICPC2ICD10ENG	CDR0000044659//dehydration//NCI_NCI-GLOSS	C57787//Dehydration//NCI_CTCAE	GTEx-BPV//Brevital//NCI	C126369//Dehydration//NCI
increasing caloric intake may be of benefit	
constipation affects the majority of individuals	
seizures are treated as in the general population	
recurrent otitis media may require placement of pe tubes	
hyperkeratoses are treated as in the general population	
nonsurgical treatment of ophthalmologic findings:	
correction of ptosis	7218.//Correction of ptosis//RCD	69769008//Repair of blepharoptosis//SNOMEDCT_US
eye muscle surgery	0000019684//eye muscle surgery//CHV	0059250//EYE MUSCLE SURGERY//CCPSS	LA14709-2//Eye muscle surgery//LNC	420419008//Strabismus surgery//SNOMEDCT_US
to correct or improve a compensatory head posture	
to improve ambulation and gross motor development in young children	
principles of surgical approach:	
profound weakening procedures (e	
orthodontic evaluation and appropriate intervention may be necessary	
treatment of colitis in cgd can be difficult	
corticosteroid treatment of heightened inflammatory response	
granulocyte infusions	
granulocyte infusions are generally well tolerated	
males with x-linked cgd	
, they are kell negative)	
kell-negative blood products are rarely available	
splints can be tried for foot drop	
choanal atresia	NOCODE//Sepsis//COSTAR	N0000000756//Choanal Atresia [Disease/Finding]//NDFRT	D002754//Choanal Atresia//MSH	Q30.0//Choanal atresia//ICD10	10008587//Choanal atresia//MDR	P80..//Choanal atresia//RCD	D4-21110//Choanal atresia//SNMI	MTHU036653//Choanal atresia//OMIM	HP:0000453//Choanal atresia//HPO	748.0//Choanal atresia//ICD9CM	204508009//Choanal atresia//SNOMEDCT_US	0000002848//choanal atresia//CHV	297932//choanal atresia//MEDCIN	99010//choanal atresia//MEDCIN
feeding/swallowing dysfunction	
renal evaluation	
renal ultrasound examination is recommended in all children	
endocrine evaluation	
coloboma	10009934//Coloboma//MDR	M-20190//Coloboma//SNM	MTHU012405//Coloboma//OMIM	N0000000810//Coloboma [Disease/Finding]//NDFRT	HP:0000589//Coloboma//HPO	D003103//Coloboma//MSH	0000003167//coloboma//CHV	MTHU017234//coloboma//ICPC2ICD10ENG	11534//coloboma//MEDCIN	1017416//COLOBOMA//CCPSS
hearing loss should be assumed until proven otherwise	
communication	U001112//Communication//LCH	D003142//Communication//MSH	U000079//Communication//PCDS	XC01S//Communication//RCD	0902//Communication//NOC	sh85029027//Communication//LCH_NW	5_5//Communication//NANDA-I	263536004//Communication//SNOMEDCT_US	10570//Communication//PSY	C16452//Communication//NCI	NOCODE//Developmental arithmetic disorder//MTH	U000149//COMMUNICATION//COSTAR	10//Spirituality//OMS	0000003920//communication//AOD	4009-0069//communication//CSP	0000003204//communication//CHV
deaf-blind service referral	
referral to deafblind education services (e	
frequent rest breaks may be needed	
myofacial release can improve posture and flexibility	
occasionally, sleep studies show obstructive apnea	
gi consultation is often indicated	
obsessive-compulsive disorder	D009771//Obsessive-Compulsive Disorder//MSH	N0000002203//Obsessive-Compulsive Disorder [Disease/Finding]//NDFRT	471//Obsessive-Compulsive Disorder//MEDLINEPLUS	C88411//Obsessive Compulsive Disorder//NCI_NICHD	NOCODE//Developmental arithmetic disorder//MTH	F42//Obsessive-compulsive disorder//ICD10	10029898//Obsessive-compulsive disorder//MDR	E203.//Obsessive-compulsive disorder//RCD	MTHU000246//Obsessive-compulsive disorder//OMIM	sh85093751//Obsessive-compulsive disorder//LCH_NW	HP:0000722//Obsessive-compulsive behavior//HPO	300.3//Other specified obsessive-compulsive and related disorder//DSM-5	191736004//Obsessive-compulsive disorder//SNOMEDCT_US	164230//OBSESSIVE-COMPULSIVE DISORDER//OMIM	0000006616//obsessive-compulsive disorder//AOD	0000008866//obsessive compulsive disorder (OCD)//CHV	P79003//obsessive-compulsive disorder//ICPC2P	CDR0000454805//obsessive-compulsive disorder//NCI_NCI-GLOSS
pervasive developmental disorder	X00TM//Autistic spectrum disorder//RCD	MTHU012301//Pervasive developmental disorder//OMIM	10061345//Pervasive developmental disorder//MDR	35919005//Autism spectrum disorder//SNOMEDCT_US	153//Autism Spectrum Disorder//MEDLINEPLUS	C97179//Pervasive Developmental Disorder//NCI_NICHD	0000006540//pervasive developmental disorder//AOD	5006-0029//pervasive developmental disorder//CSP	0000038288//pervasive developmental disorder//CHV	HP:0000729//Autistic behavior//HPO
sensory processing issues are likely implicated	
attention-deficit hyperactivity disorder	32643//attention-deficit hyperactivity disorder//MEDCIN	sh85063661//Attention-deficit hyperactivity disorder//LCH_NW	MTHU045734//Attention-deficit hyperactivity disorder//OMIM
understanding this is critical to devising appropriate interventional strategies	
general	G-A366//Generalized//SNMI	C63764//Generalized//NCI	LA17571-3//General//LNC	MPN-SAF//Problem//NCI	60132005//Generalized//SNOMEDCT_US	0000020435//general//CHV	0056036//GENERAL//CCPSS	GENRL//General//HL7V3.0	C115727//Safety Reporting Communications and Tracking Subcategory//NCI_CareLex
adequate nutrition and weight maintenance are essential	
appropriate bracing and stretching can minimize contractures	
mitochondrial myopathy	590000//TRANSFER RNA, MITOCHONDRIAL, ALANINE//OMIM	251900//MITOCHONDRIAL MYOPATHY//OMIM	N0000003559//Mitochondrial Myopathies [Disease/Finding]//NDFRT	C101328//Mitochondrial Myopathy//NCI	D017240//Mitochondrial Myopathies//MSH	10027710//Mitochondrial myopathy//MDR	X709I//Mitochondrial cytopathy//RCD	DA-51600//Mitochondrial myopathy//SNMI	MTHU005171//Mitochondrial myopathy//OMIM	HP:0003737//Mitochondrial myopathy//HPO	16851005//Mitochondrial myopathy//SNOMEDCT_US	0000017938//mitochondrial myopathy//CHV	5000-0048//mitochondrial disease/disorder//CSP	337551//mitochondrial myopathy//MEDCIN
assistance with ambulation and posture	
surgical correction of ptosis as needed	
amyotrophic lateral sclerosis	NOCODE//Sepsis//COSTAR	D000690//Amyotrophic Lateral Sclerosis//MSH	N0000000376//Amyotrophic Lateral Sclerosis [Disease/Finding]//NDFRT	135//Amyotrophic Lateral Sclerosis//MEDLINEPLUS	C34373//Amyotrophic Lateral Sclerosis//NCI	0062056//AMYOTROPHIC LATERAL SCLEROSIS//CCPSS	U000220//Amyotrophic lateral sclerosis//LCH	10002026//Amyotrophic lateral sclerosis//MDR	F152.//Motor neurone disease//RCD	D-8141//Amyotrophic lateral sclerosis//SNM	DA-23010//Amyotrophic lateral sclerosis//SNMI	G12.21//Amyotrophic lateral sclerosis//ICD10CM	MTHU038375//Amyotrophic lateral sclerosis//OMIM	sh85004728//Amyotrophic lateral sclerosis//LCH_NW	HP:0007354//Amyotrophic lateral sclerosis//HPO	LA27534-9//Amyotrophic lateral sclerosis//LNC	335.20//Amyotrophic lateral sclerosis//ICD9CM	86044005//Amyotrophic lateral sclerosis//SNOMEDCT_US	0000006207//amyotrophic lateral sclerosis//AOD	4000-0117//amyotrophic lateral sclerosis//CSP	0000001073//Lou Gehrig's disease (ALS)//CHV	32257//amyotrophic lateral sclerosis//MEDCIN
(als)	
frontotemporal dementia (ftd)	
spinal motor neuronopathy	
seizures should be managed by an experienced pediatric neurologist	
hematologic and immunologic defects	
select individuals may also receive intrathecal methotrexate and prednisilone	
once remission occurs, prompt hsct is recommended	
correction of refractive errors may improve visual acuity	
skin hypopigmentation	C78610//Skin Hypopigmentation//NCI	MTHU003037//Skin hypopigmentation//OMIM	10040868//Skin hypopigmentation//MDR	E13721//Skin hypopigmentation//NCI_CTCAE	HP:0001010//Hypopigmentation of the skin//HPO	0000017999//hypopigmentation//CHV	11442//skin hypopigmentation//MEDCIN
skin protection varies depending on the degree of hypopigmentation	
neurologic abnormalities	HP:0000707//Abnormality of the nervous system//HPO
skeletal dysplasia	HP:0002652//Skeletal dysplasia//HPO	C84978//Osteochondrodysplasia//NCI_NICHD	X70BZ//Skeletal dysplasia//RCD	10072610//Skeletal dysplasia//MDR	MTHU042509//Skeletal dysplasia//OMIM	105986008//Skeletal dysplasia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000032821//skeletal dysplasia//CHV
orthopedic surgery may be complicated by low bone density	
immunodeficiency and infection	
nutrition and ocular health have become increasingly topical:	
preparedness for appropriate countermeasures (e	
an apnea monitor is recommended	
anticonvulsants may be required	
surgical instrumentation or prolonged	
bracing may be required to correct a progressive thoracolumbar scoliosis	
paradoxical sweating	MTHU057598//Paradoxical sweating//OMIM
treatment should be reserved for adults and older children	
clonidine	U001056//Clonidine//LCH	x01Cz//Clonidine//RCD	E-7657//Clonidine//SNM	C-81130//Clonidine//SNMI	2599//Clonidine//RXNORM	MN3L5RMN02//Clonidine//MTHSPL	N0000006505//Clonidine [Chemical/Ingredient]//NDFRT	LP32548-7//Clonidine//LNC	LP14987-9//Clonidine//LNC	MTHU002290//Clonidine//LNC	sh85027121//Clonidine//LCH_NW	DB00575//Clonidine//DRUGBANK	372805007//Clonidine//SNOMEDCT_US	62782004//Clonidine//SNOMEDCT_US	09740//Clonidine//PSY	C380//Clonidine//NCI	MTHU000775//Clonidine//USPMG	D003000//Clonidine//MSH	0000020738//clonidine//AOD	1549-3722//clonidine//CSP	4478//Touro DM//MMSL	257582//clonidine//MEDCIN	0000003057//clonidine//CHV	004495//ACETAMINOPHEN 120 mg ORAL WAFER//NDDF	N02CX02//clonidine//ATC	C02AC01//clonidine//ATC	S01EA04//clonidine//ATC	CDR0000630972//clonidine//NCI_NCI-GLOSS	CDR0000041228//clonidine//PDQ	N0000146207//CLONIDINE//NDFRT	4017850//CLONIDINE//VANDF	d00044//cloNIDine//MMSL
oral clonidine, at starting doses of 0	
05 mg to 0	
1 mg four times daily may be required	
abrupt cessation of clonidine can lead to prominent hypertension	
moxonidine was well tolerated in the short term	
however, long-term observations are not yet available	
niccd	605814//CITRULLINEMIA, TYPE II, NEONATAL-ONSET//OMIM	C536398//Neonatal-onset citrullinemia type 2//MSH
the treatment with therapeutic formulas is not lifelong	
fttdcd	
ctln2	603471//CITRULLINEMIA, TYPE II, ADULT-ONSET//OMIM
other treatments include the following:	
saheki et al 2010	
yazaki et al 2010	
ohura et al, personal communication	
okano et al, personal communication]	
aro	D000761//anesteziologické oddělení nemocnice//MSHCZE	HGNC:2594//cytochrome P450 family 19 subfamily A member 1//HGNC	107910//CYTOCHROME P450, FAMILY 19, SUBFAMILY A, POLYPEPTIDE 1//OMIM	C52322//CYP19A1 wt Allele//NCI
adoii	
orthopedic treatment is often required for fractures and arthritis	
no specific dietary or other metabolic treatment is available	
a trial of antiepileptic drugs (aeds) (e	
treatment of behavioral problems is standard and requires periodic reassessment	
no definitive treatments exist for the congenital muscular dystrophies	
speech therapy may be indicated	
close attention to oral hygiene is indicated	
medical treatment	
acetylcholineesterase (ache) inhibitors (pyridostigmine)	
3,4-diaminopyridine (3,4-dap)	
quinidine, fluoxetine	
however, it may induce suicidal ideation	
non-medical treatment	
orthotics or a wheelchair	
a percutaneous gastric tube	
exercise within the affected individual's capability	
note: (1) fatigue may improve with exercise	
wheelchair for mobility because of gait instability	
lower urinary tract involvement [krhut et al 2014]	
vocal cord paresis	D014826//Vocal Cord Paralysis//MSH	10049234//Vocal cord paresis//MDR	Xa9Bv//Vocal cord palsy//RCD	MTHU002849//Vocal cord paresis//OMIM	HP:0001604//Vocal cord paresis//HPO
treatment may include:	
ankle/foot orthoses	
forearm crutches or canes	
rarely, wheelchairs	
career and employment counseling	
anticipatory counseling is appropriate	
forearm crutches or canes for gait stability for some individuals	
many remain physically active	
the following may be indicated:	
wheelchairs for mobility because of gait instability	
for treatment of findings common to all	
trpv4-associated disorders	
pain and depression	
neuropathy	N94010//neuropathy//ICPC2P	U005825//Neuropathy//LCH	XC0eJ//Neuropathy//RCD	D-8X30//Peripheral nervous system disease or syndrome//SNM	MTHU016030//Neuropathy//OMIM	1095//Peripheral Nerve Disorders//MEDLINEPLUS	338712//Neuropathy//MEDCIN	C4731//Neuropathy//NCI_NICHD	1465//Diabetic Nerve Problems//MEDLINEPLUS	1983//Neuropathy//NCI_FDA	HP:0009830//Peripheral neuropathy//HPO	10029328//Neuropathy//MDR	02957//Neuropathy//NANDA-I	386033004//Neuropathy//SNOMEDCT_US	33800//Neuropathy//PSY	NOCODE//Developmental arithmetic disorder//MTH	1009040//NEUROPATHY//CCPSS	516//NEUROPATHY//COSTAR	NEUROPATHY//NEUROPATHY//CST	0130//NEUROPATHY//WHO	0000006110//neuropathy//AOD	BI00553//neuropathy//BI	CDR0000046041//neuropathy//NCI_NCI-GLOSS	MTHU052562//neuropathy//ICPC2ICD10ENG	0000035183//neuropathy//CHV
vocal cord involvement	
respiratory therapy/support (e	
, bipap)	
physical therapy/exercise to maintain as much function as possible	
orthopedic evaluation with consideration of surgical intervention (i	
patients undergoing surgical fusion typically do well	
appropriate treatment includes:	
prosthetic and adaptive devices for weak hands	
ankle/foot orthoses to correct foot drop and aid walking	
fewer than 5% of affected individuals need wheelchairs	
treatment of spinal deformities	
physiotherapy helps to preserve flexibility	
treatment of foot deformities	
physiotherapy to preserve flexibility	
treatment of pain and cramps	
, pregabalin, gabapentin)	
cramps can be controlled with quinine	
some need wheelchairs	
surgery to correct spine deformities	
wheelchairs as needed because of gait instability	
no specific treatment reverses the manifestations of cmt4j	
severely affected individuals need wheelchairs	
bipap for those with respiratory muscle weakness	
peripheral neuropathy	D010523//Peripheral Nervous System Diseases//MSH	CDR0000044705//Peripheral Neuropathy//NCI_NCI-GLOSS	C119734//Peripheral Neuropathy//NCI	NOCODE//Developmental arithmetic disorder//MTH	XC0eJ//Neuropathy//RCD	D-8X30//Peripheral nervous system disease or syndrome//SNM	MTHU000700//Peripheral neuropathy//OMIM	1095//Peripheral Nerve Disorders//MEDLINEPLUS	HP:0009830//Peripheral neuropathy//HPO	03038//Peripheral neuropathy//NANDA-I	302226006//Peripheral nerve disease//SNOMEDCT_US	575//PERIPHERAL NEUROPATHY//COSTAR	R0121713//PERIPHERAL NEUROPATHY//QMR	U003097//PERIPHERAL NEUROPATHY//DXP	0000006111//peripheral neuropathy//AOD	BI00555//peripheral neuropathy//BI	2042-6617//polyneuritis//CSP	9438//peripheral neuropathy//MEDCIN	0000009515//peripheral neuropathy//CHV	N94011//peripheral neuropathy//ICPC2P	311304//peripheral neuropathy//MEDCIN
see charcot-marie-tooth hereditary neuropathy overview, management	
individualized educational program for developmental delay	
feeding gastrostomy tube placement for failure to thrive	
management of hearing loss	
management of cataracts and other ophthalmologic complications	
use of sunscreens for cutaneous photosensitivity	
use of sunglasses for lens and retina protection	
spectacle correction of refractive errors	
psychosocial support for affected individuals and their families	
recurrent infections should be treated per standard therapy	
no specific support exists for individuals with col4a1-related disorders	
seizures are managed using standard protocols	
glaucoma is initially treated with topical anti-glaucoma medication	
coenzyme q10 supplementation	
coq4-related coenzyme q10 deficiency	
coq6-related coenzyme q10 deficiency	
homozygotes for the pathogenic variants p	
gly255arg or p	
ala353asp responded [heeringa et al 2011]	
coq8b-related coenzyme q10 deficiency	
pdss2-related coenzyme q10 deficiency	
coq8a-related coenzyme q10 deficiency	
coq9-related coenzyme q10 deficiency	
most infants require nasogastric or gastrostomy feeding	
pyloric stenosis is treated surgically	
anecdotally, affected children have very high caloric needs	
kyphoscoliosis may require surgical correction	
dental abnormalities should be addressed by a pediatric dentist	
papillomata	10033725//papillomata//MDRDUT	0000009247//non cancerous skin tumor//CHV
thus, cortisol deficiency may also be considered	
malignant tumors	0000002337//cancer//CHV
treatment of malignant tumors follows standard protocols	
info and ghr	
nlm	C82620//National Library of Medicine//NCI	D009317//National Library of Medicine, USA//MSHNOR
nih	LA17113-4//NIH//LNC	C16895//National Institutes of Health//NCI	CDR0000044269//NIH//NCI_NCI-GLOSS	D009316//National Institutes of Health, USA//MSHNOR	C14476//NIH Mouse//NCI
gov	604350//RAS-ASSOCIATED PROTEIN RAB3D//OMIM
current treatment for long-chain fatty-acid oxidation disorders:	
avoid known triggers	
treatment consists primarily of surgical intervention	
cytokine administration may shorten the consolidation period	
timing of subsequent craniofacial surgeries influences their success	
limbs	MTHU000040//Limbs//OMIM	C12429//Limb//NCI	LP7395-9//Limbs//LNC	MTHU002838//Limbs//LNC	D005121//Extremities//MSH	0000004807//arms and legs//CHV
behavior therapy for behavior problems by developmental pediatrician	
seizure management with antiepileptic drugs by epilepsy specialist	
treatment of movement disorder by movement disorder specialist	
gamt deficiency	C537622//Guanidinoacetate methyltransferase deficiency//MSH	612736//CEREBRAL CREATINE DEFICIENCY SYNDROME 2//OMIM
treatment is as follows:	
4-0	
8g/kg/day)	
available databases (e	
treatment outcome of symptomatic individuals with gamt deficiency	
in 18% of individuals seizures were eliminated	
in 49% seizure frequency decreased	
improvement was seen in 60% of individuals	
treatment outcome of asymptomatic individuals with gamt deficiency	
agat deficiency	C567192//Arginine:Glycine Amidinotransferase Deficiency//MSH	612718//CEREBRAL CREATINE DEFICIENCY SYNDROME 3//OMIM
treatment outcome of symptomatic individuals with agat deficiency	
treatment outcome of asymptomatic individuals with agat deficiency	
crtr deficiency	
the goal of treatment is to replenish cerebral creatine levels	
treatment has included:	
glycine 150 mg/kg bw/day in 3 doses	
treatment outcome of individuals with crtr deficiency	
spectacles or contact lenses for correction of refractive errors	
management of strabismus	
penetrating keratoplasty	72452//Penetrating keratoplasty//RCD	42101009//Penetrating keratoplasty//SNOMEDCT_US	0000007063//penetrating keratoplasty//CHV	D015948//Keratoplasty, Penetrating//MSH
most grafts remain clear after penetrating keratoplasty	
see acmg-act sheet, acmg algorithm	
acute management of hyperammonemia	
rapidly decreasing plasma ammonia concentration	
scavenger therapy should be continued while dialysis is being performed	
note: exchange transfusions have no place in hyperammonemic treatment	
0-1	
control of intracranial pressure	
cerebral edema and ischemia may be documented by mri	
chronic management	
protein restriction	
nitrogen scavenger therapy	
as children grow, doses change to 9	
9-13 g/m2/day of sodium phenylbutyrate and 8	
8-15	
4 g/m2/day of arginine	
the initial dosage for phenylbutyrate-naïve patients is 4	
5-11	
2 ml/m2/day (5-12	
4 g/m2/day)	
living related-donor liver transplantation	
renal fanconi syndrome	D005198//Fanconi Syndrome//MSH	134600//FANCONI RENOTUBULAR SYNDROME 1//OMIM	MTHU007375//Renal Fanconi syndrome//OMIM	HP:0001994//Renal Fanconi syndrome//HPO
phosphate replacement to prevent and treat rickets	
renal glomerular disease	NOCODE//Developmental arithmetic disorder//MTH	0000026347//glomerular disease//CHV
renal transplantation	0000007098//kidney transplant//CHV	1683-2651//kidney transplantation//CSP	1057//Renal transplantation//ICD10AM	1299//Kidney Transplantation//MEDLINEPLUS	36503-00//Renal transplantation//ICD10AM	C15265//Kidney Transplantation//NCI	43927//Renal Transplantation//PSY	D016030//Kidney Transplantation//MSH
73 m2 and azotemia and hypertension rapidly progress	
symptoms often determine the exact time of transplantation	
retinal involvement is irreversible	
nutrition must be adequate for growth	
oral l-thyroxine replacement for hypothyroidism	
insulin for diabetes mellitus	
speech therapy and physical therapy	
standard treatment for benign intracranial hypertension	
other central nervous system complications are irreversible	
chenodeoxycholic acid (cdca)	
normalization of nerve conduction velocities and subsequent stabilization	
cdca treatment may be more useful when started early	
luyckx et al 2014]	
coenzyme q10 (coq10) treatment may improve muscle weakness	
repair of inguinal hernia(s)	
routine management of hip dislocation	
routine management of refractive errors	
antiepileptic drugs (aeds): valproate	
or a combination of aeds can be used	
psychological help as needed for self-image issues	
recommended drugs are nadolol (1-2	
flecainide	x01QJ//Flecainide//RCD	C-803F0//Flecainide//SNMI	4441//Flecainide//RXNORM	C62029//Flecainide//NCI	N0000006966//Flecainide [Chemical/Ingredient]//NDFRT	LP16148-6//Flecainide//LNC	MTHU004259//Flecainide//LNC	NSC0719273//Flecainide//NCI_DTP	DB01195//Flecainide//DRUGBANK	31980//Flecainide//CPM	372751001//Flecainide//SNOMEDCT_US	46576005//Flecainide//SNOMEDCT_US	MTHU000899//Flecainide//USPMG	D005424//Flecainide//MSH	d00234//flecainide//MMSL	42125//flecainide//MEDCIN	0000005089//flecainide//CHV	C01BC04//flecainide//ATC	CDR0000045381//flecainide//NCI_NCI-GLOSS	004483//ACETAMINOPHEN 80 mg/5 mL ORAL ELIXIR//NDDF	K94FTS1806//flecainide//MTHSPL	N0000147848//FLECAINIDE//NDFRT	4019757//FLECAINIDE//VANDF
however, urinary ne excretion exceeds normal levels	
fludrocortisone, at dosages of 0	
ptosis can be corrected by surgery	
sinus problems should be treated as needed	
dilated cardiomyopathy	I42.0//Dilated cardiomyopathy//ICD10	XE0Uz//Congestive cardiomyopathy//RCD	MTHU001652//Dilated cardiomyopathy//OMIM	3754//Cardiomyopathy//MEDLINEPLUS	HP:0001644//Dilated cardiomyopathy//HPO	10056419//Dilated cardiomyopathy//MDR	02196//Dilated cardiomyopathy//NANDA-I	399020009//Dilated cardiomyopathy//SNOMEDCT_US	0000005394//dilated cardiomyopathy//AOD	BI00079//dilated cardiomyopathy//BI	0000002450//dilated cardiomyopathy//CHV	35909//dilated cardiomyopathy//MEDCIN	C84673//Dilated Cardiomyopathy//NCI	N0000000686//Cardiomyopathy, Dilated [Disease/Finding]//NDFRT	D002311//Cardiomyopathy, Dilated//MSH	C91470//Dilated cardiomyopathy//NCI_KEGG
mean lvef increased from 36% to 53%	
measurement of reduced sphericity indicated improved ventricular geometry	
scoliosis treatment as needed is appropriate	
corticosteroid therapy	0000016698//steroid treatment//CHV	CDR0000038714//steroid therapy//PDQ
prednisone	U003802//Prednisone//LCH	D011241//Prednisone//MSH	fe7..//Prednisone//RCD	E-8536//Prednisone//SNM	8640//Prednisone//RXNORM	VB0R961HZT//Prednisone//MTHSPL	N0000006687//Prednisone [Chemical/Ingredient]//NDFRT	LP18109-6//Prednisone//LNC	4557//Steroids//MEDLINEPLUS	MTHU003245//Prednisone//LNC	sh85106259//Prednisone//LCH_NW	00934//Prednisone//NCI_DCP	DB00635//Prednisone//DRUGBANK	116602009//Prednisone//SNOMEDCT_US	C770//Prednisone//NCI	MTHU001276//Prednisone//USPMG	NOCODE//Developmental arithmetic disorder//MTH	0000021014//prednisone//AOD	0059-8338//prednisone//CSP	5351//povidone iodine ophthalmic 5% ophthalmic solution//MMSL	40982//prednisone//MEDCIN	0000010044//prednisone//CHV	002164//ASCORBIC ACID 750 mg ORAL TABLET, EXTENDED RELEASE//NDDF	H02AB07//prednisone//ATC	A07EA03//prednisone//ATC	CDR0000045492//prednisone//NCI_NCI-GLOSS	CDR0000042487//prednisone//PDQ	0054339//PREDNISONE//CCPSS	N0000146229//PREDNISONE//NDFRT	4017876//PREDNISONE//VANDF	d00350//predniSONE//MMSL	287//PredniSONE//MMSL
75 mg/kg/day or 1	
5 and 0	
6 mg/kg/day [fenichel et al 1991]	
follow-up studies showed that a dose of 0	
3 mg/kg/day [fenichel et al 1991]	
35 mg/kg/day) in both dmd and bmd	
4 mg/kg/day	
at lower doses of 0	
alternate-day dosing and intermittent dosing (e	
side effects did not negatively affect quality of life	
initiation and length of treatment	
75 mg/kg/day, prednisone 0	
published guidelines	
the optimal maintenance dose of prednisone (0	
3 mg/kg/day	
5 mg/kg/day	
3 mg/kg/day after three to four months	
deflazacort (0	
bmd	CDR0000415882//BMD//NCI_NCI-GLOSS	C61545//Bone Mineral Density Test//NCI	153700//MACULAR DYSTROPHY, VITELLIFORM, 2//OMIM	300376//MUSCULAR DYSTROPHY, BECKER TYPE//OMIM	HGNC:2928//dystrophin//HGNC	HGNC:12703//bestrophin 1//HGNC	C75321//DMD wt Allele//NCI
elements of the guidelines include the following:	
consider therapy based on cardiac phenotype (i	
, dcm or arrhythmia)	
cardiac conduction system disease and arrhythmias	
, atrial or atrioventricular node ablations)	
lmna-related dcm	
symptomatic dcm represents late disease	
individuals with idiopathic or familial dilated cardiomyopathy should:	
epileptic seizures require antiepileptic drugs (aeds)	
special adaptive chairs or positioners may be required	
educational	
spectacle correction is appropriate where indicated	
manifestations of the 16p11	
early diagnosis and provision of therapies facilitate the best outcome	
referral to other appropriate medical specialists (sue	
neurodevelopmental disabilities including asd	
obesity and overweight	
maintain an active lifestyle	
chiari i malformation or syringomyelia	
the spasms are responsive to acth	
special feeding techniques or devices, e	
structural anomalies (e	
hypothyroidism is treated in a standard manner	
no guidelines have been established for treatment of dent disease	
thiazide diuretics in doses greater than 0	
however, their effectiveness has not been clear	
the response to antiepileptic drugs (aeds) is variable	
routine ophthalmologic management of strabismus, if present	
routine correction of refractive error	
see hereditary deafness and hearing loss overview for details	
hearing habilitation	
for those with nonsyndromic bilateral congenital hearing loss	
hearing aids should be fitted as soon as possible	
educational programs designed for individuals with hearing impairment are appropriate	
see deafness and hereditary hearing loss overview	
management of neurologic manifestations in neonatal multisystem disease	
hypotonia may be significant	
the one-year survival rate was 64%	
five of the 14 survived longer than five years	
corticosteroid administration	
corticosteroids may be slowly tapered to the minimal effective dose	
the recommended maximum maintenance dose is ≤0	
red blood cell transfusion	D017707//Erythrocyte Transfusion//MSH	NOCODE//Developmental arithmetic disorder//MTH	0000015877//red blood cell transfusion//CHV
7% ±10	
1% ±11	
survival was the best (92	
cancer treatment	304181//cancer treatment//MEDCIN	LP114959-2//Cancer treatment//LNC	MTHU038130//Cancer treatment//LNC	C16212//Cancer Therapeutic Procedure//NCI
treatment of malignancies should be coordinated by an oncologist	
, for clubfeet)	
comprehensive coordinated care among specialties is required	
bone marrow failure (bmf)	
, aggression, mood swings)	
the suggested starting dose of oxymetholone is 0	
hematopoietic growth factors may be useful in bmf	
this risk has not been quantitated	
studies are ongoing	
dld pathogenic variants cause variable deficiency in three enzymatic pathways	
branched chain alpha-ketoacid dehydrogenase (bckdh) complex	
α-ketoglutarate dehydrogenase (αkgdh) complex	
pyruvate dehydrogenase (pdh) complex	
early-onset neurologic presentation	
review of treatment strategies	
protein/bcaa-restriction	
ketogenic/high-fat diet	
five had no clinical or biochemical benefit	
two improved clinically	
carbohydrate tolerance	
dichloroacetate (dca)	
additional therapies used with limited success include:	
coenzyme q10	C024989//coenzyme Q10//MSH	21406//coenzyme Q10//RXNORM	199475//coenzyme Q10//MEDCIN	N0000010094//coenzyme Q10 [Chemical/Ingredient]//NDFRT	CDR0000346488//coenzyme Q10//NCI_NCI-GLOSS	CDR0000039187//coenzyme Q10//PDQ	NOCODE//Developmental arithmetic disorder//MTH	0000013780//coenzyme q10//CHV	N0000148739//COENZYME Q10//NDFRT	4021303//COENZYME Q10//VANDF	C916//Coenzyme Q10//NCI	NSC0140865//Coenzyme Q10//NCI_DTP	46285//Coenzyme Q10//MMSL	412130008//Coenzyme Q10//SNOMEDCT_US	412129003//Coenzyme Q10//SNOMEDCT_US
lipoic acid	C61595//Alpha-Lipoic Acid//NCI	N0000010560//Thioctic Acid [Chemical/Ingredient]//NDFRT	DB00166//Lipoic Acid//DRUGBANK	NOCODE//administration devices//MMSL	D008063//Thioctic Acid//MSH	0000018231//lipoic acid//AOD	0000007460//alpha lipoic acid//CHV	F-630A0//Lipoic acid//SNMI	sh96009518//Lipoic acid//LCH_NW	70496003//Lipoic acid//SNOMEDCT_US
biotin	D001710//biotin//MSHCZE	U000584//Biotin//LCH	X80LX//Biotin//RCD	F-16280//Biotin//SNM	F-BB380//Biotin//SNMI	1588//Biotin//RXNORM	118935//Biotin//MMSL	13813003//Biotin preparation//SNOMEDCT_US	6SO6U10H04//Biotin//MTHSPL	N0000005852//Biotin [Chemical/Ingredient]//NDFRT	LP15451-5//Biotin//LNC	5376//B Vitamins//MEDLINEPLUS	MTHU008664//Biotin//LNC	sh85014267//Biotin//LCH_NW	C309//Biotin//NCI_CRCH	DB00121//Biotin//DRUGBANK	8919000//Biotin//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000018225//biotin//AOD	3147-0366//biotin//CSP	d06867//biotin//MMSL	11819//Hyalgan//MMSL	191869//biotin//MEDCIN	0000001914//biotin//CHV	001035//PHENYLPROPANOLAMINE/ACETAMINOPHEN/CHLORPHENIRAMINE/CAFFEINE ORAL TABLET//NDDF	A11HA05//biotin//ATC	CDR0000556403//biotin//NCI_NCI-GLOSS	N0000146018//BIOTIN//NDFRT	NSC0063865//BIOTIN//NCI_DTP	4017638//BIOTIN//VANDF	C74902//Biotin//NCI_CDISC
empiric recommendations	
for acute management (based on the above review)	
this is typically achieved by the following:	
promotion of an anabolic state:	
maintain serum glucose concentration in the normal range	
protein should then be reintroduced gradually	
hepatic presentation	
correction of metabolic acidosis with sodium bicarbonate	
correction of any coagulopathy with fresh frozen plasma	
avoidance of liver-toxic medications	
episodes of catabolic stress (e	
caution:	
high doses are usually required (0	
4-1	
0 mg/kg/day of glibenclamide)	
transfer protocols are available at www	
diabetesgenes	
org	C19711//Professional Organization or Group//NCI
high caloric intake should be maintained to achieve weight gain	
insulin can be discontinued when blood glucose concentrations stabilize	
, some residual endogenous insulin remains)	
note: macroglossia could potentially cause airway obstruction	
currently no effective treatment exists for any type of hsan	
provision of corrective lenses for myopia	
treatment of retinal detachments or glaucoma	
antiepileptic drugs for seizures	
children	U005340//Children//LCH	sh85023418//Children//LCH_NW	C16423//Child//NCI	D002648//Child//MSH	0000007008//children//AOD	0000002765//child//CHV	5002-0012//children//CSP	0060058//CHILDREN//CCPSS	C42708//Offspring//NCI
adults	D000328//Adult//MSH	0000000783//adult//CHV
gradual increase to higher doses is recommended	
for affected children, adaptation of educational programming to abilities	
duane anomaly	N0000001002//Duane Retraction Syndrome [Disease/Finding]//NDFRT	D004370//Duane Retraction Syndrome//MSH	126800//DUANE RETRACTION SYNDROME 1//OMIM	MTHU019421//Duane anomaly//OMIM	HP:0009921//Duane anomaly//HPO
severe strabismus may require eye surgery	
radial ray malformations	
hearing deficits	
hearing aids may be required	
nonsurgical treatment of ophthalmologic findings	
surgical treatment of ophthalmologic findings (extraocular muscle surgery)	
to correct or improve compensatory head posture	
to improve upshoot or downshoot	
principles of surgical approach as reviewed in	
kekunnaya et al [2015]	
type 1 and type 3	
type 2	X7A5V//Type 2//RCD	258195006//Type 2//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000034899//type 2//CHV	C125395//Bristol Stool Type 2//NCI	BSF//Bristol Stool Scale//NCI
approach for non-treatment	
approach for treatment	
the galactose challenge	
for example:	
, after the introduction of solid foods)	
supportive care may include the following:	
occupational and physical therapy	
alternative and augmentative communication	
behavioral therapy (e	
, applied behavioral analysis therapy)	
psychotropic medications for behavioral manifestations	
many of these are preventable	
seizures should be managed by a neurologist using standard practice	
childhood apraxia of speech	602081//SPEECH-LANGUAGE DISORDER 1//OMIM
anxiety/selective mutism	
autism spectrum disorder (asd)	
attention deficit hyperactivity disorder (adhd)	0000056595//attention deficit hyperactivity disorder (ADHD)//CHV	MTHU018058//Attention deficit hyperactivity disorder (ADHD)//OMIM	MTHU000353//Attention Deficit Hyperactivity Disorder (ADHD)//LNC
aggression	P80001//aggression//ICPC2P	10001488//Aggression//MDR	F-90940//Aggression//SNM	F-93032//Aggressive behavior//SNMI	MTHU003629//Aggression//OMIM	C117262//Aggression//NCI_NICHD	00052//Impaired social interaction//NANDA-I	61372001//Aggressive behavior//SNOMEDCT_US	D000374//Aggression//MSH	0000003725//aggression//AOD	2483-0139//aggression//CSP	GO:0002118//aggressive behavior//GO	0000000823//aggression//CHV	HP:0000718//Aggressive behavior//HPO	BASC-2//Emotional Symptoms Index//NCI
applied behavior analysis intervention is recommended	
oppositionality	C117261//Oppositionality//NCI_NICHD
specific medical problems are treated in the following ways:	
hydrocephalus as needed with ventriculo-peritoneal shunting	
aortic dilation with beta blocker therapy in some affected individuals	
strabismus in the usual manner	
recurrent otitis media in the usual manner	
poor feeding in infants	
human growth hormone replacement therapy	
club feet	MTHU004124//Club feet//OMIM	HP:0001762//Talipes equinovarus//HPO
casting	
educational program should be tailored to individual needs	
educational programs to address the specific needs identified	
speech therapy directed at improving communication skills	
therapeutic management of sleep disturbances if necessary	
early intervention with occupational therapy for feeding problems	
consideration of tube feeding for severe persisting feeding problems	
anticholinergics (e	
, trihexyphenidyl)	
if medications fail	
, prior to sufficient medication trials)	
acetazolamide	U000023//Acetazolamide//LCH	D000086//Acetazolamide//MSH	x02MU//Acetazolamide//RCD	E-8881//Acetazolamide//SNM	C-97910//Acetazolamide//SNMI	167//Acetazolamide//RXNORM	O3FX965V0I//Acetazolamide//MTHSPL	N0000007364//Acetazolamide [Chemical/Ingredient]//NDFRT	LP16018-1//Acetazolamide//LNC	MTHU005569//Acetazolamide//LNC	sh85000458//Acetazolamide//LCH_NW	DB00819//Acetazolamide//DRUGBANK	33664007//Acetazolamide//SNOMEDCT_US	372709008//Acetazolamide//SNOMEDCT_US	00420//Acetazolamide//PSY	C28809//Acetazolamide//NCI	MTHU000958//Acetazolamide//USPMG	NOCODE//Developmental arithmetic disorder//MTH	2840-2359//acetazolamide//CSP	4121//salicylic acid topical 20% topical liquid//MMSL	41316//acetazolamide//MEDCIN	0000000604//acetazolamide//CHV	002286//RUTIN 50 mg ORAL TABLET//NDDF	S01EC01//acetazolamide//ATC	N0000146250//ACETAZOLAMIDE//NDFRT	4017898//ACETAZOLAMIDE//VANDF	d00161//acetaZOLAMIDE//MMSL	814//albuterol with CFC 90 mcg/inh inhalation aerosol//MMSL
sulthiame 50-200 mg daily may reduce the attack rate	
this medication is generally well tolerated	
surgical intervention is required to correct pyloric atresia	
many children need medical treatment for gastroesophageal reflux disease	
primary layers may include any the following:	
ordinary band-aids®	
non-stick products (e	
, telfa® or n-terface®)	
, mepitel® or mepilex®)	
other nutritional deficiencies must also be addressed:	
calcium and vitamin d supplementation for osteopenia and osteoporosis	
selenium and carnitine replacement to help prevent dilated cardiomyopathy	
zinc replacement to enhance wound healing	
occupational therapy may be helpful in preventing progressive hand contractures	
psychosocial support including social services and psychological counseling is essential	
ordinaryband-aids®	
the most common secondary complication is infection	
both antibiotics and antiseptics need to be employed	
dressings usually involve three layers:	
some individuals with ebs can use ordinary bandages	
foam dressings and/or rolls of gauze (e	
, one-layer) dressing	
dystrophic nails	0000021365//nail dystrophy//CHV	MTHU036408//Dystrophic nails//OMIM	HP:0008404//Nail dystrophy//HPO
in many cases, wigs are helpful	
palmoplantar hyperkeratosis	MTHU013230//Palmoplantar hyperkeratosis//OMIM	HP:0000972//Palmoplantar hyperkeratosis//HPO
skin emollients may help relieve palmoplantar hyperkeratosis	
however, pain can be difficult to control	
career counseling is recommended	
deep stitches should be applied generously	
anti-inflammatory drugs may help with joint pain	
cardiovascular problems should be treated in a standard manner	
modalities must be tailored to the individual	
assistive devices	24-504//Assistive Devices//UMD	3136//Assistive Devices//MEDLINEPLUS	D012656//Self-Help Devices//MSH	0000011179//self-help devices//CHV
braces are useful to improve joint stability	
pain medication	40164//analgesics//MEDCIN
adjustments may be necessary for other populations	
nsaids (nonsteroidal anti-inflammatory drugs) (e	
cox-2 inhibitors (e	
they are also sometimes helpful in treating neuropathic pain	
all require gradual titration before reaching therapeutic levels	
topiramate and lamotrigine have also been used successfully	
nausea is the most common side effect	
routine use of benzodiazepines is not recommended	
medication precautions	
abrupt cessation of anti-seizure medications can precipitate a seizure	
when discontinuing, they should be tapered gradually	
severity can range from mild to life threatening	
surgery and other procedures	
anesthetic nerve blocks can provide temporary relief of neuropathic pain	
bone density	D015519//Bone Density//MSH	5935//Bone Density//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	2715-3972//bone density//CSP	0000002064//bone density//CHV	011302//Bone density//NOC	021102//Bone density//NOC	LP34385-2//Bone density//LNC	MTHU011986//Bone density//LNC	CDR0000407755//bone density//NCI_NCI-GLOSS
for severe bleeding (e	
other treatable causes, such as h	
pylori infection, should be investigated	
rarely, severe enlargement (>4	
5-5	
0 cm) requires surgical evaluation	
periodontal disease should be identified and treated	
temporomandibular joint laxity and dysfunction are difficult to treat	
there are no specific interventions of proven benefit	
intra-oral devices are sometimes helpful	
psychiatric	PSY//Psychiatric//HL7V2.5	C17026//Psychiatry//NCI	G-B112//Psychiatric//SNMI	LP7508-7//Psychiatric//LNC	MTHU002618//Psychiatric//LNC	27296002//Psychiatric//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000020622//psychiatric//CHV	0043166//PSYCHIATRIC//CCPSS	Psy//Psychiatric//HL7V2.5	PSYCH//Psychiatric//HL7V3.0
antidepressants are also of great benefit	
consumer support groups are available and can be very beneficial	
, the uterus in pregnancy)	
bracing may be required to support unstable joints	
swimming is recommended	
vascular surgery is fraught with danger	
antispastic medications	
muscle relaxants	LP31447-3//Muscle relaxants//LNC	sh85088683//Muscle relaxants//LCH_NW	NOCODE//Developmental arithmetic disorder//MTH	M03//MUSCLE RELAXANTS//ATC	0000031374//muscle relaxant//CHV	41041//muscle relaxants//MEDCIN	C05AE//Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE//ATC
contractures	D003286//Contracture//MSH	MTHU002170//Contractures//OMIM	02086//Contractures//NANDA-I	HP:0001371//Flexion contracture//HPO	0000003326//contracture//CHV
severe diarrhea	MTHU026059//Severe diarrhea//OMIM	409587002//Severe diarrhea//SNOMEDCT_US
maintain hydration & caloric intake	
tube feeding often necessary	
poor energy metabolism & oxidative stress	
, contractures)	
, feeding, grooming, dressing, writing)	
routine repair is appropriate	
pulmonary emphysema is treated symptomatically	
no definitive treatment is available	
based on experience in other related disorders (e	
aortic aneurysm replacement has been performed successfully	
joint hypermobility can be supported by muscle reinforcing physical therapy	
standard management of gastroesophageal reflux	
standard interventions for:	
cardiac defects	MTHU015745//Cardiac defects//OMIM	0000047328//cardiac defects//CHV
hip dysplasia and other skeletal complications	
cryptorchidism and/or micropenis	
refractive errors, strabismus, or other ophthalmologic issues	
seizures, if present	
then 1 mg 1x daily thereafter)	
prevnar-13® and h	
the incidence of post-splenectomy sepsis varies among studies	
cholecystectomy	47600//Cholecystectomy//CPT	965//Cholecystectomy//ICD10AM	30443-00//Cholecystectomy//ICD10AM	D52005//cholecystectomy//ICPC2P	U000984//Cholecystectomy//LCH	10008611//Cholecystectomy//MDR	7810.//Cholecystectomy//RCD	P-1100//Excision, NOS (-ectomy)//SNM	P1-5C330//Cholecystectomy//SNMI	C51676//Cholecystectomy//NCI	259//Gallbladder Diseases//MEDLINEPLUS	1014153//Cholecystectomy//CPT	sh85024639//Cholecystectomy//LCH_NW	LA14290-3//Cholecystectomy//LNC	38102005//Cholecystectomy//SNOMEDCT_US	51.2//Cholecystectomy//ICD9CM	51.22//Cholecystectomy//ICD9CM	D002763//Cholecystectomy//MSH	0060034//CHOLECYSTECTOMY//CCPSS	175//CHOLECYSTECTOMY//COSTAR	0000008311//cholecystectomy//AOD	BI00756//cholecystectomy//BI	0413-8805//cholecystectomy//CSP	0000002863//surgical removal of the gallbladder//CHV	41673//cholecystectomy//MEDCIN
valproic acid is the first drug of choice	
it diminishes myoclonus and the frequency of generalized seizures	
the phototoxic pain is not responsive to narcotic analgesics	
tanning products	
β-carotene	
hepatic complications may be accompanied by motor neuropathy	
the pain is not responsive to narcotic analgesics	
sun creams containing a physical reflecting agent (e	
reports on treatments in a series involve heterogeneous populations	
cooling the extremities reduces pain in a symptomatic person	
01) [mork et al 2004]	
experts have reported typically mild to moderate pain relief	
remissions (i	
carbamazepine	U000779//Carbamazepine//LCH	D002220//Carbamazepine//MSH	U000138//Toxic erythema//MTH	X7957//Carbamazepine - chemical//RCD	dn3..//Carbamazepine product//RCD	E-7761//Carbamazepine//SNM	C-61110//Carbamazepine//SNMI	2002//Carbamazepine//RXNORM	33CM23913M//Carbamazepine//MTHSPL	N0000007470//Carbamazepine [Chemical/Ingredient]//NDFRT	LP16061-1//Carbamazepine//LNC	MTHU003352//Carbamazepine//LNC	sh85020070//Carbamazepine//LCH_NW	DB00564//Carbamazepine//DRUGBANK	30461//Carbamazepine//CPM	387222003//Carbamazepine//SNOMEDCT_US	40820003//Carbamazepine//SNOMEDCT_US	07483//Carbamazepine//PSY	C341//Carbamazepine//NCI	MTHU000272//Carbamazepine//USPMG	U001779//Carbamazepine//MTH	0000020942//carbamazepine//AOD	0314-6873//carbamazepine//CSP	4350//hydrogen peroxide topical 3% topical solution//MMSL	41094//carbamazepine//MEDCIN	0000002381//carbamazepine//CHV	001634//carbamazepine//NDDF	N03AF01//carbamazepine//ATC	CDR0000042418//carbamazepine//PDQ	N0000146226//CARBAMAZEPINE//NDFRT	4017873//CARBAMAZEPINE//VANDF	d00058//carBAMazepine//MMSL	513//aminophylline 100 mg oral tablet//MMSL	1011157//Carbamazepine//CPT
oxcarbazepine use in treating em has not been reported	
topical application of 1	
0% amitriptyline hydrochloride and 0	
calcium antagonists	
magnesium	D008274//hořčík//MSHCZE	U002778//Magnesium//LCH	5535//acetaminophen 650 mg/25 mL oral liquid//MMSL	X80D2//Magnesium//RCD	F-10400//Magnesium//SNM	6574//Magnesium//RXNORM	N0000006335//Magnesium [Chemical/Ingredient]//NDFRT	LP14343-5//Magnesium//LNC	I38ZP9992A//Magnesium//MTHSPL	4298//Minerals//MEDLINEPLUS	MTHU002163//Magnesium//LNC	sh85079651//Magnesium//LCH_NW	03072//Magnesium//NCI_DCP	32031//Magnesium//CPM	DB01378//Magnesium//DRUGBANK	72717003//Magnesium//SNOMEDCT_US	29110//Magnesium//PSY	C29239//Magnesium//NCI	MTHU001746//Magnesium//USPMG	U002057//Magnesium//MTH	0000005765//magnesium//AOD	1852-6512//magnesium//CSP	5005//chlorhexidine topical 4% topical soap//MMSL	199598//magnesium//MEDCIN	0000007660//magnesium//CHV	004557//CARBAMAZEPINE 100 mg/5 mL ORAL SUSPENSION, ORAL (FINAL DOSE FORM)//NDDF	000784//POTASSIUM GUAIACOLSULFONATE/D-METHORPHAN/PROMETH/SOD CITRAT ORAL EXPECTORANT//NDDF	CDR0000373087//magnesium//NCI_NCI-GLOSS	004558//CARBAMAZEPINE 200 mg ORAL TABLET//NDDF	004560//CLONAZEPAM 0.5 mg ORAL TABLET//NDDF	004559//CARBAMAZEPINE 100 mg ORAL TABLET, CHEWABLE//NDDF	0046813//MAGNESIUM//CCPSS	N0000146038//MAGNESIUM//NDFRT	4017660//MAGNESIUM//VANDF	10025430//magnesium//MDRDUT	83735//Magnesium//CPT	U000302//White color//MTH	SDTM-LBTEST//Glomerular Filtration Rate//NCI_CDISC	C64840//Magnesium//NCI_CDISC	C68264//Dietary Magnesium//NCI_CRCH	A12CC//Magnesium supplements//ATC	N0000029441//[TN460] MAGNESIUM//NDFRT	4021888//MAGNESIUM//VANDF
cyclosporine was successful in one person with erythromelalgia	
sympathetic block, surgical sympathectomy, and epidural infusion	
the main problems to manage are:	
adaptation of education to the level of cognitive handicap	
epilepsy, which is amendable to standard treatments	
osteochondromas require no therapy in the absence of clinical problems	
leg-length inequalities greater than 2	
surgical resection is the treatment for sarcomatous degeneration	
3% (±5	
9%) [mehta et al 2017]	
mds/aml treatment remains challenging	
solid tumors	0000027308//solid tumor//CHV
acroparesthesia	X205S//Acroparesthesia//RCDAE	F-82580//Acroparesthesia//SNM	F-A2580//Acroparesthesia//SNMI	10062860//Acroparesthesia//MDR	HP:0031006//Acroparesthesia//HPO	79256006//Acroparesthesia//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000023280//acroparesthesia//CHV	MTHU003020//acroparesthesia//ICPC2ICD10ENG	275694//acroparesthesia//MEDCIN
diphenylhydantoin	E-7812//Diphenylhydantoin//SNM	C-61640//Phenytoin//SNMI	C741//Phenytoin//NCI	N0000006023//Phenytoin [Chemical/Ingredient]//NDFRT	DB00252//Phenytoin//DRUGBANK	387220006//Phenytoin//SNOMEDCT_US	14320//Diphenylhydantoin//PSY	D010672//Phenytoin//MSH	0000009622//phenytoin//CHV	1548-7299//phenytoin//CSP
a potential side effect of diphenylhydantoin is gingival hypertrophy	
carbamazepine has similar effects	
chronic hemodialysis and/or renal transplantation have become lifesaving procedures	
therefore, successful renal transplantation corrects renal function	
thrombosis	U004672//Thrombosis//LCH	10043607//Thrombosis//MDR	D013927//Thrombosis//MSH	XC0fW//Thrombosis//RCD	M-35100//Thrombus//SNM	MTHU005312//Thrombosis//OMIM	439127006//Thrombosis//SNOMEDCT_US	N0000002936//Thrombosis [Disease/Finding]//NDFRT	LP31622-1//Thrombosis//LNC	sh85135077//Thrombosis//LCH_NW	C26891//Thrombosis//NCI_NICHD	2100//Thrombosis//NCI_FDA	264579008//Thrombosis//SNOMEDCT_US	453.9//Thrombosis//MTHICD9	NOCODE//Developmental arithmetic disorder//MTH	0019080//THROMBOSIS//CCPSS	THROM//THROMBOSIS//CST	U004006//THROMBOSIS//DXP	0481//THROMBOSIS//WHO	0000005938//thrombosis//AOD	0571-8378//thrombosis//CSP	0000058002//thrombosis//CHV	MTHU075597//thrombosis//ICPC2ICD10ENG	0000012227//thrombosis//CHV	C27083//THROMBUS//NCI_CDISC	CDR0000044231//thrombosis//NCI_NCI-GLOSS
5 (therapeutic range 2	
colonic polyps	D003111//Colonic Polyps//MSH	N0000000814//Colonic Polyps [Disease/Finding]//NDFRT	3134//Colonic Polyps//MEDLINEPLUS	NOCODE//Developmental arithmetic disorder//MTH	BI00227//colonic polyps//BI	0000003174//colon polyp//CHV	MTHU036752//Colonic polyps//OMIM	V18.51//Colonic polyps//MTHICD9
types of colectomy include the following:	
total colectomy with ileorectal anastomosis (ira)	
this is a single-stage procedure	
total proctocolectomy with permanent ileostomy	
the choice of procedure depends on the clinical circumstances	
small-bowel polyps	
osteomas may be removed for cosmetic reasons	
desmoid tumors	0000015129//desmoid//CHV	HP:0100245//Desmoid tumors//HPO
adrenal tumors	0000000767//adrenal tumor//CHV
chemoprevention	C15604//Chemoprevention//NCI	CDR0000045487//chemoprevention//NCI_NCI-GLOSS	D018890//Chemoprevention//MSH	sh92002504//Chemoprevention//LCH_NW	NOCODE//Developmental arithmetic disorder//MTH	0000027626//chemoprophylaxis//CHV	4001-0027//chemoprevention//CSP
nsaids	40457//nonsteroidal anti-inflammatory drugs//MEDCIN	CDR0000045807//NSAIDs//NCI_NCI-GLOSS	D000894//Anti-Inflammatory Agents, Non-Steroidal//MSH	0000001258//nonsteroidal anti-inflammatory drugs (NSAIDs)//CHV	4007-0090//nonsteroidal antiinflammatory agent//CSP
appropriate treatment for:	
inguinal hernias	D006552//Hernia, Inguinal//MSH	0000006085//inguinal hernia//CHV	MTHU036928//Inguinal hernias//OMIM	10022017//Inguinal hernias//MDR
routine repair	
cutis laxa	D003483//cutis laxa//MSHCZE	10011692//cutis laxa//MDRDUT	C84663//Cutis Laxa//NCI	N0000000884//Cutis Laxa [Disease/Finding]//NDFRT	NOCODE//Developmental arithmetic disorder//MTH	X50CO//Cutis laxa//RCD	M-56810//Cutis laxa//SNM	MTHU006920//Cutis laxa//OMIM	HP:0000973//Cutis laxa//HPO	58588007//Cutis laxa//SNOMEDCT_US	2716-6258//cutis laxa//CSP	0000003512//loose skin//CHV	31802//cutis laxa//MEDCIN
pulmonary emphysema	D011656//Pulmonary Emphysema//MSH	NOCODE//Developmental arithmetic disorder//MTH	C3348//Pulmonary Emphysema//NCI	N0000002542//Pulmonary Emphysema [Disease/Finding]//NDFRT	3623//Emphysema//MEDLINEPLUS	1832//Emphysema, Pulmonary//NCI_FDA	42290//Pulmonary Emphysema//PSY	U002201//Pulmonary Emphysema//MTH	X101n//Pulmonary emphysema//RCD	M-32800//Emphysema//SNM	HP:0002097//Emphysema//HPO	87433001//Pulmonary emphysema//SNOMEDCT_US	R0121746//PULMONARY EMPHYSEMA//QMR	0000010388//lung emphysema//CHV
no treatment available	
no definite treatment is available to date	
inadequate nutrition	01226//Inadequate nutrition//NANDA-I
standard treatment w/antiepileptic drugs	
immobility/wheelchair dependence	
, wheelchair	
cardiomyopathy and arrhythmia	
standard treatment per cardiology recommendations	
consider granulocyte colony stimulating factor 2	
significant acidosis	
consider bicarbonate therapy	
cataract and/or strabismus	
surgical treatment if indicated	
hearing aids	11-967//Hearing Aids//UMD	5216//Hearing Aids//MEDLINEPLUS	22430//Hearing Aids//PSY	D006310//Hearing Aids//MSH	U002102//Hearing aids//LCH	sh85059616//Hearing aids//LCH_NW	0000005855//hearing aids//CHV
there is no definite treatment for fcmd	
monitoring for orthopedic complications such as foot deformity and scoliosis	
prompt treatment of acute respiratory tract infections	
antiepileptic drugs (aeds) when indicated	
surgical treatment for gastroesophageal reflux when indicated	
gastrostomy when indicated to assure adequate caloric intake	
routine therapy of cardiomyopathy	
feeding problems	0000022945//feeding problems//CHV	1850//Feeding Problems//NCI_FDA	MTHU002106//Feeding problems//OMIM	HP:0011968//Feeding difficulties//HPO	0000044561//feeding problems//CHV
maintain adequate nutrition and avoid aspiration	
gastroesophageal reflux	N0000001319//Gastroesophageal Reflux [Disease/Finding]//NDFRT	512//GERD//MEDLINEPLUS	D005764//Gastroesophageal Reflux//MSH	GI DIS//GASTROINTESTINAL DISORDER//CST	NOCODE//ABDUCENS NERVE PALSY IN CHILDREN, BENIGN, RECURRENT//DXP	1149//GASTROESOPHAGEAL REFLUX//WHO	109350//GASTROESOPHAGEAL REFLUX//OMIM	F-52440//Gastroesophageal reflux//SNMI	530.81//Gastroesophageal reflux//MTHICD9	MTHU002522//Gastroesophageal reflux//OMIM	BI00251//gastroesophageal reflux//BI	0000005382//gastroesophageal reflux disease (GERD)//CHV	C113396//Gastroesophageal Reflux//NCI_NICHD	U001928//Gastroesophageal reflux//LCH	sh85053480//Gastroesophageal reflux//LCH_NW	10017924//Gastroesophageal reflux//MDR	HP:0002020//Gastroesophageal reflux//HPO	C92560//Gastroesophageal Reflux//NCI	1018151//GASTROESOPHAGEAL REFLUX//CCPSS	1248-5846//reflux esophagitis//CSP	CDR0000257517//gastroesophageal reflux//NCI_NCI-GLOSS
orthostatic hypotension	537//ORTHOSTATIC HYPOTENSION//COSTAR	HYPOTENS POST//POSTURAL HYPOTENSION//CST	U002936//ORTHOSTATIC HYPOTENSION//DXP	I95.1//Orthostatic hypotension//ICD10	10031127//Orthostatic hypotension//MDR	PRB_11000.03//Orthostatic hypotension//PCDS	G870.//Orthostatic hypotension//RCD	D3-04100//Orthostatic hypotension//SNMI	060106//Orthostatic hypotension//NOC	040107//Orthostatic hypotension//NOC	MTHU001817//Orthostatic hypotension//OMIM	HP:0001278//Orthostatic hypotension//HPO	02986//Orthostatic hypotension//NANDA-I	458.0//Orthostatic hypotension//ICD9CM	28651003//Orthostatic hypotension//SNOMEDCT_US	BI00122//orthostatic hypotension//BI	0571-5870//postural hypotension//CSP	38311//orthostatic hypotension//MEDCIN	0000006494//orthostatic hypotension//CHV	K88005//orthostatic hypotension//ICPC2P	6059//orthostatic hypotension//MEDCIN	C84970//Orthostatic Hypotension//NCI	N0000001650//Hypotension, Orthostatic [Disease/Finding]//NDFRT	4242//Autonomic Nervous System Disorders//MEDLINEPLUS	1225//Low Blood Pressure//MEDLINEPLUS	D007024//Hypotension, Orthostatic//MSH
counter-maneuvers (e	
squatting had the greatest effect	
kidney and bladder	
bradyarrhythmia	NOCODE//Sepsis//COSTAR	10049765//Bradyarrhythmia//MDR	353825//Bradyarrhythmia//MEDCIN	421869004//Bradyarrhythmia//SNOMEDCT_US	0000005360//bradyarrhythmia//AOD	MTHU012485//bradyarrhythmia//ICPC2ICD10ENG	1393-3297//bradycardia//CSP	0000015098//bradyarrhythmia//CHV	0027788//BRADYARRHYTHMIA//CCPSS	N0000000600//Bradycardia [Disease/Finding]//NDFRT	D001919//Bradycardia//MSH
soft contact lenses can promote corneal healing	
corneal transplantation has had limited success	
spinal fusion may be necessary	
many adults use walkers or wheelchairs when outside the home	
sialorrhea is a common	
surgical treatment of gastrointestinal atresia when present	
follow up and treatment of possible cardiac and renal anomalies	
treatment for significant hearing loss	
developmental or educational intervention for children with learning difficulties	
retinal avascularity per se often requires no treatment	
individualized management of behavior problems	
neurologic management of seizures	
standard management of chronic constipation for individuals with fgs1	
communication rehabilitation with sign languages or alternative means of communication	
standard treatment for any of the following if identified:	
refractive errors and strabismus	
orthopedic complications	
investigation for celiac disease if indicated by clinical features	
cervical spine instability	N1489//Cervical spine instability//RCD	HP:0010646//Cervical spine instability//HPO	202821008//Cervical spine instability//SNOMEDCT_US	NOCODE//Developmental arithmetic disorder//MTH	0000032832//cervical spine instability//CHV	155013//cervical spine instability//MEDCIN
large joint dislocations	HP:0005008//Large joint dislocations//HPO
scoliosis is treated medically	
no effective surgical intervention has been described	
club feet are managed in a routine manner	
febrile and inflammatory episodes are usually treated with nsaids	
papillomatosis	10051278//papillomatosis//MDRDUT	Xa98C//Papillomatosis//RCD	M-8060/0//Papillomatosis//SNM	MTHU003001//Papillomatosis//OMIM	82049002//Squamous papillomatosis//SNOMEDCT_US	C3713//Papillomatosis//NCI	D010212//Papilloma//MSH	0000020739//papillomatosis//CHV
camptodactyly often improves with physical and occupational therapy	
consultation with:	
folate formulations	
leucovorin is available in oral and parenteral formulations	
neither drug is available for parenteral administration	
deplin® is available as a 15-mg tablet	
folate dosing	
with intramuscular injections of approximately 1	
speech and language deficits	
no single recommended treatment exists	
dysarthria [pennington et al 2009]	
language deficits [law et al 2003]	
literacy impairments [snowling & hulme 2012]	
cognitive deficits	0000043077//cognitive deficits//CHV	10075//Cognitive Deficits//PSY	MTHU004914//Cognitive deficits//OMIM	HP:0100543//Cognitive impairment//HPO
fine and gross motor deficits	
fragile x syndrome	D005600//Fragile X Syndrome//MSH	C84717//Fragile X Syndrome//NCI	N0000001290//Fragile X Syndrome [Disease/Finding]//NDFRT	3690//Fragile X Syndrome//MEDLINEPLUS	20295//Fragile X Syndrome//PSY	NOCODE//Developmental arithmetic disorder//MTH	U001873//Fragile X syndrome//LCH	10017324//Fragile X syndrome//MDR	X78FB//Fragile X syndrome//RCD	D4-00504//Fragile X syndrome//SNMI	Q99.2//Fragile X chromosome//ICD10CM	sh85051162//Fragile X syndrome//LCH_NW	759.83//Fragile X syndrome//ICD9CM	613003//Fragile X syndrome//SNOMEDCT_US	1254-8431//fragile X syndrome//CSP	38282//fragile X syndrome//MEDCIN	0000005246//fragile x syndrome//CHV	309550//FMR1 GENE//OMIM	300624//FRAGILE X SYNDROME//OMIM
therapy must be individualized and closely monitored	
fxtas	C564105//Fragile X Tremor Ataxia Syndrome//MSH	C126566//Fragile X Tremor/Ataxia Syndrome//NCI	300623//FRAGILE X TREMOR/ATAXIA SYNDROME//OMIM
poi	X90eP//Poi//RCD	262059009//Poi//SNOMEDCT_US	0000038635//personal orientation inventory (POI)//CHV	0000024359//POI//AOD
there is little objective evidence regarding management of frda	
speech therapy to maximize communication skills	
treatment of sleep apnea by continuous positive airway pressure	
measures include the following:	
in fryns syndrome, additional anomalies may dictate further consultations	
see also congenital diaphragmatic hernia overview	
physical therapy and rehabilitation	
consultation with a physical therapist is indicated	
exercise in fshd	
ophthalmologic disease	
orthopedic intervention	
there is no consensus treatment guideline for ftd3	
individuals with seizures are treated with antiepileptic drugs	
nutritional intervention (e	
wheelchairs can be useful for some individuals	
5x109/l can vary greatly among patients	
fevers and infections require prompt treatment with antibiotics	
treatment of arterial calcification	
bisphosphonate therapy	723950005//Bisphosphonate therapy//SNOMEDCT_US
026, log-rank test)	
the dose of pamidronate has varied from 0	
cardiovascular treatment	
anti-hypertensive therapy	
017-0	
068 μg/kg/min [ciana et al 1997]	
prevention of coronary thrombosis	
treatment of hearing loss	
generalized epimerase deficiency galactosemia	
, some fruits and vegetables, organ meats)	
, hepatic cirrhosis or mature cataracts)	
peripheral epimerase deficiency galactosemia	
intermediate epimerase deficiency galactosemia	
however, insufficient data exist to make firm recommendations	
